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ABSTRACT 
The aim of this study was to evaluate seven GCC regulatory authorities and pharmaceutical 
companies active in the region in order to identify the strengths and weakness of the current 
GCC centralised procedure. The GCC regulatory authorities and the pharmaceutical companies 
who had registered their products through the GCC centralized registration procedure and the 
national registration systems were recruited into the study and asked to complete the 
questionnaires specifically designed for this study.  
The regulatory review process in Oman was evaluated to identify areas for improvement in the 
system. Information on the total application numbers and approval dates were obtained directly 
from the Oman Ministry of Health archives. Another study was conducted to evaluate the 
regulatory review process and approval times of the remaining six GCC countries (Bahrain, 
Kuwait, Qatar, Saudi Arabia, UAE and Yemen) and the GCC central registration, with respect to 
review time for new and existing substances, to identify the strengths and weaknesses of the 
process and to propose strategies that could help the policy maker in the GCC to enhance the 
review process.   
The results of the Omani regulatory system showed no significant increase (p>0.05) in the total 
number of registered pharmaceutical products from 2006 to 2010. The approval time in Oman 
showed that there was a significant increase in approval times for pharmaceutical products from 
2006 to 2010 (p<0.001). The findings show that although there was an increase in the approval 
time for all pharmaceutical company products, the median approval time for the five year period 
was 117 days. This was within the time limit (4 months) fixed by the health authority for the 
overall registration time. The comparative study of the GCC States showed a downward trend in 
the median approval time for most of the GCC States, during 2008 to 2010. However, the 
approval time for all approved products in the GCC States during this period varied from 60 
days in Qatar and Oman (2009 and 2010) to 609 days in Saudi Arabia (2008). The main 
reasons for the decrease in approval time in the Gulf States were due to the positive effect of 
the Gulf Central Registration, the rise in the number of reviewers in some GCC drug authorities, 
and the parallel procedure used in the regulatory approval review process. The study of the 
regulatory review process of the  GCC central registration showed that a total of 413 products 
(96 NASs and 317 EASs) were approved during the period 2006-2010 with an overall significant 
increase in the EASs (p<0.001). The approval times increased from 107 calendar days in 2006 
to 265 in 2010 (p<0.001). The lowest approval time was for EASs submitted by the Gulf 
companies (134 days) and the longest for NASs submitted by international companies (346 
days) (p<0.001).  
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Both the regulatory authorities and the pharmaceutical companies agreed that the centralised 
procedure is an effective system for authorising medicinal products in all seven GCC countries 
in one procedure and is the way forward in the future but there is room for improvement in the 
procedure and the follow ups. They also agreed that clear guidelines, transparency of 
procedures, effective interactions between authorities and companies, increase in the number 
of the committee meetings per year, use of electronic on-line submissions will improve approval 
time for registration of new medicines, enhance the quality of review practice and encourage 
the pharmaceutical companies to use the GCC central registration system. This research has 
enabled development of a new model of the GCC central registration procedure to be proposed 
for the GCC Health Authorities which could improve patient access to medicines in the GCC 
states. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII 
 
TABLE OF CONTENTS 
Acknowledgements …………………………………………………………………… IV 
Abstract  ………………………………………………………………………………. V 
Table of contents  …………………………………………………………………….. VII 
Glossary of abbreviations  …………………………………………………………… IX 
Glossary of terms  ……………………………………………………………………. XI 
List of figures  …………………………………………………………………………     XVI 
List of tables  …………………………………………………………………………..     XIX 
Chapter one……………………………………………………………………………. 1 
     Background………………………………………………………………………….. 2 
Regulatory Reviews Process, Approval Times and Patients' Access to Medicines 2 
Quality of the Review Process  …………………………………………………… 5 
Benefit-risk assessment and decision-making  …………………………………… 7 
Role of harmonisation  ……………………………………………………………. 8 
The Gulf Cooperation Council (GCC) States  ……………………………………. 9 
GCC Drug Regulatory Authorities  ………………………………………………. 10 
Evolution of GCC-DR  …………………………………………………………… 11 
The quality of the review in the GCC  …………………………………………… 15 
Global drug development and its influence on the regulatory environment in the Gulf     
Region  ……………………………………………………………………………. 16 
Aims and objectives of the study  ………………………………………………….. 18 
Chapter two  ……………………………………………………………………….... 19      
Study rationale & methodological framework 
Rational of the study  ……………………………………………………………....        20 
Methodology framework  …………………………………………………………. 21 
     Development of the Study Plan  ………………………………………………..... 31 
Development of the Study Instruments  ………………………………………….... 33 
Data processing and analysis  …………………………………………………... … 35 
    Summary  ………………………………………………………………………….. 40 
Chapter three  ……………………………………………………………………… 41 
Evaluation of the Pharmaceutical Regulatory Review Process in Oman 
Introduction  ………………………………………………………………………         42 
Objectives  ………………………………………………………………………..          43 
Methods  ………………………………………………………………………….          43 
Results  …………………………………………………………………………...          44 
Discussion  ……………………………………………………………………….           61 
Conclusion  ………………………………………………………………………           65 
Summary  …………………………………………………………………………         66 
Chapter four  ……………………………………………………………………….          67 
Evaluation of Regulatory Review Times in the Gulf States 
Introduction  ………………………………………………………………………         68 
Objectives  ………………………………………………………………………..          69 
Methods  ………………………………………………………………………….          69 
Results  ……………………………………………………………………………        70 
VIII 
 
Discussion  ………………………………………………………………………….. 90 
Summary  …………………………………………………………………………… 95 
Chapter five  …………………………………………………………………………... 96 
An Evaluation of the GCC Centralised Regulatory Review Process 
Introduction  ………………………………………………………………………… 97 
Objectives ………………………………………………………………………….. 98 
Methods  ……………………………………………………………………………. 99 
Results  ……………………………………………………………………………... 101 
Discussion  …………………………………………………………………………. 112 
Summary  …………………………………………………………………………... 115 
Chapter six  …………………………………………………………………………... 117 
An Evaluation of the Gulf States Views and Experiences with GCC Centralised Procedure 
Introduction  ………………………………………………………………………… 118   
Objectives  ………………………………………………………………………….. 119 
Methods  ……………………………………………………………………………. 119 
Results  ……………………………………………………………………………... 119 
Discussion  …………………………………………………………………………. 147 
Summary  …………………………………………………………………………... 150 
Chapter seven  ………………………………………………………………………… 152 
An Evaluation of the Pharmaceutical Companies Experiences with the GCC Centralised 
Procedure 
Introduction  ………………………………………………………………………... 153 
Objectives  …………………………………………………………………………..      154 
Methods  ……………………………………………………………………………. 154 
Results  ……………………………………………………………………………... 155 
Discussion  ………………………………………………………………………………... 183 
Summary  …………………………………………………………………………………. 187 
Chapter eight  ………………………………………………………………………... 188 
The Gulf Centralised Procedure- A Comparison between the Experiences of Regulatory 
Authorities and Pharmaceutical Companies, a proposed new model   
Introduction  ……………………………………………………………………….. 189 
Objectives   ………………………………………………………………………… 190 
Methods  …………………………………………………………………………… 190 
Results &Discussion   …………………………………………………………………… 191 
Summary  ………………………………………………………………………………… 209 
Chapter nine  ………………………………………………………………………... 210 
    General Discussion   
Limitation of the study ……………………………………………………………         219 
Recommendations  …………………………………………………………….....          220 
Future work  ………………………………………………………………………         223 
Conclusion  …………………………………………………………………….....         224   
References  ………………………………………………………………………….         225 
Publications  ………………………………………………………………………..          237 
Appendix…………………………………………………………………………….          239 
 
IX 
 
LIST OF ABBREVIATIONS 
AMRH: African Regulatory Harmonization Initiative  
APEC: Asia Pacific Economic Cooperation  
ADEC: Australian Drug Evaluation Committee. 
ATC: Anatomical Therapeutic and Chemical code. 
CACP: Companies Assessment of Central Procedure  
CATI: Computer assisted telephone interviewing  
CBER: Centre for Biologics Evaluation and Research. 
CIF: Cost, Insurance and Freight 
CIRS: Centre for Innovation in Regulatory Science  
CDER: Centre for Drug Evaluation and Research. 
CLADF: Central Laboratory for Analysis of Drugs and Food. 
CTD: Centralised Technical Document 
CHMP: Committee for Medicinal Products for Human Use. 
CMR: Centre for Medicines Research 
CPP: Certificate of Pharmaceutical Product. 
DGPA&DC: Directorate General of Pharmaceutical Affairs and Drug Control 
EMA: European Medicines Agency. 
EU: European Union. 
FDA: Food and Drug Administration. 
GACP: Gulf Assessment of Centralised Procedure  
GCC: Gulf Cooperation Council 
GCC-CP: Gulf Cooperation Council Centralised Procedure  
GCC-DR: Gulf Cooperation Council Drug Registration committee. 
GCP: Good Clinical Practice. 
GRP: Good Review Practice. 
HAS: Health Sciences Authority of Singapore. 
ICH: International Conference on Harmonisation. 
IND: Investigational New Drug. 
IT: Information Technology. 
KSA: Kingdom of Saudi Arabia. 
MA: Marketing Authorisation. 
MCA: Medicines Control Agency. 
X 
 
MEB: Medicines Evaluation Board. 
MERC: Middle East Regulatory Conference. 
MERCOSUR: Mercado Comundel Sur  
MHLW: Ministry of Health, Labour and Welfare. 
MHW: Ministry of Health and Welfare. 
MPA: Medical Products Agency. 
NAS: New Active Substance. 
NCE: New Chemical Entity. 
NDA: New Drug Application. 
NME: New Molecular Entity. 
NGT:Nominal Group Technique 
OCD: Office Centre Director. 
PD: Pharmacodynamics. 
PDUFA: Prescription Drug User Fee Act. 
PANDRH:Pan American Network for Drug Regulatory Harmonisation  
PK: Pharmacokinetics. 
PMS: Post Marketing Surveillance. 
PPRS: Pharmaceutical Pricing Regulation Scheme. 
QA: Quality Assurance. 
QCL: Quality Control Laboratory 
R&D: Research and Development. 
RC: Registration Committee. 
RMS: Reference Member State. 
SADC: Southern African Development Community  
SOP: Standard Operating Procedure. 
TCR&P: Technical Committee for Registration of Pharmaceutical Manufacturers & Their 
                 Products & Pricing   
TGA: Therapeutics Goods Administration. 
TRIPS: Trade-Related Aspects of Intellectual Property Rights. 
UAE: United Arab Emirates. 
WHO: World Health Organisation. 
WTO: World Trade Organisation. 
XI 
 
GLOSSARY OF TERMS 
Adverse event: Any untoward medical occurrence in a patient or clinical investigation of a subject 
administered a pharmaceutical product and which does not necessarily have a causal relationship 
with this treatment. 
Africa, the Southern African Development Community (SADC): Angola, Botswana, Democratic 
Republic of Congo, Lesotho, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, 
Swaziland, Tanzania, Zambia and Zimbabwe. 
Approval: The active substance has been approved for licence by a regulatory authority in one or 
more markets (when the authority grants a licence and subject to pricing/ reimbursement issues the 
product can be legally marketed). 
Arab Central Registration (ACR): Jordan, UAE, Bahrain, Tunisia, Algeria, Djibouti, KSA, Sudan, 
Syria, Somalia, Iraq, Oman, Palestine, Mauritania, Yemen, Qatar, Comoros, Kuwait, Lebanon, 
Libya, Egypt and Morocco. 
Asia-Pacific Economic Cooperation (APEC): Australia, Brunei Darussalam, Canada, Chile, China, 
Hong Kong, Indonesia, Japan, South Korea, Malaysia, Mexico, New Zealand, Papua New Guinea, 
Peru, Philippines, Russia, Singapore, Taiwan, Thailand, USA and Vietnam. 
Association of Southeast Asian Nations (ASEAN): Brunei, India, Thailand, Philippines, Indonesia, 
Malaysia, Singapore, Myanmar and Cambodia. 
Benefit/risk ratio: The benefit to risk ratio relates the potential or actual benefit that a patient 
derives from a treatment to the risks incurred by the patient through using the treatment. The benefit 
to risk ratio can be described in qualitative terms (high, low, equal, very low etc). 
Binding: Advice provided by a regulatory authority prior to submission that is acknowledged and 
considered a regulatory agreement. 
Biological: A substance isolated from animal tissues e.g. vaccines, hormones, antigens. 
Biotech product: A naturally occurring or modified polypeptide, protein, DNA or RNA product 
(produced by recombinant DNA or hybridoma  technology and expressed in cell lines, transgenic 
animals or transgenic plants) for therapeutic, prophylactic or in vivo diagnostic use in humans. The 
only types of vaccines included in the biotech category are recombinant vaccines. 
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Centralised procedure: The Centralised procedure is used when marketing authorization 
covering the entire EU region is applied for, for example, for new biotechnological medicinal 
products and new innovative medicinal products. The applications for marketing authorization 
are then submitted to the European Agency for the Evaluation of Medicinal Products (EMEA). 
Clinical trial: Any investigation in human subjects intended to discover or verify the clinical, 
pharmacological and/or other pharmacodynamic effects of an investigational product, and/or to 
identify any adverse reactions to an investigational product, and/or to study the absorption, 
distribution, metabolism and excretion of an investigational product, with the objective of 
ascertaining its safety and/or efficacy. 
Collaborative or sponsored research: The active substance is discovered as a result of research 
carried out in collaboration with, or sponsored by, another company, a university, government 
agency or an individual. 
Co-operation Council of the Arab Gulf States (GCC): Bahrain, Kuwait, Oman, Qatar, United 
Arab Emirates and the Kingdom of Saudi Arabia. 
Drug product: A finished formulation, for example, a tablet or capsule that contains the active 
substance, generally in association with one or more other ingredients. 
Drug Regulatory Authority (DRA): The agency that develops and implements most of the 
legislation and regulation of medicines. 
European Union Member States (EU): Austria, Belgium, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 
Luxembourg, Malta, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden The Netherlands and 
the United Kingdom. 
Extrapolation of foreign clinical data: The generalisation and application of the safety, 
efficacy and dose response data generated in a population of a foreign region to the population of 
the new region. 
Foreign region: Any region outside the new region where product authorisation is being sought. 
ICH Regions: European Union, Japan and USA. 
ICH: International Conference on Harmonisation. 
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Indication: The specific indication for which the active substance for the project is designed. 
This may represent the cure, alleviation, treatment, prevention or diagnosis of disease in humans. 
Investigational New Drug (IND): An application that a drug sponsor must submit to FDA 
before beginning tests of a new drug in humans. The IND contains the plan for the study and is 
supposed to give a complete picture of the drug, including structural formula, animal test results, 
and manufacturing information. 
Launched: The active substance is made available for sale as an ethical prescription only 
medicine in the first market in any country. 
Line extension: NASs which are already marketed but are being further developed for new 
indications, formulations, dosages, routes of administration, or novel drug delivery systems. 
Local study: A study conducted in a single country with the primary aim of providing local 
experience with a compound. 
Marketing Authorisation (MA): Legal approval granted to a company by a national (or 
regional) authority to market a medicinal product in that particular country (or region). 
Marketing Authorisation Application (MAA): An application by a company for a marketing 
authorisation to be submitted to each country (or region) in which marketing approval is sought. 
Mutual Recognition procedure: The Mutual Recognition (MR) procedure utilizes the 
marketing authorization granted for an active substance by another EU Member State, Norway, 
or Iceland. The Member State whose assessment is recognized as a basis for marketing 
authorization is called the Reference Member State (RMS). 
National procedure: The national procedure is mainly used in cases where marketing 
authorisation is being applied for in a single member state within the. 
New Active Substance (NAS): A chemical, biological or radiopharmaceutical substance not 
previously authorised as a medicinal product. The term NAS also includes: an isomer, mixture of 
isomers, a complex or derivative or salt of a chemical substance previously authorised as a 
medicinal product but differing in properties with regard to safety and efficacy from that 
substance previously authorised; a biological substance previously authorised as a medicinal product, 
but differing in molecular structure, nature of source material or manufacturing process; a 
radiopharmaceutical substance that is a radionuclide or a ligand not previously authorised as a 
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medicinal product. Alternatively, the coupling mechanism linking the molecule and the radionuclide 
that has not been previously authorised. 
New Chemical Entity (NCE): An entity produced by chemical synthesis. 
New Drug Application (NDA): An application requesting regulatory approval to commercially 
market a new drug for human use. 
New Molecular Entity (NME): A product (including new chemical entities, biological products, 
vaccines and products of biotechnology) that has not been previously available for therapeutic use in 
man and is destined to be made available as a „prescription-only medicine‟, to be used for the cure, 
alleviation, treatment, prevention or in vivo diagnosis of diseases in man. New salts, pro drugs and 
esters of existing products and certain biological compounds (e.g. antigens) are excluded. 
Combination products are also excluded unless one or more of the active constituents has never been 
previously marketed. 
Pan-America Network for Drug Regulatory Harmonisation (PANDRA): Mexico, Costa Rica, 
Trinidad, Argentina and Colombia. 
Pharmacodynamics (PD): Involves the study of the effect that a drug has on the body. This will 
include looking at what effect the amount of drug has, called a dose response, and will also look at 
the site of action of the drug, such as the kinetics of how a drug interacts with a receptor. 
Pharmacogenetics: is the study of interindividual variations in DNA sequence related to drug 
response. 
Pharmacogenomics: is the study of the variability of the expression of individual genes relevant to 
disease susceptibility as well as drug response at cellular, tissue, individual or population level. The 
term is broadly applicable to drug design, discovery, and clinical development. 
Pharmacokinetics (PK): Involves the study of the manner in which the body handles a drug. It 
looks at the rate at which drug concentrations change in the body, and is involved with analysing the 
kinetics of absorption, distribution, metabolism and excretion of a drug. 
Phase I: Initial safety trials on a new medicine, usually conducted in normal male volunteers. An 
attempt is made to establish the dose range tolerated by volunteers for single and multiple doses. 
Phase I trials are sometimes conducted in severely ill patients (e.g. in the field of cancer) or in less ill 
patients (e.g. metabolism of a new antiepileptic medicine in stable epileptic patients whose 
microsomal liver enzymes have been induced by other epileptic medicines). Pharmacokinetic trials 
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are usually considered Phase I trials regardless of when they are conducted during the development 
of medicines. 
Phase II: Clinical trials (pilot and well-controlled) to evaluate efficacy (and safety) in patients with 
the disease or condition to be treated, diagnosed, or prevented. Objectives may focus on dose-
response, type of patient, frequency of dosing, or numerous other characteristics of safety and 
efficacy. 
Phase III: Clinical trials conducted in patient populations for which the medicine is eventually 
intended. These generate additional data on both safety and efficacy in relatively large numbers of 
patients, in both controlled and uncontrolled trials. Clinical trials are also conducted in special 
groups of patients (e.g. renal failure patients) or under special conditions dictated by the nature of the 
medicine and disease. These trials often provide much of the information needed for the package 
insert and labelling of the medicine and also include trials that are conducted after the regulatory 
submission of a new drug application or other dossier, but prior to the medicine‟s approval and 
launch. 
Phase IV: Phase IV clinical trials are (other than routine surveillance) performed after drug approval 
and related to the approved indication. They are not considered necessary for approval but are often 
important for optimising the drug‟s use. They may be of any type but should have valid scientific 
objectives. Commonly conducted studies include additional drug-drug interaction, dose-response, or 
safety studies and studies designed to support an extended claim under the approved indication, e.g., 
mortality/morbidity studies. 
Pivotal study: Well-controlled trial to evaluate efficacy (and safety) in patients with the disease or 
condition to be treated, diagnosed, or prevented. These clinical trials usually represent the most 
rigorous demonstration of a medicine‟s efficacy. 
Preclinical: In vivo and in vitro studies to support administration to man. 
Pre-submission: The last patient visit for the last pivotal study to be included in the regulatory 
dossier is complete and the dossier is being prepared but has not yet been submitted to a regulatory 
authority. 
Reference Member State (RMS): The EU member state that is chosen by a company to conduct the 
first review in the EU for marketing authorisation through the Mutual Recognition procedure. 
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BACKGROUND 
 
Modern medicines regulations are the foundation of any country‟s drug policy. This ensures a 
viable pharmaceutical industry as well as a high standard for the drug approval process.  
Throughout history, governments have regulated food and drug products and in general, the 
focus of this regulation has been safeguarding the quality, safety and efficacy of these 
products. Drug regulation is almost universal in the industrialised nations of the world and is 
being progressively developed in third world countries. It is increasingly based on the 
hypothesis that regulation is needed to ensure that new medicines will be comparatively safe 
and effective, labelled accurately and marketed responsibly. In short, potential benefits and 
harms of modern medicines are too important to be left to the market place and the 
unregulated functioning of the pharmaceutical industry (Philip et al 1986).  
 
Today, pharmaceutical products are highly regulated in most countries and need to comply 
with strict legislative requirements before being authorised for sale. Therefore, individual 
pharmaceutical regulatory bodies in each country are responsible for ensuring the safety and 
effectiveness of human and veterinary medicines in their jurisdiction, in compliance with 
local pharmaceutical legislation. 
 
Regulatory Reviews Process, Approval Times and Patients' Access to 
Medicines  
 
Anderson (2004) commented on the importance of timeliness for national regulatory 
authorities in order to approve new medicines, which may influence directly the stakeholders 
and patients during the process. A lengthy approval process results in a delay in marketing 
new approved medicines for patients. Normally, the length of the review process depends on 
the type of products being registered, the requirements of the approval process and the type of 
review carried out.  
 
Governments are obligated to provide their citizens with access to new medicines and 
therapies when they are needed.  In other words, conducting safety and efficacy reviews of 
marketing authorisation applications for new medicines and biotherapy products in a timely 
manner should be a major priority for safeguarding and enhancing public health, which is 
part of the core mission of health authorities. However, expediting the review process for new 
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medicines and biological products to ensure it is completed within predefined deadlines 
should never mean that regulatory standards can be compromised as they are essential to 
proving the safety, efficacy and quality of new medicines.  
 
During the process of review and approval of new applications, the most important hurdles to 
the pharmaceutical industry is the length of the review time (CMR, 2001). Therefore, efforts 
have been made by several national authorities to allow patients‟ access to medicinal 
products in a timely manner by reviewing their strategies to monitor the efficiency of the 
review process, as well as the performance of the regulatory authorities (Mallia-Milanes, 
2010). 
 
Hill and Johnson (2004) suggested that in order to exploit the differences in registration 
requirements of different countries for manufacturers they should synchronize and streamline 
the registration process. Ultimately these unifying processes reduce the time lag for 
registering new products, as well as reinforcing the 'assurance of quality' of medicines. 
Furthermore, it is possible to complete and monitor the whole review process transparently 
within a reasonable time frame satisfying both the manufacturers and regulatory authorities. 
An effective review process is perceived through the overall approval times from submission 
to patients‟ access to new medicines (Rawson, 2000; Anderson, 2004). 
 
Many countries have legislated maximum times allowed for the review of dossiers. For 
example, the target time-frame for completing the review process in the European Union 
centralised system is 210 days. This authorisation period has two points known as „clock-
stops‟- at 120th day and 180th day. A time-scale of three months and one month, respectively, 
will now be mandated for applicants to respond and these periods may be doubled upon 
request (EMA, 2009). The longest review time usually occurs when the benefits of the 
product are not evident. 
 
A study reported  by the Centre for Innovation  in Regulatory Science (CIRS, 2013) on New 
Active Substances (NASs) approved in the emerging markets between 2007 and 2011 
indicated that there were considerable differences among countries in the time taken to 
review medicinal products with median approval times ranging from one to three years 
(Figure1.1 ). 
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Figure 1.1 Regulatory approval times from date of submission to date of approval  
for New Active Substances (NASs) approved 2007-2011 
Data are shown for NASs that were approved between 01/01/2007 and 31/12/2011. (n1) = number of drug applications, (n2) 
= number of companies providing data. Box: 25th and 75th percentiles. Whiskers 5th and 95th percentiles =median 
 
These study data (CIRS, 2013) for the median times for patients‟ access  to NASs approved 
by the three major drug regulatory authorities namely, FDA, PMDA, and EMA from 2003 to 
2012 showed that the median time for patients access achieved by the US FDA was the 
shortest among these three authorities (Figures 1.2 and 1.3). 
 
 
Figure.1.2.Number of NASs approved by ICH agencies (EMA, FDA, PMDA)  
by approval year (2003-2012) 
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Figure.1.3. Median approval time of NASs approved by ICH agencies (2003-2012) 
 
 
Quality of the Review Process 
It is a recognised fact that the efficiency of the drug regulatory review process does not 
depend only on the speed of the review. In reality, the effectiveness of the regulatory process 
should be measured in terms of the approval time and the quality of decision-making. Both 
pharmaceutical companies and patients require a rapid registration process, but they should 
understand that this must not be at the expense of the quality of the review (Jefferys, 
1997;Lumpkin, 2000).  
 
In the case of new drug applications (Lumpkin, 2000) the quality of the review depends 
mainly on (i) the competence, consistency and experience of the reviewer and (ii) the 
scientific soundness in communication, transparency, consistency and adequacy of the 
process and feedback to the industry. Ultimately, the regulatory authority‟s primary 
responsibility to the public is to expedite the availability of safe and effective new therapies, 
however, pressure is also exerted on the authorities to constantly improve the efficiency and 
quality of their review processes. On the other hand, dossier quality, as well as the robustness 
and quality of the data submitted, are critical factors for achieving successful registration and 
expediting market access (McAuslane et al, 2004). Furthermore, companies and regulatory 
authorities have established open and frequent dialogue as regulatory factors that may 
6 
 
invariably result in enhancing the review process and review time (Cocchetto et al, 2000). 
Normally, the drug review process (Jefferys, 1997) depends on the following parameters: 
 
The review input: In order to ensure the availability of safe and effective medicines in the 
market, governments usually have both legal requirements and guidelines. The assessment of 
quality involves identifying and defining the role of legal requirements and how they can be 
uniformly met with consistency. The clarity of information and communication between the 
regulatory agency and the pharmaceutical companies about the expected quality will 
influence the efficiency of the review process. 
 
Clarity of roles: The credibility of the review process depends largely on the experts 
involved although conflicts of interest undermine the process. The scientific review must be 
independent of conflicts with suppliers of technology and they must also be protected from 
political influence. An independent scientific review process will hold both suppliers and 
purchasers accountable for decisions in the light of the scientific data. 
 
Quality of data: Setting high standards of evidence are essential to the integrity of the drug 
review process. However, it is often uncertain whether all of the data from the available trials 
are being provided for the review. Requiring public registration of clinical trials and protocols 
will enable agencies to know which findings are not being reported by manufacturers.  
 
The scientific assessment: It is the responsibility of the reviewing personnel to establish the 
consistency of the review and to maintain the quality and rigour of the scientific analysis. The 
scientific basis on which a decision is made must be underpinned on up to date scientific 
knowledge, procedures and expertise. 
 
Transparency of rationale: Accountability in drug coverage decision-making requires that 
all stakeholders understand the reasons for decisions. One of the major obstacles to such 
transparency is currently the commercial confidentiality imposed by manufacturers (Morgan 
et al 2006).  
 
The output:  The review process should help to ensure greater accountability of both 
decision-makers and manufacturers by requiring full disclosure of all reasonable evidence 
relevant to a medicine‟s potential coverage. The final decision and its communication to the 
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pharmaceutical company generally and the wider public must be rational, well-documented, 
well-organised and transparent (Lumpkin, 2000). The quality of the review (Moss, 2004) will 
finally depend on the methodical assessment of the reviewers and the reliable evidence 
embedded in the data. 
 
Benefit-risk assessment and Decision-making 
 
Benefit-risk assessment is the basis of any regulatory authority‟s decisions in the pre-market 
and post-market review process (EMA, 2012). A framework for medicines' benefit-risk 
decision-making that summarises the relevant facts, uncertainties, and key areas of judgment, 
clearly explains how these factors influence a regulatory decision and can greatly inform and 
clarify the regulatory discussion. A universal eight step framework has been developed for 
the Benefit-Risk assessment of medicines (Figure 1.4). This consists of the decision context 
(step one), building the value tree (step two), refining the value tree (step three), assessing the 
relative importance of Benefits and Risks (step four), evaluating the options (step five), 
evaluating uncertainty (step six), a concise presentation and visualisation of results (step 
seven) and expert judgment and communication (step eight).  Such a framework can provide 
transparency regarding the basis of conflicting   recommendations made by different agencies 
using the same information. Benefits and risks or harms assessment provide a summary of the 
submitted evidence regarding the drug under review (Coplan et al, 2011). Key considerations 
of benefits include the results of the pivotal clinical trials as well as appropriate analyses of 
subpopulations for efficacy. Also the key considerations of risks include the robustness of the 
safety database, the severity and reversibility of adverse events, and the sub-optimal 
management of the post-market surveillance studies. In assessing benefits and risks, 
consideration is also given to some factors that may be significant for a particular drug 
review, including nonclinical pharmacology and toxicology data, pharmacodynamics and 
pharmacokinetics, chemistry, manufacturing and controls and clinical microbiology. Risk 
Management or ideally benefit risk management provides a summary and assessment of any 
efforts that could help to lessen the identified safety concerns, or in other words ensure that 
the medicine  is prescribe for  those patients for whom the risk or harm is considered 
acceptable in the light of the benefits. Measures to reform the drug approval process have 
focused increasingly on the decision bias that minimises unsafe or ineffective medicines but 
neglects the costs of denying safe and effective drugs. 
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Figure 1.4 The Eight Step of the Benefit Risk Framework 
  
 
 
 
 
Role of harmonisation 
 
Harmonisation involves the formation of effective networks between regulatory authorities 
(nationally, regionally and internationally) to facilitate the sharing of best practices, making 
the best use of scarce resources and eliminating duplication of effort. Such networks are an 
important element in building regulatory capacity and trust between different regulatory 
systems (WHO, 2008). In recent years, considerable efforts have been made to harmonise 
regulatory requirements in terms of scientific content and presentation of data in the 
registration dossier, across various regions and countries. The meaning of „harmonisation‟ in 
terms of the regulatory point of view is the standardisation of technical requirements for 
medicines regulation. The policies of global standardisation (Trouiller, 2002) of regulatory 
requirements have been set up, with the most notable example being the initiation of the 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH). This initiative has disseminated a common set of 
technical requirements relating to quality control (validation of procedures), drug safety and 
efficacy as well as certain aspects of manufacturing practice for active ingredients. 
 
Since medicines are essential to healthcare they should be available to the population of every 
country. Medicines regulations remain an important component of promotion and protection 
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of public health because they help to ensure that patients have access to high quality, safe, 
and effective medicines. Investing in the regulatory harmonisation initiative provides an 
opportunity for strengthening regulatory capacity and the cost-effective use of limited 
financial and human resources. Today regulatory authorities are thinking in terms of 
regionalisation (Molzon.2010, 2011) through the efforts made by the International 
Conference on Harmonisation. 
 The Global Cooperation Group (GCG) now includes the European Medicine Agency 
(EMA), the African Regulatory Harmonisation Initiative (AMRH), the United States FDA, 
the Association of Southeast Asian Nations (ASEAN), the Pan American Network for Drug 
Regulatory Harmonisation (PANDRH), the Asia Pacific Economic Cooperation (APEC), 
Southern African Development Community (SADC) and Japan. The Mercado Comundel Sur 
(MERCOSUR) is the South American “Common Market” consisting of Brazil, Bolivia, 
Argentina, Chile, Paraguay and Uruguay. This organisation is highly structured among the 
Central and South American trade groups for regulatory harmonisation of pharmaceuticals 
(Marcelo et al, 1998). 
 
The structures of medicines regulation that exist today which include the drug laws,  drug 
regulatory agencies, the drug evaluation boards, quality control (QC) laboratories, drug 
information centres, have evolved over time. Regulation of medicines encompasses a variety 
of functions including licensing, inspection of manufacturing facilities and distribution 
channels, product assessment and registration, adverse drug reactions (ADR) monitoring, 
laboratory testing for the quality control of promotion and advertising and control of clinical 
trials (Sauwakon et al, 2002). Each of these functions target a different aspect of 
pharmaceutical activity and act in concert for effective consumer protection. 
 
The Gulf Cooperation Council (GCC) States 
 
The Gulf Cooperation Council (GCC) was established by an agreement concluded on the 25
th
 
May 1981 in Abu Dhabi (UAE) among Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and 
UAE in view of their special relationship, geographic proximity, similar political systems 
based on Islamic beliefs, joint destiny and common objectives (Figure 1.5). The GCC States 
are located in the Arabian Peninsula southwest of Asia, bordered by Iraq and Jordan in the 
North, the Republic of Yemen and the Arabian Sea in the South, the Arabian Gulf in the East, 
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and the Red Sea in the West. The total population of the six member states is 44,223,488 
inhabitants in a total area of 2,572,954 square kilometres. Yemen is currently in negotiations 
for GCC membership and hopes to join by 2016. The GCC has already approved Yemen‟s 
accession to some areas such as the GCC Council of Health Ministers and the GCC Council 
of Labour and Social Affairs Ministers. The demographic characteristics of the GCC are 
shown in the table 1.1.                                                             
Figure 1.5 Map of the Seven Gulf Cooperation Council (GCC) States 
 
GCC Drug Regulatory Authorities  
 
The GCC authorities official names are as follows, Bahrain National Health Regulatory 
Authority; Kuwait Drug and Food Control; The Directorate General of Pharmaceutical 
Affairs & Drug Control Oman; The Pharmacy & Drug Control Department Qatar, Saudi 
Food & Drug Authority; The Registration & Drug Control Department UAE; and the 
Supreme Board of Drugs & Medical Appliances Yemen. These seven authorities form the 
membership of the GCC Centralised Procedure system (GCC-CP). Five authorities are under 
their respective Health Ministries and fully funded by their respective governments. Saudi 
Arabia and Yemen, however, are independent stand-alone authorities that rely on registration 
fees as the major source of their funding. 
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  Table 1.1 The demographic structure of the Gulf Cooperation Council (GCC) States 
Ref. The Cooperation Council for the Arab States of Gulf  Secretariat General, Statistical  Bulletin, Information Sector, Statistical 
Department (Volume Twenty, 2012).              
The seven GCC authorities regulate pharmaceutical products for human use with their main 
activities such as marketing authorisation, post-marketing surveillance and quality control of 
pharmaceutical and health products (Al-Essa, 2011). They also have a variety of other 
responsibilities depending on the size and resources available for each regulatory authority 
(Table 1.2). 
 
Evolution of GCC-DR 
 
The harmonisation of regulatory processes in the GCC States was initiated following the 
consent of the GCC Health Ministers‟ Council Decree No. 8 in 1976 regarding the formation 
of a study group to report on how a centralised registration system should be set up to 
monitor medicines and establish common guidelines for the participating authorities (Hashan, 
2005). In 1997, the State of Bahrain submitted a proposal for the formation of a Central 
Committee of Gulf States to register pharmaceutical companies and their products to ensure 
basic standards for the manufacture of good quality medicines and also to unify the 
regulations relating to export of medicines from the Council States.  
Country Area / sq 
Km 
Population Median 
age (years) 
Life expectancy 
at birth (years) 
GDP ($) GDP per 
capita ($) 
Bahrain 760 1,234,571 30.4 75.4 28.27 billion 17763 
Kuwait 17,818 2,672,926 26.4 77.89 137.7 billion 46509 
Oman 309,500 2,773,479 23.9 73.97 72.78 billion 21355 
Qatar 11,586 1,715,010 30.8 75.51 100.8 billion 74839 
Saudi 
Arabia 
2,149,690 27,563,432 24.9 73.87 590.9 billion 16355 
UAE 83,600 8,264,070 30.2 76.32 191.9 billion 36017 
Yemen 527,968 23,495,361 17.9 63.36 57.95billion 2,500 
Total 3,100,922 67,718,849 - - - - 
Average - - 26.4 73.76 168.47 30,762.57 
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Table 1.2 The structure, responsibilities and scope of activities within each of the seven GCC regulatory authorities* 
     *Adopted from Al-Essa, 2011 
Country Bahrain Kuwait Oman Qatar Saudi Arabia UAE Yemen 
Name of Authority National Health 
Regulatory 
Authority 
Kuwait Drug and 
Food Control 
The Directorate 
General of 
Pharmaceutical 
Affairs & Drug 
Control  
The Pharmacy & 
Drug Control 
Department 
Saudi Food & 
Drug Authority 
The Registration 
& Drug Control 
Department 
Supreme Board of 
Drugs & Medical 
Appliances 
Independent stand-alone authority X X X X √ X √ 
Budget / GBP NA 2million NA NA 85million 1.6million 2million 
Fees / GBP 9 230 130 None >5000 NA 470 
Scope of 
registration 
responsibilities 
Medicines for 
human use 
√ √ √ √ √ √ √ 
Veterinary 
medicines 
X √ X X √ √ √ 
Medical devices 
and in-vitro 
diagnostics 
√ √ √ √ √ √ X 
Cosmetic 
products 
X √ X X X X X 
Food 
supplements 
X √ X X X X X 
Herbal medicines X √ X X X X X 
Scope of 
activities 
Marketing 
authorisation 
√ √ √ √ √ √ √ 
Post-marketing 
surveillance 
√ √ √ √ √ √ √ 
Sample analysis √ √ √ √ √ √ √ 
Advertising 
control 
X √ √ X √ √ X 
Price regulation √ √ √ √ √ √ √ 
GMP inspection  √ √ X √ X X 
Clinical trial 
authorisation 
√ X X X √ √ X 
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The Gulf Central Committee for Drug Registration (GCC-DR) was formed in May 1999 and 
includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE, and Yemen. The GCC Drug 
Registration Committee, composed of two members from each of the seven countries, advanced 
in three stages. In September 2005, an  intra-GCC Free Trade Area Agreement, came into effect 
by which all GCC national products including pharmaceuticals were exempted from custom 
duties within the GCC and any single consignment of foreign goods were charged import duty 
only at the port of entry into the GCC area. The formation of effective networks among national 
regulatory authorities participating in various harmonisation initiatives has several advantages. It 
facilitates the sharing of limited resources; eliminates duplication of activities; saves capital 
expenditure for all; supports cooperation and collaboration and international understanding; 
facilitates the building of an efficient regulatory capacity; and enhances public trust in the 
regulatory efforts (Jamel, 1998). The first stage of this initiative was a two year period during 
which all pharmaceutical and research-based companies in the Gulf region were registered; in 
the second stage the GCC-DR systems were evaluated and generic medicines from local 
manufacturers registered and the third stage involved the appraisal and registration of all 
complementary pharmaceutical products such as cosmetics and herbal compounds. 
 
The Ministers of Health in 1999 agreed the two-phase proposal submitted by the Executive 
Office of the GCC Ministers of Health for Central Registry and approved the registry 
regulations. During phase one (1999-2001) new pharmaceutical products were assigned to 
register with both the local authority and the new Central Registration authority and included the 
registration of pharmaceutical companies. This also applied to new chemical entities and 
biological products. Phase two of this process started in 2002, mainly targeted to assess the 
whole system of the registration process and the inspection of pharmaceutical manufacturing 
plants. In fact, it was recognised that if the knowledge and experience of different authorities are 
shared for a specific task or responsibility, the best practice from each system could be combined 
for the advantage of all member states. 
 
Since the GCC States constitute one regional community in its religion, language, population, 
similarity in geography, values, history, traditions, economic resources, social and cultural 
circumstances, they had to unify their efforts in different fields of life to face the rapid changes 
and the overall development requirements. The procurement of safe and effective pharmaceutical 
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products, hospital sundries and equipment of high quality at appropriate prices are organised 
through a central group purchasing program. Furthermore, the mission of GCC–DR is to 
establish a unified Gulf Drug Registration System that ensures effectiveness, safety and quality 
of medications as well as good manufacturing practices (GMP) according to  international 
standards and post marketing surveillance after registration. The GCC-DR also emphasizes the 
use of highly effective and safe medications to protect public health in the Gulf Countries. The 
government control over medicines has grown in the last hundred years and now 
pharmaceuticals are among the most-regulated products in the world. At present, about 20% of 
countries have fully operational medicines regulations, 30% have either none or very limited 
drug regulation and a few have regulations of varying capacity (WHO 2006). In reality, many 
developing countries cannot ensure the safety, efficacy and quality of medicines available in 
their markets because they are resource constrained in terms of staffing, standard systems and 
training (WHO, 2008). However, the globalisation of pharmaceutical markets and production has 
also increased the spread and prevalence of unsafe medicines.  
 
Protection of public health is the primary aim of any drug regulatory authority and is the 
foundation of any country‟s national drug policy that ensures a viable pharmaceutical industry as 
well as a high standard drug approval process.  However, regulation is perceived as an obstacle 
to the availability of medicines in national or regional markets and has placed a significant 
demand on regulators to accelerate reviews and evaluations to approve new medicines in the 
shortest possible time (Hill, 2004) 
 
The study by Hashan (2005) emphasized the differences between authorities in the GCC States in 
the areas which include structures, procedures, available resources, measures of quality & 
performance, degree of harmonisation within and between processes and approval times. The 
study provided a comprehensive understanding of the medicine regulatory processes in the Gulf 
States. It also elaborated the need for greater standardisation in requirements, performance, 
procedures and guidelines in the Gulf and other Arab countries which may lead to one regulatory 
body in the Gulf region.  
 
The study by Al-Essa (2011) demonstrated the added value of the a harmonised strategic 
planning process in the GCC region. This research explored the differences in the Gulf States 
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which included structures, procedures, resources, quality measures and strategic parameters 
which facilitate an effective drug approval process for pharmaceutical companies in the GCC 
region. 
  
The quality of the review in the GCC 
 
The regulatory review process consists of the scientific evaluation of all data generated during 
product development which are described in the registration dossier and when data are 
considered satisfactory a marketing approval is granted. The key advantage of the centralised 
system in the Gulf is the availability of external expertise to complement the internal evaluators. 
This enhances the quality of the reports and more information is focused on the registration to 
ensure that product evaluation is carried out according to the required standards. In this manner, 
the quality of the product registration is assured across the GCC States. 
 
Apart from obtaining an improved scientific evaluation from more than one state following an 
evaluation of the application dossiers, the CP allows further scope for the exchange of 
knowledge, ideas and experiences among the National Drug Regulatory Authorities in the GCC. 
This results in better coordination and quality reviews within the GCC.  
The scientific evidence developed by a pharmaceutical company is evaluated to ensure that the 
product can be made available for use or prescribed to patients. Regulators must balance between 
the speed of access of the medicine to patients and ensuring that its benefits outweigh any risks. 
According to Dureja el al (2010) a well-funded, consistent, robust and transparent regulatory 
review system is indispensable to protect the public health and build confidence in the marketed 
medicines. Gradual strengthening of the regulatory authorities in the GCC region is fundamental 
so that they have the expertise and tools for evaluating new medicines efficiently. Also it is very 
important to analyse and scrutinise the differences and uniformity among the regulatory review 
processes carried out in all the GCC authorities.  
 
Mallia-Milanes et al (2010) reported on the influence of the type of assessment carried out by 
different authorities which may affect the regulatory approval times. The study pointed out the 
existence of three types of review process offered for  pharmaceuticals in Singapore which 
includes full, abridged and verification reviews.  
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A full review relates to products that have not yet received approval elsewhere and takes around 
270 working days in Singapore to be completed and supported by external reviewers. The 
abridged review usually takes 180 working days, which is  used for applications that  have been 
approved by a recognized regulatory authority, (eg. US FDA, EMA, TGA, etc), before 
submission in Singapore. The verification review can be effected if the medicine has been 
approved by at least two benchmark authorities and takes a minimum of 120 working days.  
 
McAuslane and Walker (2007) reported in a study of ten agencies, that Argentina alone utilizes 
the verification review system for pharmaceuticals and biologicals while Mexico, Egypt, Saudi 
Arabia, Malaysia and Singapore make use of the abridged assessment for most of their 
applications. Walker et al., (2005a, 2005b and 2005c) stressed the significance of the pattern of 
the review process carried out by the regulatory authorities for pharmaceuticals in a timely 
manner.  
The primary issue to be addressed is the understanding of the type of model being used to carry 
out dossier assessment in each GCC country and to quantify the extent of the scientific review 
approved in each member state. Karlton et al (1997) pointed out the importance of the quality of 
the dossiers in the realisation of rapid regulatory reviews and approval of new applications.  
Mediocre documents complicate the review process and may impact negatively upon the 
confidence in quality of the medicinal product and its manufacturer (Zellerhoff, 2001). It is the 
duty of the manufacturing companies to submit high quality dossiers for improving the 
efficiency of the approval process. Valuable capacity development and an effective application 
tracking system, assessment and decision-making, appropriate use of information technology, 
effective working, accountability and transparency of the medicine registration related decisions 
finally result in the overall competence of a unified registration process.  
 
 
Global drug development and its influence on the regulatory environment in   
the Gulf Region 
 
The World Trade Organisation (WTO) established a global patent protection act named  TRIPS 
(Trade-Related Aspects of Intellectual Property Rights) (WHO, 2003a)  in regards to New 
Chemical Entities (NCEs) in 1994. Patents can relate directly to active ingredients, formulations, 
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pharmaceutical salts, isomers, polymorphs, combinations, manufacturing processes and also the 
patent holder has the complete freedom to set the price. The seven Gulf States, with the 
exception of Yemen, recognised the TRIPS agreements. However, the TRIPS agreement 
eventually results in a  price increase for  new medicinal products which is unaffordable to most 
people living in developing countries (WHO, 1999,2004).  
 
The world pharmaceutical market in 2014 is estimated to be around one thousand billon US$. 
The Middle East and North Africa (MENA) in 2007 comprise around 2% of the global 
pharmaceutical market, with an average annual growth of 10.4%, the Arab market (22 Arab 
countries) comprises 1.5%, valued at around US$6.2 billion, of which the largest market is the 
Saudi Arabia, valued at around US$1.2 billion (Veronica, 2011; Nixon et al, 2013). The 
increasing number of conferences and studies on the central drug registration process reflects the 
need for greater harmonisation in medicine regulation within the Middle East and it is with this 
background that this research was initiated. 
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AIM AND OBJECTIVES OF THE STUDY                              
 
Aim 
 
The aim of this study is to evaluate the GCC centralised procedure and the approval times since 
it inception in 1999 to 2010. 
Objectives 
 Evaluate the regulatory review process in Oman and identify the milestones and timelines 
(2006-2010) 
 
 Identify the strengths and weaknesses of the Oman regulatory review process and propose 
strategies for improvement. 
 
 Determine the similarities and differences in the regulatory reviews in each of the seven GCC 
states together with the characteristics of the review process.           
 Examine the trends in the submission, registration and the associated approval timelines for 
patients‟ access to medicines in the GCC states. 
 
 Appraise the GCC central registration regulatory review process.  
 
 Examine the views and experiences of the GCC states and the pharmaceutical companies 
with respect to the GCC registration procedure. 
 
 Identify the strengths and weaknesses of the centralised review process and propose 
strategies for improvement 
 
 Develop a new model for the GCC-DR based on the evaluation and outcome of the 
centralised procedure since its inception.  
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RATIONALE OF THE STUDY  
  
The decision to centralise Drug registration within the GCC was a political one. Many were 
skeptical as to whether such centralisation would improve the time line in registering new 
medicines and thus facilitate earlier availability of new drugs to the population. Furthermore, 
individual countries were experienced in registration processes and believed that they were 
efficient enough. A number of such officials indicated that the individual countries were being 
deprived of their sovereignty and equality, they were therefore skeptical about the success of 
such initiative. Pharmaceutical companies were also doubtful about the GCC-DR system as to 
whether it would improve the review process and the approval timelines in the GCC region. 
 
Many countries had adopted joint drug registration procedures and it is assumed that the process 
works and delivers efficiency. As it is now more than 10 years (1999) since the centralised drug 
registration system was established in the GCC, it was timely for an assessment of the GCC-DR 
timelines and the number of registered products to be evaluated. In addition it was decided to 
conduct a comparative study between the GCC-DR and the national approval timelines to 
complete the picture for both the individual authorities and the pharmaceutical companies. 
 
It is intended to conduct studies involving the major stakeholders in the registration process. 
Current officials responsible for registration in the respective country, pharmaceutical 
manufacturers and those within the GCC-DR secretariat will be requested to participate in these 
studies. The questionnaire technique will be used for data collection to determine the success and 
impediment to the intended progress of the GCC-DR. 
 
In the light of the GCC Central Drug Registration system, the seven regulatory authorities have 
had a long experience in joining their efforts to centrally register pharmaceutical products in the 
Gulf region. They were apprehensive about the possibility of changing their entire procedures 
and practices. 
 
These concerns led to the conceptualisation of this study in order to examine the views of the 
seven GCC authorities about the current status of the GCC-DR system and its impact on their 
individual processes.  Also the current research has focused on evaluating the pharmaceutical 
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industry‟s views about the advantages and disadvantages of the GCC-DR system and how this 
has impacted the speed of marketing authorisation for their products in each Gulf State. 
  
METHODOLOGICAL FRAMEWORK 
Development of the Study design  
The present study employs the principles of quantitative, exploratory and constructive research 
methodologies with the primary aim of evaluating the GCC central drug registration procedure.  
 
Background and review of the Study design 
 
The Quantitative data collection methods rely on random sampling and structured data collection 
instruments that fit diverse experiences into programmed response categories. These methods 
produce results that are easy to summarise, compare, and generalise. Depending on the research 
questions, participants may be randomly assigned to different treatments and data collected on 
participants relevant to the outcome being measured. (Kidder et al,1987).  
 
A cross sectional design will be adopted for data collection to gather specific data pertaining to 
all the seven Gulf States at different phases of the study.  There are several advantages of the 
cross-sectional design, such as requiring less resources and being able to collect a large volume 
of data in the shortest possible time. The questionnaires, as assessment tools are important 
aspects of any research of such nature and usually reflect the perception of individual members 
of the target population about a particular issue. Furthermore, questionnaires techniques are used 
in studies to elicit reports of facts, attitudes, and other subjective states. A questionnaire is 
usually composed of a set of questions, answered by potential clients or the target population. 
The results can be presented as a table or a graph. A well-structured study using questionnaire 
techniques includes a clear and comprehensive statement of the study goals, data requirements, 
and the analysis plan (Dillman & Don et al, 1978; Bradburn et al, 1982). 
 
 Several different types of studies are utilized depending on the approach used and the overall 
study objectives expected. A one-off data collection is selected for the present study which can 
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also impart the advantages of baseline and comparative assessment points (Salant et al, 1994; 
Anon, 2000; Passmore et al, 2002). 
Th e  ma jo r  s t reng th s  and  w ea kn ess e s  o f  questionnaire techniques are as follows: 
S t reng th s  
1. Are particularly useful in describing the characteristics of a large population. 
2. Can be self-administered making it feasible to recruit large samples.  
3. Are flexible and the least costly method of data collection. 
4. Results can be generalised. 
 W eakn es s es  
1. Often appear superficial in their coverage of complex topics. 
2. There is no way of telling how much thought a respondent has put in to the responses. 
3. There is no way to tell how truthful a respondent is being. 
4. Lacks validity. 
5. People may read differently into each question and therefore reply based on their own 
interpretation of the question.  
6. Questionnaires also invite people to lie and answer the questions very vaguely which they 
would not do in an interview. 
 
Data Collection 
Development of Data Collection Techniques 
In deicing an appropriate data collection technique for this study questionnaires were reviewed 
alongside interviews. The cardinal difference between the two is that the questionnaires can 
produce either quantitative or qualitative data whereas interviews produce qualitative data. The 
attributes and different types of the two techniques are presented here. 
 
Questionnaires 
Questionnaires are usually an inexpensive and efficient method where no special conditions or 
equipment are required. It can also be compiled anywhere and distributed easily and the 
information can be collected from a large group of people in a timely manner. In a questionnaire 
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everyone answers the same questions therefore it can be compared easily. Learning how to 
design and use structured interviews, questionnaires and observation instruments is an important 
skill for researchers. Interviews have certain advantages over self-completion questionnaires. 
The interviewer can explain questions that the respondent has not understood and can ask for 
further elaboration of replies. However, interviews are more time consuming and it may also be 
open to interviewer bias, where the interviewer influences the replies by revealing their own 
opinions. Such biases can be avoided by using self-completion questionnaires. 
 
Interviews  
The interview is a more flexible form than the questionnaire technique and, if wisely used, can 
generally be employed to gather information of greater depth and be more sensitive to contextual 
variations in meaning. Interviews, however, can be non-scheduled, though still partly 
standardised. This is sometimes called a semi-structured interview. Here, the interviewer works 
from a list of topics (checklist) that need to be covered with each respondent, but the order and 
exact wording of questions is not important. Generally, such interviews gather qualitative data, 
although this can be coded into categories to be made amenable to statistical analysis. 
 
The main advantages of the interview technique include (McNamara, 1999; Bourque and 
Fielder, 2003a): 
 The presence of an interviewer allows for complex questions to be explained, if 
necessary, to the interviewee. 
 Interviews can generally be longer than when self-completion techniques are used as 
interviewees are less likely to be put off by the length or to give up halfway through. 
 There is more scope to ask open questions since respondents do not have to write in their 
answer and the interviewer can pick up on non-verbal clues that indicate what is relevant 
to the interviewees and how they are responding to different questions. 
 Visual aids can also be used in the face-to-face situation. 
 
The major limitations of the face to face interview are discussed below. 
The cost associated with face-to-face interviews can limit the size and geographical coverage of 
the study. Interviewers can introduce bias, which will affect the reliability of responses. Such 
bias might emerge from the way in which questions are asked, or in the personal characteristics 
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of the interviewer, or in respondents‟ wish to give socially desirable responses. For instance, 
there tends to be an over-reporting of voting activity and of participation in voluntary activities 
in data gathered through interviews. 
 
The studies using self-completion questionnaires have some distinct advantages over face-to-
face interviews:  
They are inexpensive to administer. The only costs are those associated with printing or 
designing the questionnaires, their postage or electronic distribution.  
They allow for a greater geographical coverage than face-to-face interviews without incurring 
the additional costs of time and travel. Thus, they are particularly useful when carrying out 
research with geographically dispersed populations. Using self-completion questionnaires 
reduces biasing error caused by the characteristics of the interviewer and the variability in 
interviewers‟ skills. The absence of an interviewer provides greater anonymity for the 
respondent. When the topic of the research is sensitive or personal it can increase the reliability 
of responses. 
 
Telephone interviews 
Telephone interviews using interview schedules are becoming increasingly efficient with 
sophisticated developments in computer technology. Computer assisted telephone interviewing 
(CATI) systems are available and these provide clear instructions for the interviewer, display the 
interview schedule and allow electronic recording of responses as they are given. This omits the 
data entry part of the research because responses are recorded directly onto the computer. 
 
The major advantages associated with telephone interviews are as follows: 
 The researcher does not have to travel; interviews can take place over a wider 
geographical area. 
 There are fewer interviewer effects ie. The personal characteristics of the researcher will 
be less obvious than in face-to face situations and is therefore less intrusive. 
  The physical safety of the interviewer is not an issue. 
 Telephone interviews are subject to greater levels of monitoring because supervisors can 
unobtrusively listen in to interviews to ensure that they are carried out correctly 
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Different Types of Questionnaire Techniques Used in Data Collection  
 Several methods are available for collecting data using the questionnaire technique and also 
depend on many factors for selecting the most appropriate method. These include the type and 
size of population being studied, timelines, budget, resources and purpose of the study (Diem, 
2002a).  
Paper or electronic mail-delivered  
This method utilizes minimum resources to prepare; enables privacy of responses and it is 
relatively inexpensive or free of charge, still it may take time and requires follow-up to obtain 
representative responses. 
 
Group-administered 
This approach involves gathering a group of responders together administering the 
questionnaires and asking the group to complete them individually.  
The method ensures a high response rate from those who receive the questionnaire and enables a 
full explanation of the study with the opportunity for questioning. The disadvantages of this 
method are the limited time availability for the responders to formulate their answers and the 
slow turnaround time. (Trochim, 2006). 
 
Telephone-administered  
This method utilizes pre-arranged telephone calls with the study participants and by recording 
the calls; the investigator can generate a digital data base with the interview texts. The time 
zones and languages among respondents may be a hurdle of this method leading to no contacts 
(Diem, 2002a; Trochim, 2006). It may also be possible to utilize an automated system where the 
study participants record their responses via a touch-tone telephone to a computer-based 
interview system. Text messages, to remind the respondents, together with cell phone facility 
may be utilised in this method. 
Web-based method 
In this method, the questionnaires may be displayed and posted on a web site which is to be 
completed by respondents in a fixed time period remotely. Web-based methods enable a quick 
and easy response and are inexpensive (Diem, 2002b; Bourque et al, 2003a ). 
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Data Source 
Information will be sought from the seven regulatory authorities who are members of the Gulf 
Cooperation Council (GCC) States (Table 2.1). 
Table 2.1 Data source for the seven Gulf authorities 
 
 
Inclusion Criteria  
 
For the Oman study and the evaluation of the review process and timeline in the individual GCC 
countries, all products from local, Gulf, Arab non-Gulf and international manufacturers, which 
have been approved for human use between 2006 and 2010 and 2008-2010 respectively, will be 
included. This includes: New Active Substances (NASs) and Existing Active Substances (EASs). 
The products which have complete date information e.g. submission date, regulatory evaluation 
time, companies‟ response time to the regulatory queries and approval dates will be included in 
the total approval time. In the GCC Centralised Procedure and GCC States studies, all products 
from local, Gulf, Arab not-Gulf and international manufacturers approved for human use 
between 2008 and 2010 will be included.  
 
Position Agency Country 
Director, Pharmacy & Drug Control Ministry of Health Bahrain 
Drug Registration and Release Superintendent Drug and Food Control - 
Ministry of Health 
Kuwait 
Director General of Pharmaceutical Affairs & 
Drug Control 
Directorate General of 
Pharmaceutical Affairs and 
Drug Control- Ministry of 
Health 
Oman 
Head of Drug Registration Section  Drug Control Department- 
Supreme Council of Health 
Qatar 
Executive Director of Licensing Department - 
Drug Sector 
Saudi Food and Drug 
Authority 
Kingdom of Saudi 
Arabia (KSA) 
Head of Registration and Pricing Department 
 
Drug Control Department - 
Ministry of Health 
UAE 
Member of the board council Supreme board of drugs and 
medical appliances 
Yemen 
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The opinions and suggestions of all the seven GCC states from the respective regulatory 
authorities as well as the pharmaceutical companies on their experiences with GCC central 
registration procedure will be collected by means of questionnaires. 
 
Exclusion Criteria 
 
Products which have incomplete data such as missing submission date or approval date will be 
excluded from the final analysis. 
 
Data Collection Procedure 
 
Confidential procedures will be used for all parts of the study. All the collected data may be 
aggregated to avoid identification of individual responders. The electronic or interviewer 
delivered questionnaires will be used to collect data which may allow the confidentiality and/or 
anonymity of the procedure ((Crow and Wiles, 2008). A questionnaire is useful when there is a 
need to collect information from the study participants in a reasonable time period. It is a 
structured technique for collecting primary data in a study using a series of structured questions 
for which the respondent provides answers. (Diem, 2002b) 
 
Data Collection Monitoring and Timeline 
A face-to-face meeting will take place to follow-up the data to be obtained from the Oman drug 
authority and to closely observe the regulatory review processes and the approval timelines in 
Oman. In addition, a face-to-face meeting with all the Directors and General Directors of 
Regulatory Affairs in the Ministry of Health in the GCC States will take place during the GCC-
DR committee meetings. All the participants will be asked to provide the registration data for 
products approved in 2008, 2009 and 2010 based on the milestones in each authority.  
Clarification (validation) regarding the data set will be obtained from the GCC authorities 
through telephonic conferences and electronic mails.                                                                        
The comparisons of the Gulf States and pharmaceutical companies' perspective on the 
effectiveness of the GCC centralized procedure require telephone-interview and email delivered 
questionnaire in order to:                                                                                                                 
 Identify the similarities and differences between the experiences of regulatory authorities 
and pharmaceutical companies with the Gulf Centralised Procedures 
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 Provide recommendations to improve the Gulf Centralised Registration Procedure   
 Propose the strategies to maximise the benefits of a centralised registration system 
 Collect feedback about the GCC centralized procedure questionnaire from the GCC 
regulatory authorities and pharmaceutical companies. Attempts will be made to clarify 
areas of the questionnaire which maybe unclear to the participants 
 
Development of Questionnaires  
There are different types of self-completed questionnaires such as mail-delivered, web-based or 
email-delivered. The email-delivered and web-based questionnaires will be adopted for this 
study . Following a series of consultations with experts and key regulators, it will be possible to 
test the applicability of the questions to evaluate views and experiences of the Gulf States with 
respect to the Centralised Procedure by conducting a pilot study involving two randomly selected 
GCC authorities.  
 
Another questionnaire will be developed to evaluate the experiences and views of 
pharmaceutical companies with respect to the central registration review process. A pilot study 
will be conducted involving five pharmaceutical companies (two innovative and three generic) to 
examine the practicality and applicability of the industry questionnaire. 
 
Chapters three, four, five, six, seven and eight will aim to provide evidence to establish 
consensus opinions on topics that do not have adequate information currently available. The 
studies in these chapters will focus on the collection of both qualitative and quantitative 
information. In situations where there is a need to define levels of agreement on controversial 
subjects but there is no unanimity of opinion because little evidence exists or available evidence 
is contradictory, consensus methods can be used.  These methods attempt to assess the extent of 
agreement (consensus measurement) and resolve disagreement (consensus development) (Jones 
et al., 2000).  
 
The most commonly used consensus methods are the Delphi process, the nominal group 
technique (also known as the expert panel) and the consensus development conference. The aim 
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of consensus methods is to determine the extent to which experts agree about a given issue (Jones 
et al., 1995). The features of consensus methods are described in table 2.2.  
 
Table 2.2 Features of Consensus Methods (Jones and Hunter, 1995) 
Anonymity To avoid  dominance; achieved by use of a questionnaire in Delphi 
and private  ranking in nominal group 
Iteration Processes occur in "rounds", allowing individuals to change their 
opinions 
Controlled feedback Showing the distribution of the group's response (indicating to each 
individual their own previous response in Delphi) 
Statistical group response Expressing judgement using summary measures of the full group 
response, giving more information that just a consensus statement 
 
 
Consensus Development Conference (CDC) method 
Consensus Development Conference is a formal method developed by the US National Institutes 
of Health in 1977, for gaining feedback facilitated through face-to-face contact. A key feature of 
this method is the appointment of a carefully selected panel of people thought to be without 
vested interest, to listen to the evidence presented at a CDC meeting and prepare a report on the 
topic under discussion with recommendations (Fink et al, 1984). 
 
Nominal Group Technique 
The nominal group technique (NGT) is a group problem solving process involving problem 
identification, solution generation and decision-making. The NGT is a structured method for 
group brainstorming that encourages contributions from everyone.  
 
This approach was developed in the USA in the 1960s which includes a highly structured 
meeting organized to collect information from appropriate experts about a given topic or issue. It 
involves two rounds in which panelists rate, discuss and then re-rate a series of items or 
questions. This technique is most commonly used in healthcare to examine the appropriateness 
of clinical interventions and has some features in common with focus groups (Jones et al, 2000). 
This method focuses on a single goal, e.g. the definition of criteria to assess the appropriateness 
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of a gene therapy intervention, rather than eliciting a range of ideas and it will therefore not be 
appropriate for the studies considered for this thesis. 
 
Delphi approach  
 
It is a forecasting method based on the results of questionnaires sent to a panel of experts. 
Several rounds of questionnaires are sent out, and the anonymous responses are aggregated and 
shared with the group after each round. The experts are allowed to adjust their answers in 
subsequent rounds.  
 
Because multiple rounds of questions are asked and each member of the panel is told what the 
group thinks as a whole, the Delphi Method seeks to reach the "correct" response through 
consensus. The Delphi technique was developed in the 1950s by RAND Corporation in Santa 
Monica, California (a non-profit institution that helps improve policy and decision-making 
through research and analysis) (Kaplan et al., 1950; Woudenberg, 1991). Since then the method 
has been adopted and interpreted widely in health services research (Mead et al, 2001) to obtain 
judgement from expert panels by systematically collecting and aggregating informed opinions 
from a group on specific issues. 
  
The Delphi method seeks to aggregate opinions from a diverse set of experts, and can be done 
without having to bring everyone together for a physical meeting. This anonymity promotes a 
sense of freedom to express opinions without negative repercussion (Annells et al, 2003). The 
Panel members are encouraged to revise previous responses in subsequent iterations after 
reviewing new information submitted by other experts. 
  
The Delphi approach can be a quick, inexpensive and a relatively efficient way of combining the 
knowledge and abilities of an expert group on a particular issue. It is viewed as a useful 
communication tool for generating debate as opposed to reaching conclusions. For the purpose 
of this study, the essence of the Delphi approach will be used to develop consensus of opinions 
in each of the previously defined topic areas as well as to collect information that can be used as 
scientific evidence (Figure 2.1). It is, therefore, imperative that detailed information be given 
about the proposed method of data collection and if questionnaires are used, their development 
should be described. Having defined the key problem in each of the research areas and identified 
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the appropriate individuals from regulatory authorities in the area, a pilot study will be conducted 
in the first round. Comments from the experts will then be incorporated and used to refine the 
questionnaire that will be mailed to all participants. Then the results from the questionnaire will 
be aggregated and analyzed before being reported back to participants.      
 
Figure 2.1 Adoption of the Delphi Approach to be used in this study (Mead et al., 2001) 
 
 
 
                                                                                
 
 
 
 
 
 
 
Development of the Study Plan 
A comprehensive review and critical analysis of the literature reported in chapter one, 
demonstrated a significant gap in the area of the drug regulatory process for the Gulf countries 
(i.e. Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE and Yemen) and the GCC Centralised 
Procedure. In order to close this gap and improve the regulatory performance, it is vital to 
understand the regulatory review practices and evaluate the Gulf States and pharmaceutical 
companies' views and experiences with GCC Centralised Procedure to achieve an effective and 
improved Gulf Centralised regulatory system. Therefore, the following study plan was developed 
to capture data on the regulatory environment in the Gulf. These were then subjected to a 
significant scrutiny to fulfill the objectives of the study.                                                                                       
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The research project will consist of six smaller studies each forming a thesis chapter that 
explores the core concepts of GCC drug regulatory field, namely, 
 
 Evaluation of Oman Pharmaceutical Regulatory Review Process (Chapter three) 
 Evaluation of the Regulatory Review Times in the GCC States (Chapter four) 
 A comparative study of the centralised regulatory review processes in the seven 
GCC States. (Chapter five) 
 An Evaluation of the Gulf States Views and Experiences with GCC Centralised 
Procedure. (Chapter six) 
 An Evaluation of the Pharmaceutical Companies Experiences with the GCC 
Centralised Procedure. (Chapter seven)  
 The Gulf Centralised Procedure- A Comparison between the Experiences of 
Regulatory Authorities and Pharmaceutical Companies (Chapter eight)  
 
The outcomes of the research will be combined to derive the major areas that require further 
improvement to achieve a standardized and efficient regulatory review process for the GCC 
centralised system. The following methods will be employed to collect the required data: 
1. To obtain a list of the key regulatory personnel in each drug regulatory authority in the 
GCC region. 
2. A review of the literature and/publications on the subject of regulatory review process in 
the GCC States their centralised system. 
3. To consult with regulatory experts and senior managers in the GCC regulatory 
authorities.  
4. To develop two questionnaires with which to evaluate the Gulf States and pharmaceutical 
companies' views and experiences with GCC Centralised Procedure.  
5. To produce two reports as a result of the assessment of the GCC centralised regulatory 
review process and the Comparison between the experiences of regulatory authorities and 
pharmaceutical companies with the GCC Centralised Procedure. 
6. The reports will form the basis of the relevant chapters in this thesis. 
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Development of the Study Instruments 
The sequence of events to be carried out to achieve the aim of the study will start with an 
evaluation of the regulatory approval timelines in Oman. This is a lengthy process which 
involves collecting data on the registration dates for 2006, 2007, 2008, 2009 and 2010 from the 
saved documents in the Oman MOH archives. 
During the course of collecting data on the approval timelines in Oman, two questionnaires to 
examine the views and experiences of the Gulf Cooperation Council states and pharmaceutical 
companies, with respect to the Gulf central registration procedure will be prepared. The first 
questionnaire is planned to be distributed among the seven regulatory authorities in the GCC 
states and the second is intended for completion by pharmaceutical companies, already registered 
or yet to register their products through GCC centralised registration procedure. A pilot study is 
planned to be carried out by coordinating two GCC states and five pharmaceutical companies to 
assess the practicality, feasibility, applicability and relevance of the study instrument for 
assessing the Gulf Centralised Procedure.  
 The review times for New Active Substances (NASs) and Existing Active Substances (EASs) 
submitted to the GCC Centralised Registration will be obtained directly from the Executive 
Board of the Health Ministers Council for GCC States. Since the GCC registration office do not 
maintain a robust and complete electronic system of data capture, the data collection will have to 
be carried out manually.  
 
Psychometric evaluation of the survey questionnaires 
 
Evaluation process  
Questionnaires should undergo evaluation of their psychometric properties before they are relied 
on for making decisions. Psychometric validation is used in various fields including education, 
psychology, and health research to define the properties of the scales which are included in such 
questionnaires. Psychometric principles such as applicability and acceptability, validity, 
reliability, consistency and responsiveness are considered in the present study (Mallia-Melanes, 
2010). 
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Applicability and acceptability for use  
Usually the applicability of a study instrument (Stewart, et al 1990) guarantees the 
appropriateness of its content to the purpose of the research being conducted. Furthermore, 
applicability describes the suitability of an instrument for its intended use in terms of wording, 
clarity and simplicity of language (Higginson and Carr, 2001). The willingness to respond to the 
questions by the study participants is another critical aspect in the acceptability of the study 
instrument. It also considers the time required from the participants to complete the 
questionnaire and whether the questions are clear, concise and easy to understand (McLeod et al, 
2008). 
Practicality 
Practicality issues include the participant‟s comfort, cost and mode of administration of the study 
instrument (e.g. interviews or self-administered), convenience and ease of understanding of the 
questions (Ware et al, 1980a, 1981). The participants‟ lack of engagement can result in a low 
response rate, and high refusal rate, missing responses and longer administration time. 
 
Validity 
According to Kaiser and Smith (2001) validity is the most fundamental consideration in 
developing and evaluating tests. The most commonly used validity methods for assessing study 
instrument are content (face) validity and criterion validity. The concept refers to the degree to 
which evidence and theory support the interpretations of test scores demanded by proposed uses 
of tests". Ultimately the concept of validity measures what the method claims to measure and 
investigate sensitive issues of such method. 
Content Validity 
This method assesses the extent to which questions in a study serve to encompass the important 
facets of the notion the indicator is supposed to represent in a balanced way. The weighting of 
the results are also reviewed with the set of indicators (Anon, 2001). 
Criterion Validity 
The aim of the criterion validity is to correlate a new indicator with reference to a previously 
well established indicator (Anon, 2001) and assesses how the observed values of the indicator 
compare with another related measure. For example piloting the questionnaires by assessesing 
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the practicality and applicability of questions will ensure that they are clear, feasible and 
unambiguous before using the final version for the main study participants  
 
Construct Validity 
Guyatt et al., (1993) describe this method as the most rigorous approach to establish validity. 
Construct validity examines the logical relationship that exists between a measure and the 
characteristics of the system being studied and also involves comparisons between the measures. 
Sub-types of construct validity include convergent validity (positive correlation with a related 
measure) and discriminate validity (low correlation coefficient) (Mallia-Milanes, 2010 ; Saw, 
2001). 
Reliability 
The consistency and reproducibility of an instrument are the main parameters to be examined for 
testing its reliability (Pinar, 2002, McLeod et al., 2008). This quality of the instrument is always 
demonstrated by using internal consistency and test-retest reliability. 
Sensitivity 
The sensitivity of an instrument lies in its ability to detect small changes in parameters such as 
approval times, milestones, quality measures and strategic goals (Mallia-Milanes, 2010; 
Higginson and Carr, 2001 and McLeod et al, 2008). 
 
DATA PROCESSING AND ANALYSIS  
 
Data will be collected using electronic mail, postal mail, fax, interviewer delivered, computer 
assisted telephone interviews and semi-structured interviews. Irrespective of the delivery 
method, data will be entered into Microsoft Excel and developed specifically for each study. 
Data processing and analysis will be carried out using Microsoft excel and the  Statistical 
Product and Service Solutions (SPSS). The sample mean will be used extensively for estimating 
the population means (the 'middle' value), as was the median (the value halfway through the 
ordered data set, below and above which there lies an equal number of data values).Where   
applicable ranges around the median and average will be shown to indicate the spread of the 
data. Scatter plot will be used to summarise data sets that are bivariate in order to give a good   
visual picture of the relationship between the two variables. Box and Whisker plot will be used 
on data sets measured on an interval scale to show the shape of the distribution, the central value 
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and variability. If the data is quantitative, descriptive statistics such as mean, median and range 
will be used and if the data is qualitative, content analysis will be employed to generate themes 
and sub-themes.  
 
Quantitative Content 
Hypothesis testing 
Hypothesis testing refers to the process of choosing between competing hypotheses about a 
probability distribution, based on observed data from the distribution. There are two types of 
statistical hypotheses. 
Null hypothesis: The null hypothesis, denoted by H0, is usually the hypothesis that sample 
observations result purely from chance.  
Alternative hypothesis: The alternative hypothesis, denoted by H1 or Ha, is the hypothesis that 
sample observations are influenced by some non-random cause. 
To perform hypothesis testing a theory needs to be presented that is believed to be true or is to be 
used as a basis for an argument, but has not been proved. An example of a hypothesis could   
 be the claim that a new drug is better than the current drug for treatment of the same symptoms 
(Easton and McColl. 2001).  In each case two contrasting hypotheses are assessed: the null 
hypothesis, denoted by H0 and alternative hypothesis denoted by H1. These two hypotheses are 
not treated on an equal basis as special consideration is given to the null hypothesis. This is due 
to the fact that the null hypothesis relates to the statement being tested, whereas alterative 
hypothesis relates to the statement to be accepted if or when the null hypothesis is rejected 
(Easton and McColl, 2001). Plausible arguments will be generated to test a series of hypotheses 
arising from the aims and objectives of the study.  
Hypothesis testing will be used to: 
 
 Evaluate the approval time in Oman 
 Evaluate the approval time in the GCC Centralised Procedure. 
Evidence will be generated to test a series of hypotheses for each of these studies. 
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Choice of Statistical testing procedures  
A statistical test provides a mechanism for making quantitative decisions about a process or 
processes. The intent is to determine whether there is enough evidence to reject a conjecture or 
hypothesis about the process. Therefore, statistical inferences make use of information from a 
sample to draw conclusions (inferences) about the population from which the sample was taken 
(Easton et al., 2001). The sample mean will be used extensively for estimating the population 
means as will the median. Where applicable, ranges around the median and mean will be shown 
to indicate the spread of the data. Scatter plots will be used to summarise data sets that are 
bivariate (two variables) to give a good visual picture of the relationship between the two 
variables. Box and whisker plots will be used on data sets measured on an interval scale to show 
the shape of the distribution, the central value, and variability. The figure produced consists of 
the most extreme values in the data set (5
th
 and 95
th
 percentile values), the lower and upper 
quartiles (25
th
 and 75
th
 percentile values), and the median. Occasionally, pie charts will be used 
for sets of categorical data, each segment representing a particular category and the area of each 
segment being proportional to the number of cases in that category (Easton et al., 2001). Several 
statistical tests will be used in the present study, depending on the research question asked, the 
distribution of the data and the number and characteristics of the data set. For each analysis, the 
test used will be specified. 
 
Regression  
In statistics, regression analysis is a statistical technique for estimating the relationships among 
variables. It includes many techniques for modeling and analysing several variables, when the 
focus is on the relationship between a dependent variable and one or more independent 
variables.  Regression analysis will be used to express the relationship between two (or more) 
variables algebraically. The regression equation indicates the nature of the relationship between 
two (or more) variables. In particular, it indicates the extent to which some variables can be 
predicted by knowing others, or the extent to which some are associated with others. A linear 
regression equation is usually written as Y = a + bX + e, where „Y‟ is the dependent variable, „a‟ 
is the intercept, „b‟ is the slope or regression coefficient, „X‟ is the independent variable (or 
covariate) and „e‟ is the error term (Easton et al., 2001). 
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Correlation 
Correlation analyses can be used to show the strength of a relationship between two variables. A 
correlation coefficient, statistically referred to as r, is a number between -1 and 1 which measures 
the degree to which two variables are linearly related. If there is a perfect linear relationship with 
a positive slope between the two variables, the correlation coefficient equals +1. There is a 
positive correlation whenever one variable has a high value and so does the other, or vice versa. 
If there is a perfect linear relationship with a negative slope between the two variables, the 
correlation coefficient equals -1. A correlation coefficient of 0 indicates that there is no linear 
relationship between the variables (Easton et al., 2001). 
 
Mann-Whitney U-test 
The Mann-Whitney U-test is a non-parametric test used to test the difference between the 
medians of two independent samples (Crichton, 2000a; Easton et al, 2001),for example males 
and females. 
 
Wilcoxon Signed Rank test 
The Wilcoxon Signed Rank test is a non-parametric test used to test the median difference in 
paired data (related samples). This test is the non-parametric equivalent of the paired t-test 
(Crichton, 2000b; Easton et al., 2001). 
 
Kruskal-Wallis test 
The Kruskal-Wallis one-way analysis of variance (ANOVA) is a nonparametric test used to 
compare three or more independent samples. It is used to test the null hypothesis that all 
populations have identical distribution functions against the alternative hypothesis that at least 
two of the samples differ only with respect to location. The outcome of this test is not conclusive 
as to which of the samples differ. The Kruskal-Wallis test is a logical extension of the Mann-
Whitney U-Test (Easton et al, 2001). 
 
Qualitative Content 
 
The content analysis is a widely used qualitative research technique. Rather than being a single 
method, current applications of content analysis show three distinct approaches: conventional, 
directed, or summative.  All three approaches are used to interpret meaning from the content of 
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text data and, hence, adhere to the naturalistic archetype. Content analysis does not proceed in a 
linear fashion and is more complex and difficult than quantitative analysis because it is less 
standardized and formulaic (Polit &Beck, 2004). Content analysis is a method of analysing 
written, verbal or visual communication messages (Cole, 1988). It is also known as a method of 
analysing documents allowing the researcher to test theoretical issues to enhance understanding 
of the data.  
 
This method also serves for making replicable and valid inferences from data to their context, 
with the purpose of providing knowledge, new insights, a representation of facts and a practical 
guide to action (Krippendorff 1980; Sandelowski, 1995). Miles & Huberman (1994) presents the 
following three parallel flows of activity to explain the analysis. 
 
 Data Reduction: the process of selecting, focusing, simplifying, abstracting and 
transforming the data. The purpose is to organize the data so that the final conclusion can 
be drawn and verified. 
 Data display: taking the reduced data and displaying it in an organized compressed way 
so that the conclusions can be more easily drawn. 
 Conclusion drawing/verification: deciding what things mean, noting regularities, 
patterns, explanations, possible configurations, causl flows, and propositions. 
 
Miles and Huberman (1994) further describe pattern coding as a way to present data for a 
qualitative analysis, pattern coding is important since it reduces large amounts of data into a 
smaller number of analytic units. Codes are tags or labels for assigning units of meaning to the 
descriptive or inferential information compiled during a study. Codes are attached to “lumps” of 
varying size – words, phrases, sentences, or whole paragraphs, connected or unconnected to a 
specific setting‟ . This allows the researcher for a better focused analysis and helps to elaborate a 
cognitive map in order to understand local incidents and interactions. Codes are used to retrieve 
and organize the data which includes descriptive codes, interpretive codes, pattern code etc. 
 
In this study, a set of steps is followed in order to analyze the generated data. The questionnaires 
prepared are decided to be piloted with two GCC regulatory authorities before the 
appropriateness of the final questionnaires is determined. Then they are e- mailed to the targeted 
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key regulators in the rest of the authorities for completion at pre-scheduled dates. The data 
present in the completed questionnaires will then be analysed and reduced where the required 
data is abstracted according to pre-set targeted information in individual GCC regulatory agency. 
Furthermore, the data will be displayed in a report format where the respondent‟s answers will 
be compared to one another in a clear organised manner. At the end the conclusions from the 
analyses will be drawn based on patterns of similarities and dissimilarities which are revealed in 
the data reduction and data display processes.  
SUMMARY 
 The chapter describes the rationale for carrying out the study to evaluate the GCC 
Centralised Procedure for the last ten years since its inception. 
 The various methodologies, techniques and instruments that will be used in analysing the 
data obtained from the seven GCC regulatory authorities and the pharmaceutical 
companies have been described. 
 A detailed description of the developmental technique of the two questionnaires was also 
provided and how the information obtained from these questionnaires are reduced, 
analysed and displayed in an organized manner. 
 Methodological choices related to database management, data processing and data 
analyses were evaluated. 
 The data to be collected from the GCC States revolve around three major areas, namely, 
the regulatory review processes and milestones, the registration timelines and the 
stakeholders views‟ and experiences with GCC Centralised Procedur 
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INTRODUCTION 
 
The regulation of pharmaceuticals is mandated such that the government takes on responsibility 
as the gatekeeper of the public‟s health and safety and it does this by regulating the behaviour of 
the private sector for public purposes (Ratanawijitrasin 2002).  Ensuring the safety, efficacy and 
quality of medicines available to the public is the main aim of drug regulation. If regulatory 
goals are to be achieved, appropriate structures must be established and the activities carried out 
to achieve the desired goals.  
 
Ideally, a government should endeavour to have a drug regulatory authority that is created by 
comprehensive and up-to-date laws, is maintained as a unified but independent organisation, 
contains competent human resources, is free from political and commercial influence, is 
maintained by adequate and sustainable financial resources, is guided by transparent standards 
and procedures, is driven by outcome-oriented implementation and is monitored and evaluated 
systematically (Ratanawijitrasin 2002). 
 
The time required by drug regulatory authorities to approve a new medicine may affect 
healthcare professionals and patients and unnecessarily long approval times delay access to new 
medicines that may improve the health status of patients (Rawson 2000). Oman had the 
advantage of being the last country in the GCC to start adopting the registration system and as a 
result the MOH review times decreased soon after the implementation of the new registration 
guideline (Ministerial Decision (86/2000). Currently the registration decision must be within 
four months from the date of first submission of the registration file. However, many factors still 
affect the review process and delay product approvals e.g. lack of experts and resources.  
 
This chapter evaluates the regulatory review process of new medicines in Oman and examines 
the regulatory aspirations, barriers, problems and priorities, related to the review of new 
medicines that could have an impact on their availability to patients. It assesses the current 
regulatory situation in Oman in order to identify the key issues for improving review practices 
and patients‟ access to new medicines. 
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OBJECTIVES 
The objectives of this study were to: 
1. Evaluate the regulatory review process in Oman and identify  the milestones.  
2. Review the regulatory timelines for pharmaceutical products in Oman between January 
2006 and December 2010 
3. Identify the strengths and weaknesses of the Oman regulatory review process. 
4. Propose strategies that can improve the regulatory review process 
 
METHODS 
Data source 
Information on the total application numbers and approval dates from January 2006 to December 
2010 were obtained directly from the Oman Ministry of Health. This includes New Active 
Substances (NASs), Existing Active Substances (EASs), biological products and vaccines. The 
data also includes the application submission date, the registration date and the overall review 
time. The products were classified into four groups (regions) according to the location of the 
manufacturing companies (GCC, non-GCC Arab, international and Asian). A questionnaire for 
studying the regulatory review process in the emerging markets was used in this research 
(McAuslane et al. 2009). This questionnaire consisted of four parts namely, a review of the 
regulatory review process, the requirements for submission of new drug applications, good 
review practices, and the timeline for the review process.  
 
Hypotheses 
This study examined the following hypotheses: 
1. There was an increase in the number of pharmaceutical products approved in Oman 
between 2006 and 2010. 
2. The largest number of products approved in Oman originated from international 
companies.  
3. There was a significant increase in the total approval time in Oman between 2006 and 
2010. 
4. The time of approval for products from the Gulf pharmaceutical companies was shorter 
than for other companies. 
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5. There was a significant increase in New Active Substances (NASs) approval times in 
Oman between 2006 and 2010. 
6. There is no difference in approval times between major therapeutic groups for NASs. 
 
DATA PROCESSING AND ANALYSIS 
The data were processed using Excel and SPSS for windows. The statistical analysis for Existing 
Active Substances (EASs) and New Active Substances (NASs) covered: the total number of 
registered products between 2006 and 2010; and regulatory approval time in Oman between 
2006 and 2010  for different cohorts of pharmaceutical products (GCC, non-GCC Arab, 
international and Asian); different dosage forms (i.e. solids, semi-solids, liquids, injectables); 
and different therapeutic indications (i.e. Cardiovascular system (CVS), Central nervous system 
(CNS), Gastro-intestinal system, and  Anti-Infectives). Non parametric tests were applied for the 
analysis of the data presented in this chapter. 
 
RESULTS 
For the purpose of clarity the results will be presented in three parts: 
Part I:     Review process map and milestones. 
Part II:   Products reviewed and their characteristics.  
Part III:  Good review practices in the assessment and registration process.  
 
Part I:  Review process map and milestones 
The review process map (figure 3.1) reflects the current situation of the Directorate General of 
Pharmaceutical Affairs and Drug Control (DGPA&DC) and is a simplified representation of the 
main steps being followed for the review of New Active Substances (NASs) and Existing Active 
Substances (EASs).  The map represents the review and authorisation of a product that is 
approved on the first cycle and does not include a second cycle for products approved subject to 
submission of additional data. The map also does not include the steps involved in the case of a 
refusal of an application (such as hearing, appeal etc.) 
 
The Drug Control and Quality Control Laboratory Departments in DGPA&DC are responsible 
for reviewing the marketing authorisation applications.  The two departments currently have a 
staff of 43 people, 22 of whom are involved in the process of review. There is no formal „fast 
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track‟ procedure, however, life saving medicines are not queued but are selected for review as a 
priority, although, the data requirements and review process are the same. The process map and 
milestones for Oman is shown in figure 3.1. The review process milestones in the review and 
approval are as follows; 
 
a) The receipt and validation stage:  This includes administrative registration (reference 
number) and validation of legal requirements, the status of the company, details of the  
local agent and manufacturer  as well as a „checklist‟ validation of the application content 
(e.g. technical sections, CPP status). The product applications received are duly recorded 
electronically which then generate a unique tracking number. After receiving the product 
file, the company must pay the registration fee within one week. The file is rejected if the 
information is not complete and a new application must be made after completing the 
missing data.  The time required for the receipt and validation procedures is only one day. 
 
b) Queuing for review:  Once the file is accepted, it will be entered into a queue for review 
which takes around one week.  The product dossier is divided into two parts; the safety 
and efficacy part which are reviewed by the Drug Control Department and quality by the 
Quality Control Laboratory. Administrative time is a measure of the „backlog‟ time while 
valid applications queue for commencement of their review.  
    
c) Scientific review:  Scientific review and analysis takes three months to complete for the 
Drug Control Department and Quality Control Laboratory, although both proceed in 
parallel. The start and finish of the scientific assessment is formally recorded. The QC 
laboratory sends the quality assessment report to the Drug Control Department where the 
reviewer, after completing a scientific product report form, submits the file to the 
Technical Committee for Registration of Pharmaceutical Manufacturers & Their Products 
& Pricing  (TCR&P) for a decision. 
 
 
 
 
46 
 
Figure 3.1 PROCESS MAP FOR SULTANATE OF OMAN 
 
 
(A)  RECEIVING OF APPLICATION  
  
  
 
 
(B)  ACCEPTED FOR REVIEW 
 
 
 
 
 
(C)    SCIENTIFIC REVIEW STARTS 
 
 
 
 
 
 
 
 
 
 
 
 
(D)   Start of Registration Committee Procedure      
         
 
 
 
 
 
(E) QUESTIONS TO COMPANY       REGISTRATION      REJECTION       
 
 
 
 
 
 
 
 
 
 
 
Receipt & Validation Procedures Validation Time:   1 day 
Queuing for review Administration Time:   2 weeks 
Safety Efficacy Sample 
analysis 
Quality 
Assessment Time:   3 months 
Drug Control Department Quality Control Department 
<<< Parallel review >>> 
Discussion in Technical Committee for Registration of Pharmaceutical 
Manufacturers & their Products and Pricing of those products Meets 
every   
2 
weeks 
Assessment Time:   1 month 
Questions Processed by Company 
Reply from Company 
TCR&P 
REGISTRATION 
Company Time: 1 -6 months (Clock stop) 
Assessment time:  1 month 
          O
verall registratio
n
 tim
e
 4
 m
o
n
th
s 
47 
 
d) Registration committee procedure: The registration committee meets routinely every 
two weeks. The TCR&P, established by the Minister of Health, consists of members 
from two different directorates of the Ministry of Health, six members from DGPA&DC 
and two members from the Directorate General Medical Supplies.  All of the members 
are Pharmacists and there are no external members. The company can meet with the 
internal directorate staff to discuss questions and queries that arise during the assessment, 
but they are only permitted to meet the Director and/or Section Heads. If the committee is 
satisfied with the safety profile of the product, it will be registered, otherwise rejected. If 
registered, a Product Registration Certificate signed by the Chairperson of TCR&P is 
issued within two weeks from the date of registration.  In the case of a rejection, the 
company can appeal within two months from the date of receiving the Committee's 
rejection decision.  
 
e) Questions to the companies:  In the case of any queries raised by the Committee, they 
will be conveyed by the Committee Secretary to the company to respond within a 
stipulated deadline which is normally given from 1 to 6 months.  Once the response from 
the company is received within this stipulated deadline, it is discussed in TCR&P within 
one month from the date of its receipt and accordingly a final decision is taken. The issue 
of product authorisation also depends on the pricing agreement and discussion of pricing 
is separate from the technical review but does not delay the approval of products.  The 
pricing negotiation starts after the end of the scientific review.  
 
Models of regulatory review: 
Many authorities apply different levels of data assessment to different applications, according to 
the type of product and/or its regulatory status with other authorities.  Three basic types of 
review models for the scientific assessment have been identified as a result of discussions with 
regulatory authorities and workshop reports from CMR International Institute for Regulatory 
Science (McAuslane, 2006), namely, 
1. Verification model (type I assessment)  
2. Abridged model (type II assessment) 
3. Full review model (type III assessment) 
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Verification model (type I assessment)  
This model is used to reduce duplication of effort by agreeing that the importing country will 
allow certain products to be marketed locally once they have been authorized by two or more 
recognized reference agencies, elsewhere. The main responsibility of the authority in the 
importing country is to „verify‟ that the product intended for local sale has been duly registered 
as declared in the application and that the product characteristics (formulation, composition) and 
the prescribing information (use, dosage, precautions) for local marketing conforms to that 
agreed in the reference authorization(s). 
 
Abridged model (type II assessment) 
This model conserves resources, by not re-assessing scientific supporting data that has been 
reviewed and accepted elsewhere but includes an „abridged‟ independent review of the product 
in terms of its use under local conditions. This might include a review of the Chemical and 
Manufacturing Control (CMC) data in relation to climatic conditions and distribution 
infrastructure and a benefit-risk assessment in relation to use in the local ethnic population, 
medical practice/culture and patterns of disease and nutrition. Approval by a recognized agency 
elsewhere is a pre-requisite before the local authorization can be granted but the initial 
application need not necessarily be delayed until formal documentation such as a Certificate of a 
Pharmaceutical Product (CPP) is available. 
 
Full review model (type III assessment) 
In this model the authority has suitable resources, including access to appropriate internal and 
external experts, to carry out a „full‟ review and evaluation of the supporting scientific data 
(quality, pre-clinical, clinical) for a major application. A Type III assessment could be carried 
out on a new application that has not been approved elsewhere but in practice legal requirements 
may dictate that the product must be authorized by a reference authority before the local 
authorization can be finalized. The module used by Oman in the assessment of all major 
application is an Abridged Assessment. Oman MOH is capable to conduct an independent 
review of product applications.  However, Oman carries out a unique practice whereby the New 
Active Substances (NASs), being considered for approval, must be marketed in the product 
country of origin for at least 24 months before it can be registered in Oman. This requirement 
may be waived, depending on the product type, if evidence of registration in recognized 
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international reference agencies such United States Food and Drug Administration (US FDA), 
European Medicines Agency (EMA) and/or GCC Centralised Drug Registration (GCC-DR) 
System.  
 
Part II: Products considered and their characteristics 
 
Approval of all products in Oman (2006 - 2010) 
A total of 807 pharmaceutical products for human use were successfully registered in Oman 
between 2006 and 2010 (Figure 3.2). This number included EASs and NASs with a similar 
portion for the years 2006, 2008, 2009 and 2010 (176; 22%; 171; 21%; 172; 21%; and 178; 22%, 
respectively), but there was dip in 2007 (110; 15%).     
 
Figure 3.2: Total number of pharmaceutical products approved in Oman (2006-2010) 
 
Statistical analysis of these data using a simple linear regression showed no significant increase in the total number 
of registered pharmaceutical products over the five year period (p>0.05). 
 
This was possibly due to the development of new regulations for the approval of health products 
and alternative medicines. These new regulations resulted in an overload for the Quality Control 
Laboratory, increasing the analysis time required for pharmaceutical products. The results 
showed no significant increase (p>0.05) in the total number of registered pharmaceutical 
products from 2006 to 2010 (Figure 3.2). 
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Approval of Existing Active Substances (EASs) and New Active Substances 
(NASs) in Oman (2006 – 2010) 
The total number of products registered in Oman between 2006 and 2010 was 807 and this 
included 573 EASs and 234 NASs. The highest number of EASs registered in Oman was seen in 
year 2010 (137) followed by year 2008 (123), year 2009 (116) year 2006 (112) and year 2007 
(87) (Figure 3.3). Statistical analysis using a simple linear regression showed a significant 
increase in EASs registered over the five year period (p<0.001). 
 
 
Figure 3.3: Number of EASs approved in Oman for the period (2006-2010) 
 
Statistical analysis using a simple linear regression showed a significant increase in EASs registered over the five 
year period, (p<0.001). 
 
The highest number of NASs was registred in 2006 (64; 36%), while the lowest number was in 
year 2007 (25; 23%) (Figure 3.4). From these 234 NASs, 226 (97%) were found to be from 
international companies. Statistical analysis using a simple linear regression showed a significant 
increase in the number of registered EASs with a significant decrease in the number of registered 
NASs (p<0.001). 
 
 
 
 
0
20
40
60
80
100
120
140
160
                    
N
um
be
r o
f P
ro
du
ct
s
Registration Year
EASs Line of best fit
51 
 
Figure 3.4: Number of NASs approved in Oman for the period (2006-2010) 
 
Statistical analysis using a simple linear regression showed a significant decrease in the number of registered  
NASs over the five year period (p<0.001). 
 
The number of pharmaceutical products registered for international, GCC, 
non-GCC Arab and Asian companies (2006-2010) 
The number of products registered during the five years period varied for different cohorts of 
companies based on their geographical location, for example the highest number was for the 
international companies products (393; 49%), followed by the GCC Companies products (962; 
33%), non-GCC Arab Companies products (95; 12%) and Asian Companies products (50; 6%) 
(Figure 3.5). 
 
The Existing Active Substances (EASs) approved for GCC, international non-
GCC Arab and Asian companies in Oman (2006-2010) 
A total of 573 Existing Active Substances (EASs) were registered in Oman between 2006 and 
2010. When examined by individual regions 267(47%) medicines were identified as being 
approved from GCC, 167(29%) from international companies, 94 (16%) from non-GCC Arab, 
and 45 (8%) from Asian companies. Statistical analysis of the data using Kruskal-Wallis Test 
(K-Test)  over the five-year period showed that there was a significant increase in the number of 
registered Existing Active Substances (EASs) between 2006 and 2010 (p<0.001). 
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Figure 3.5: Approved pharmaceutical products (EASs & NASs) for GCC, international, non-GCC 
Arab and Asian companies (2006-2010)  
 
 
Approval times of all pharmaceutical products in Oman (2006 – 2010) 
The total approval times for pharmaceutical products in Oman for the period of the study (2006 - 
2010) was calculated for all of the 807 Existing Active Substances (EASs) and New Active 
Substances (NASs) from different pharmaceutical companies. The median approval time varied 
from 55 days in 2006 to 207 in 2008 while in 2010 it was 138 days showing a 33% decrease in 
the approval time(Figure 3.6). Statistical analysis using Kruskal-Wallis Test (K-Test) over the 
five-year period showed that there was a significant increase in approval times for 
pharmaceutical products from 2006 to 2010 (p<0.001).  
 
Approval time for Existing Active Substances (EASs) in Oman (2006 - 2010)  
Approval time for 573 Existing Active Substances (EASs) registered in Oman varied over the 
period (2006-2010) (Figure 3.7).  The lowest median in this period was seen for 2006 (39 days) 
and the highest median for 2009 (176 days).  Statistical analysis using Kruskal-Wallis Test (K-
Test) over the five-year period showed that there was a significant upward trend in the median 
approval time (39, 93, 149, 176 and 138 days respectively) for EASs between 2006 to 2010 
(p<0.001).   
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Figure 3.6: Median approval time for all pharmaceutical products in Oman (2006-2010) 
 
Statistical analysis using Kruskal-Wallis Test (K-Test) showed that there was a significant increase in approval 
times for pharmaceutical products from 2006 to 2010 (p<0.001). 
 
 
Figure 3.7: Median approval time for Existing Active Substance (EASs) in Oman (2006-2010) 
 
Statistical analysis of the data using non-parametric K- test shows a significant upward trend in the median 
approval time over the five year period (P<0.001). 
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Approval time for New Active Substances (NASs) in Oman (2006 - 2010) 
The highest number of products (64) was registered in the year 2006 with the median approval 
time of 72 days followed by 133 days for 25 products in 2007 and 292 days for 48 products in 
2008. In year 2009, 56 products were registered with a median approval time of 147 days and 
159 days for 41products in 2010.  The drop in the number of registered products in year 2007 
was due to the development of the new regulations for approval of health and alternative 
products. These new regulations created an overload for the Quality Control Laboratory, 
increasing the time of analysis of pharmaceutical products. The results obtained from performing 
analysis of variance test showed that there was a significant upward trend in the median approval 
time for NASs products between 2006 and 2010 (p<0.05). (Figure 3.8) 
 
Figure 3.8: Median approval time for NASs in Oman (2006-2010) 
 
The results of variance test analysis showed that there was a significant upward trend in the median approval time 
between 2006 and 2010 (p<0.05).    
 
Approval time for Existing Active Substances (EASs) submitted by GCC, 
international, non-GCC Arab and Asian companies (2006-2010) 
The median approval time for different cohorts of companies varied from 80 for the GCC 
companies to 254 for the Asian companies (Figures 3.9). The rapid approval time for the GCC 
States is due to their efforts; particularly Oman, Saudi Arabia, UAE, and Kuwait, to improve 
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their local manufacturing capabilities and the production capacity for the local population. EASs 
from Asian companies had the longest median approval time of 254 days. Statistical analysis  of 
the data using non-parametric K- test showed that there was a significant difference in approval 
times between different cohorts of companies (P<0.001).  
 
Figure 3.9: Median approval time for GCC, international, non-GCC Arab, and Asian companies 
Existing Active Substances (EASs) in Oman (2006-2010). 
 
Statistical analysis of the data using non-parametric K- test showed a significant difference in approval time 
between different cohorts of companies (P<0.001). 
 
Approval time for different dosage forms for all Existing Active Substances 
(EASs) and New Active Substances (NASs) in Oman, (2006-2010) 
During the five years, 573 EASs were registered in Oman with the lowest number represented by 
the semi-solid dosage forms (48) followed by injectables, liquid dosage forms and the highest 
number was represented by solid dosage forms (364). Out of 234 NASs registered, the lowest 
number is represented by the semi-solid dosage forms (3) with a median approval times of 73 
days and the highest by the solid dosage forms both in term of numbers (121) and median 
approval time (145 days) (Figure 3.10). 
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Figure 3.10 Median approval time for different dosage forms for EASs and NASs in Oman,  
(2006-2010) 
 
 
Approval times for Existing Active Substances (EASs) and New Active 
Substances (NASs) by therapeutic class, (2006-2010) 
An examination of EASs by therapeutic class showed that the lowest number was represented by 
the immunological preparations (1 preparation) and the highest number by the injectables (117 
preparations). The analysis of the approval time of EASs registered between 2006 and 2010 
involved the four major therapeutic groups which dominate the pharmaceutical market in Oman, 
namely, 
 The cardiovascular system (CVS) 
 The central nervous system (CNS) 
 The gastro-intestinal system 
 Anti-Infectives 
 
The range of median approval times for EASs analysed by therapeutic class varied from 141 
calendar days for CNS products to 57 for gastro-intestinal products. The differing patterns of 
approval times for EASs from different therapeutic groups were attributed to the authority‟s 
assessment requirements which may or may not include the need for clinical and bioequivalent 
studies. This can be a lengthy process and has an impact on the overall approval timeline. 
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Another reason for such differences is the sponsor‟s response time to the authority‟s request and 
the level of communication between the two parties. During the period of study, 234 NASs were 
approved in Oman, with the lowest number represented by the ear, nose and oro-larynx 
preparations (1) and the highest number by cardiovascular preparations (40). Figure 3.11 shows 
the range of approval times for NASs analysed by therapeutic class and these varied from 216 
days for anti-infectives to 49 for gastro-intestinal products. 
 
Figure 3.11: Median approval times for different therapeutic classes for EASs and NASs in Oman 
(2006-2010) 
 
 
There were several factors leading to the variation in approval times for different therapeutic 
groups. In some cases, consultations with different therapeutic committees within the Ministry of 
Health, for example Central Drug Committee (CDC) and National Antibiotic committee, which 
do not have regular meetings, may have caused delays in the approval time. Some medicines 
have longer pricing times due to a protracted period of negotiation with the companies.  
 
Part III: Good review practice in the assessment and registration process 
 
The ultimate measure of success in regulatory performance is the quality reviews and decisions, 
as well as the quality of the dossiers (Kendle, 2009; Karlton and Johnson, 1997 and McAuslane 
and Cone, 2006). The regulatory authority, industry and patients benefit from having a high 
quality review process that is well managed (Hynes et al., 2001 and Booz Allen Hamilton, 2008). 
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An efficient review allows the regulatory authorities to fulfill their public health mission to 
ensure that safe and effective medicines are made available to patients in a timely manner and 
allows for efficient use of resources. Patients benefit from the timely access to safe and effective 
therapies while pharmaceutical companies are able to market the product sooner and generate 
revenues (Booz Allen Hamilton, 2008). The regulatory challenge is to allow access to the safest 
and most effective pharmaceutical products in the shortest possible time with a highest degree of 
certainty (Alder, 2001).The results showed that the Oman regulatory authority, the Directorate 
General of Pharmaceutical Affairs & Drug Control (DGPA&DC), intends to implement a 
number of quality measures in the review and authorisation of medicinal products.  It includes a 
well defined internal quality policy, good review practices, standard operating procedures, 
assessment templates and a peer review process. 
 
General measures used to achieve quality 
The DGPA&DC currently does not have an internal quality policy which defines the intentions 
and directions of the organisation related to quality as formally expressed by top management.  
But it is likely to be established in the near future.  Similarly, good review practices are not 
formally documented at present but will be established soon.  A well defined code about the 
process and documentation of review procedures would standardize and improve the overall 
documentation and ensure timeliness, predictability, consistency and high quality reviews. 
 
Standard operating procedures were implemented in the DGPA&DC for certain procedures 
while for the remaining processes, SOPs will soon be established.  Assessment templates would 
set out the content and format of written reports on scientific reviews however they are not in use 
currently but are likely to be established within the next few years.  A peer review procedure is 
currently used for vaccines as there are two committees reviewing the vaccines marketing 
authorisation applications. Peer review, defined as an additional evaluation of the original 
assessment that is carried out by an independent person or committee, is unlikely to be 
established in the next few years. 
 
Quality management 
The three most important measures which the DGPA&DC identified for establishing quality 
measures were (1) to be most efficient, (2) to minimise errors and (3) to increase transparency. 
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To improve quality, the following activities were undertaken to bring about continuous 
improvement in the assessment and authorisation process: 
 
 Reviewing stakeholders‟ feedback (e.g. through complaints, meetings or workshops) and 
taking necessary action. 
 Carrying out internal quality audits (e.g. self assessments) and using the findings to 
improve the system. 
 Having external quality audits by an accredited certification body to improve the system 
(e.g. WHO) 
 
The DGPA&DC does not have a dedicated department for assessing and/or ensuring quality in 
the assessment and registration process for new medicines, however, there are plans to set up 
such a department in the future. 
 
Quality in the review and assessment process 
The guidelines issued under the Ministerial Decision No. 86/2000 serve as an official document 
to assist the industry in the registration of medicinal products in Oman. This Ministerial Decision 
is also available on the Ministry of Health website. Pre-application scientific advice is not 
available to applicants, but can be obtained during the file submission day.  The applicants are 
allowed to make formal contacts with DGPA&DC staff to discuss an application during its 
review process.  
 
There is a registration committee called “The Technical Committee for Registration of 
Pharmaceutical Companies and their Products and Pricing”. The committee consists of eight  
members and  meets once every two weeks.  New Active Substances (NASs) applications are 
reviewed by this committee while Major Line Extensions (MLE) are reviewed by the Drug 
Control Department in the DGPA&DC and not forwarded to the registration committee.  The 
committee receives assessment reports from the Drug Control and Quality Control Laboratory 
staff that review the applications. Shared/Joint reviews are undertaken when products are 
submitted through the GCC Central Registration Procedure. 
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Training and continuing education  
To maintain or improve the quality of the work, it is essential that reviewers follow training or 
refresher courses from time to time. These may concern general training about new 
developments in the regulatory science field or specialized training in carrying out a quality 
review process. The DGPA&DC does not currently have any formal training programmes for 
assessors.  Training is mainly carried out through external courses, post-graduate degrees, 
participation in international workshops/conferences, placements and secondments in other 
regulatory agencies and inviting speakers to the authority.  After training or attending a course, 
the reviewer should report and convey his/her experience or knowledge to colleagues and top 
managers and make proposals for any change of existing procedures or adoption of new 
practices to improve the overall performance of the reviewing staff.  
 
Transparency of the review procedure 
The DGPA&DC assigns a high priority to transparency of the review procedure. It has identified 
the following three top incentives for assigning resources to activities that enhance the openness 
of the regulatory system namely: political will, the need to increase confidence in the system and 
to provide assurances to the pharmaceutical industry. Information such as product approval and 
the price of medicines is routinely provided to the general public.  The information can be 
accessed from the ministry‟s official website or provided on submission of a formal request. As 
far as transparency is concerned, the companies can follow up the progress of their application 
either through phone contact, email or meetings with the officials with prior appointment. There 
is an electronic system for registration and tracking of applications, which also can be used to: 
 Track applications that are under review and identify the stage of the process 
 Signal that target review dates have been exceeded 
 Record the terms of the authorisation once granted 
 Archive information on applications in a way that can be retrieved. 
 
Drivers and barriers facing the review process in Oman 
Understanding the drivers and barriers to achieving a quality regulatory review process can 
promote innovative and creative ideas and practices to help reviewers assess new products and 
underline the importance of monitoring the quality of the review process.  
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There are several motivating factors identified by DGPA&DC that contribute to accomplishing 
the desired effectiveness and efficiency of the authority‟s review procedures and decision-
making for new applications, namely: 
 Good tracking system 
 Utilization of an assessment template. 
 Good Management Plan 
 Well qualified, trained and experienced reviewers 
However, the DGPA&DC is facing several obstacles that are hindering its ability to ensure that 
new medicines are available in a timely manner, i.e: 
 Shortage of experience personnel 
 Lack of  an independent budget 
 Lack of an internal quality policy 
 
 
DISCUSSION 
 
This study has evaluated the pattern of total regulatory approval time in Oman between 2006 and 
2010. It has also addressed the various factors which may have a positive or negative effect on 
the total approval time. It has been shown that the total number of registered Pharmaceutical 
Products in Oman (2006 - 2010) is 807 and this number includes Existing Active Substances 
(EASs) and New Active Substances (NASs).   
 
Six hypotheses were generated for this study, as outlined previously and the findings are 
discussed below. 
 
1)  There was an increase in the number of pharmaceutical products 
     approved in Oman between 2006 and 2010. 
The largest number of registered medicines was found in 2006. In this year, there was no 
overload on the quality control laboratory since the actual approval of health products, using the 
recent guidelines and regulations (Circular 64/2005) did not start until 2005. However, the 
number of the registered medicines was similar in the years 2006, 2008 & 2009 with the 
exception of 2007 when there was a fall. This was largely due to the development of new 
regulations for approval of health products. These new regulations resulted in an overload on the 
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Quality Control Laboratory, increasing the time of analysis of pharmaceutical products. This 
hypothesis has therefore rejected. 
 
2) The largest number of the products approved in Oman originated from 
    international companies.  
The number of products registered during the five year period (2006-2010) varied for different 
companies based on their geographical location. The largest number was for the international 
companies products, followed by the GCC companies, non-GCC Arab, and finally the Asian 
companies. International companies were the largest group registering products every year in 
Oman. This was due to the fact that the pharmaceutical companies must submit a full registration 
application when the manufacturing site has been changed for the same registered company. 
Thus, there was an increase in the number of changes in product manufacturing sources 
applications from the international companies during this five year period. Furthermore, 
international companies increased the number of their submissions to the Omani authority to 
obtain registration approval as evidence that would support their GCC-DR approval. The pricing 
process in Oman is the final step and price negotiations occur at the end of the scientific 
assessment. The Registration Committee makes the decision on the product registration and 
pricing.  Oman has a robust pricing control system and this is one of the main reasons that 
pharmaceutical companies register their products in Oman prior to other GCC states. Using a 
price reference system, the pricing committee considers the manufacturer's wholesale and retail 
prices in the country of origin, export Cost-Insurance-Freight (CIF) prices to Oman as well as 
CIF prices in other GCC states. This hypothesis was accepted. 
 
 3) There was a significant increase in the total approval time for  medicines in 
Oman between 2006 and 2010. 
During the five years, the median approval time varied from 55 days in 2006 to 119 days in 
2010. There was a significant increase in the median approval time between 2006 and 2008 
which was due to the new regulations that were implemented by Oman MOH in 2006 for the 
registration of human health products. This was due to the increase in the number of local 
registration applications and the applications received from GCC-DR for Oman MOH 
evaluations. Registration for the pharmaceutical companies and their products must be renewed 
every five years as required by the Oman registration system. In 2006 Oman MOH requested 
63 
 
pharmaceutical companies to re-register their products. This re-registration was for the first time 
and led to an increase in the number of applications and an overload for the Drug Control 
Department and Quality Control Laboratory.   
 
The WHO has clearly stated  that the shortage of qualified personnel is the greatest problem 
faced by drug regulatory authorities (WHO, 2003a), and is one of the factors affecting patients‟ 
access to new medicines in Oman. All staff are paid according to established salary bands for the 
entire public service. Consequently, Oman MOH is unable to use salaries to attract and retain 
some of the skills that would strengthen the regulatory role. This hypothesis was therefore 
accepted. 
 
4)  The time of approval for products from Gulf pharmaceutical companies 
was shorter than other companies. 
Median approval time varied for different companies from 80 to 254 days for GCC and Asian 
companies respectively. The rapid approval time is mainly due to the GCC States making efforts, 
particularly Oman, Saudi Arabia, UAE, and Kuwait, to improve their local manufacturing 
capabilities and the production capacity for the local population (Al-Essa, 2011). This led to a 
positive outcome in approval times, giving a median time of 80 days. There are other factors 
which have a positive effect on the approval time for local and Gulf companies but have a 
negative effect on the international, non-GCC Arab and Asian companies. For example, in 
decision-making, the geographical proximity of the company to the authority leads to an 
effective interaction and thus a faster response to any questions from the authority. Additionally, 
most locally manufactured products are EASs and do not need very much consultation during the 
scientific review compared to NASs. Furthermore, an understanding of the culture of the 
regulatory authority where there is no language barrier has a positive effect on the review 
process. However, a priority procedure is a common practice in many authorities, but often in 
relation to the importance of the medicine rather than geographic location. In Canada and 
Australia, pharmaceutical companies can apply to receive a priority review for their medicines 
and the regulatory authority then decides which medicines will be reviewed in this way. The 
FDA classifies all new medicine applications to receive either a priority or a standard review 
(Rawson et al., 2000a). In this study, it was found that the 31% of the products, which received 
priority approval, were manufactured by local companies or were for serious life-threatening 
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medical groups, e.g. cancer medicines. For the 5-year study period, products from Asian 
companies had the longest median approval time of 254 days.  Oman requests limited clinical 
data in the form of bioequivalence studies to demonstrate that the EAS is bioequivalent to the 
original product. Bioequivalence presents the first challenge for the EAS registration because 
many manufacturers find it difficult and costly to perform high standard controlled trials that 
compare the proposed EAS with the original product.  Meanwhile, for EAS‟s the laboratory 
sample analysis is carried out in parallel with the scientific review but the analytical step can be 
waived if the product is registered in Saudi Arabia, UAE, and/or Kuwait, which have recognized 
laboratories in the region. From these results this hypothesis has confirmed.    
  
5)  There was a significant increase in New Active Substances (NASs)  
     approval time in Oman between 2006 and 2010. 
The pricing process can markedly affect the registration time in Oman. The pricing time for 
NASs is longer than for EASs due to the period of negotiation. The registration committee sets 
the lowest possible price for the original brand product, which is usually the export price to the 
Saudi market. Saudi Arabia has much better negotiating power and hence the Omani agency 
wants to use this power to reduce the medicine prices. Pricing is the final step and no product 
will be issued a registration certificate before it is priced, but that proposed by the company is 
not necessarily agreed, although the company is given an opportunity to appeal before the final 
price is decided. Pricing negotiations start after the granting of registration approval of the 
medicine. This approach prevents the pricing step from being integrated into the review process 
and this delays the final approval time. Therefore, it would be preferable for the pricing process 
to be carried out in parallel with the review process rather than after granting registration 
approval. The analytical step is one of the approval requirements and takes up to almost 50% of 
the total approval time for all companies. Unlike Oman, none of the international authorities 
analyse the products pre-registration. Therefore, it is recommended that this step be carried out 
post-approval with product samples being selected from the market for analysis. This would 
reduce the registration time. Another inappropriate milestone is the submission of a Certificate of 
pharmaceutical Product and the price certificate which has to be legalized by the relevant 
authority and Oman embassy in the country of origin. Such regulations lead to registration delays 
and increase the burden for the companies and it is not a WHO requirement.  
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The findings from this study indicate that the company time for answering questions from the 
authority when companies submit analytical data are longer than the authority time for all 
cohorts of companies. No doubt this issue also causes a further delay in the registration of 
products, which affects patients‟ access to medicines submitted by international companies. 
Furthermore, the delay caused by companies leads to a waste of authority time and resources. In 
order to reduce the company time, it is recommended to implement an official clock-stop system 
by the Omani health authority while the company respondes. This hypothesis was accepted. 
 
6)  There is no difference in approval time between major therapeutic groups 
for the NASs. 
The results of this study shows that there are significant differences in the approval time between 
therapeutic groups, for example the approval time for the anti-infectives is three times longer 
than those for gastrointestinal products. There are several factors leading to these differences in 
approval times. In some cases, consultations with different therapeutic committees within the 
Ministry of Health for example the Central Drug Committee (CDC) and the National Antibiotic 
committee may cause delays in the approval time. In addition, the nature of the products 
evaluated, e.g. biological products may require a more detailed review than others. Some 
medicines have longer pricing time due to periods of protracted negotiations. Using a price 
reference system, the pricing committee considers the manufacturers wholesale and retail prices 
in the country of origin, export CIF (Cost, Insurance, and Freight) prices to Oman and CIF prices 
in other GCC states. These results do not support this hypothesis. 
 
CONCLUSIONS 
This study has assessed the trend in the regulatory approval times in Oman for the period 2006 to 
2010. The findings show that although there is an increase in the approval time for all 
pharmaceutical company products, the median approval time for the five year period was 117 
calendar days. This is within the time limit (4 months) which is fixed by the health authority for 
the overall registration time. It was found that products in the different cohorts of companies, 
which include local, GCC, non-GCC Arab and international companies have varying approval 
times which may be due to an internal unpublished policy of prioritization within the authority. 
However, there are many factors affecting the approval time, which include the quality of the 
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dossier, the geographical location of the company, communication within companies and various 
cultural factors. This study enabled the regulatory authority in Oman to be made aware of its 
own review time and the timing of each step within the process. Furthermore, since this study 
was based on regulatory authority data, a reliable and accurate source, it may enable 
pharmaceutical companies to better understand the factors that influence the review process and 
the overall review time. This, in turn, may help to accelerate the registration procedure and save 
time and resources by allowing a more rapid access to innovative medicines. The companies 
have the responsibility for most of the delay of their own product registration in Oman because 
they take a long time to respond to questions asked by the authority or to submit the analytical 
data. 
 
SUMMARY 
 The review time for the registration process during the period 2006 to 2010 is within the 
time limit fixed by the Oman health authority, but there has been an upward trend in 
regulatory approval times since 9206. 
 The total approval time varies according to the geographical location of the company, 
and it was found that the shortest approval time was for products from local and Gulf 
companies. 
 In addition to the factors already mentioned, the absence of separate sections for health 
products and herbal preparations in the Drug Control and Quality Control Laboratory 
Departments and the large number of samples to be analysed by the QCL from 
Directorate of medical supplies has a significant impact on total approval time. 
 The pricing process for the NASs, the pre-registration analysis, lack of  official clock-
stop system and the delay in replying to regulatory queries, all have a delaying impact on 
approval time. 
 The fees for the registration of the companies and their products are very low in Oman. 
This has led to a high number of applications and an increase in the median time of 
registration. 
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CHAPTER 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of Regulatory Review Times 
in the Gulf States 
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INTRODUCTION 
Long regulatory approval timelines for new medicines delay their access to the market that may 
have the potential to improve patients' health status and of alleviating suffering. Variation in the 
availability of medicines in different countries has been studied since the early 1970s (Rawson, 
2000), and some marked differences have been identified. Regulatory approval time is a key 
metric that is used to evaluate the performance of regulatory agencies (Hirako et al., 2007). A 
study was previously made to evaluate the milestones and timelines involved in the regulatory 
review processes for different authorities (Hirako et al., 2007). A specific study of the Gulf 
regulatory authorities (Hashan, 2005) highlighted important aspects of the drug approval 
procedures in each of the seven member states. However, the study provided limited information 
about the approval timelines and the duration of the milestones and stages involved in the review 
process because the authorities did not have electronic tracking systems to monitor such 
activities. This made it difficult, if not impossible, to allow cohorts of pharmaceutical products to 
be monitored retrospectively (Al-Essa, 2011).  
 
Currently, within the GCC States, there are two registration systems, the national and the 
centralised procedure. In order to benchmark and make true comparisons between the different 
authorities, it is essential to identify first the common processes that occur during registration. 
However, there are no major differences in the legislation, regulations or requirements for 
marketing pharmaceutical products in the GCC States (Bahrain, Kuwait Oman, Qatar, Saudi 
Arabia, UAE and Yemen). All the national regulatory departments in the GCC States have 
regulations that govern and regulate most aspects of the pharmaceutical services by effective 
laws (Hashan, 1998). Apart from the registration process of medicinal products, some countries 
have price control also, in their remit. 
 
It is recognized that individual authorities have different experiences and knowledge that could 
be of value to other member states through comparison of various systems and sharing of best 
practices to the benefit of all. To this effect, this study was conducted to explore the timelines of 
the approval processes in the GCC States. However, it is important to have a basic understanding 
of the regulatory review process in these countries in order to place the approval time in an 
appropriate context.    
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OBJECTIVES 
The major objectives of this study are to: 
 
1. Compare the number of registration applications submitted for pharmaceutical products over 
the three-year period from January 2008 to December 2010 in the GCC States. 
2.  Compare the regulatory approval times for registered products for Gulf, Arab non-Gulf, 
Asian and International pharmaceutical companies in the GCC States. 
3. Assess the trends in approval times over the period 2008-2010. 
4.  Identify areas of the approval process in each of the seven Gulf States which might lead to 
delays in the registration of new medicines.  
5. Provide possible solutions for addressing the delays in the registration timelines in the Gulf 
States. 
 
METHODS 
Participants 
The participants were the authorities responsible for the regulation of pharmaceutical products in 
the GCC States (i.e. (Bahrain, Kuwait Oman, Qatar and Saudi Arabia) Yemen was excluded 
from this study because they could not provide data due to the unstable political situation in the 
country during the period of this study. The United Arab Emirates was also excluded from this 
study, as they are unable to furnish the full data due to changes in the drug regulatory 
organization that took place during the time this study was conducted. Additionally, they were 
also unable to extract some of the data as it was manually stored making retrieval of the required 
information very difficult.   
 
Data collection  
A face-to-face meeting with all the Directors and General Directors of Regulatory Affairs in the 
Ministry of Health in the GCC States took place during the GCC-DR meetings in 2011and 2012.  
They provided the data on approval timelines as an Excel spreadsheet including the registration 
data for products approved in 2008, 2009 and 2010, based on the milestones in each authority. 
Clarification regarding the data set was obtained from the five authorities during 2012 through 
telephonic conferences and electronic mails.  
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The data consisting of all products from Gulf, Arab non-Gulf, Asian and International   
manufacturers, approved for human use in 2008, 2009 and 2010 in the GCC States, were 
included in this study. Products reviewed included both New Active Substances (NASs) and 
Existing Active Substances (EASs) and only those with a complete data set e.g. submission date 
and approval date were included in the analyses. In addition, relevant information regarding the 
regulatory review process of the five Gulf countries was collected by literature search. The 
overall data includes milestone and tables reflecting the specific characteristic of each system 
(Al-Essa et al, 2012).  
 
Models of regulatory review: 
 
Three GCC authorities utilize an abridged assessment (Bahrain, Oman and Qatar) as describe in 
chapter three. This is a critical practice to ensure the appropriateness of the product under local 
conditions. Bahrain uses a verification review for biological and biotech products because they 
have to be registered in other reference authorities to be accepted for review in Bahrain, and an 
abridged review for other major applications. Saudi Arabia is the only country that performs a 
full review on all types of applications, while Kuwait carry out a simple verification review on 
the registration dossiers.  
 
DATA PROCESSING AND ANALYSIS 
The Regulatory approval times were calculated as the time from submission of the product 
dossier to the regulatory authority until the final approval. The data sets processed include: the 
total number of registered products between 2008 and 2010 and regulatory approval time in 
GCC States between 2008 and 2010 for different groups of pharmaceutical products (GCC, non-
GCC Arabs, International and Asian). Descriptive statistics including frequencies was used to 
present the results. 
 
RESULTS 
The results of this study are presented in two parts, 
Part 1: Includes the process maps for the regulatory reviews in each of the five states together 
with characteristics of the review process. 
Part 2: The results are presented under three headings: 
71 
 
I: Total number of product approved in each Gulf states. 
II: Median approval times for the Gulf States by year 2008-2010  
III: Median approval times for the different pharmaceutical companies. 
 
Part 1: The regulatory process maps for the Gulf States: 
All the GCC authorities share similar goals and obligations to safeguard public health when 
assessing the safety, quality and efficacy of medicines before they are authorized for marketing. 
They also have a similar structure when reviewing pharmaceutical product dossiers, but the 
position of each milestone in the review process differs from one state to another. 
 The first study in the GCC was initiated by Hashan (2005) to assess the regulatory environment 
in the six GCC states (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and UAE) using 
comparative data on a country and regional level, in order to identify the key issues for 
improving regulatory practices and ensuring new medicines were available in an efficient and 
timely manner. The second study by Al-Essa (2011) was to map the key milestones and 
associated activities for each agency in the GCC region and to determine the quality measures 
employed by the agencies in their different procedures.  Figures 4.1- 4.7 illustrate the process 
maps for each of the countries participating in this study as well as the characteristics of the 
process. 
This part describes the comparison between the regulatory review processes in the seven GCC 
regulatory authorities.   
 
Validation process 
The validation process is the first contact between the sponsors and the regulatory authorities. 
Validation is an important checking point to ensure the correctness and completeness of the 
submitted data before entering the scientific assessment stage. The seven authorities record the 
date of receiving the registration dossier and carrying out a validation process to ensure that the 
documents submitted for registration are complete before they can be accepted for review. After 
examining the validation process, a considerable difference was observed in the time taken to 
validate the registration dossier from one country to another, with Oman performing the 
validation process immediately after submission while Bahrain takes 14 days to complete it.   
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Figure 4.1 PROCESS MAP FOR BAHRAIN 
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Figure 4.2 PROCESS MAP FOR KUWAIT 
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Figure 4.3 PROCESS MAP FOR OMAN 
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Figure 4.4 PROCESS MAP FOR QATAR 
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Figure 4.5 PROCESS MAP FOR KINGDOM OF SAUDI ARABIA 
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Figure 4.6 PROCESS MAP FOR UNITED ARAB EMIRATES 
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Figure 4.7 PROCESS MAP FOR YEMEN 
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Table 4.1 Models of assessment and characteristics in the Gulf States 
 
Type of review 
model 
Bahrain Kuwait Oman Qatar Saudi 
Arabia 
UAE Yemen 
Verification 
review   
  x x x x  
Abridged review    x   x  x 
Full review   x x x x   x 
        
 Number of 
reviewers   
7 15 22 3 40 12 10 
Validation time 
(days) 
14 7 1 NA 10 1 NA 
Queuing time 
(calendar days) 
14-56 14-56 14-56 60-90 NA NAS: 60-180 
EAS:180-365 
NA 
 Scientific 
assessment  
(calendar days) 
NA NA 90 NA 180-245 NA NA 
Positive scientific 
opinion to final 
approval 
(calendar days) 
30- 90 30 30   30 -90 30   30 to 90  180 
Overall approval 
time (calendar 
days) 
NA 180 120 NA EAS: 165 
NAS: 290 
NA 180- 365 
                    *NA= Not Applicable 
 
Queuing stage 
The queuing process is straightforward and allows appropriate handling of the received 
registration dossiers in an organized fashion. However, the lack of regular monitoring of queue 
time could lead to a backlog. The queuing time varies considerably across the Gulf region 
ranging from 14 days to over 365 days. For a medicine to remain in this stage for three months 
unjustifiably delays patients‟ access to medicines. 
 
Scientific review Phase  
The scientific assessment stage is the major part of the regulatory review process where the 
product quality, safety and efficacy dossiers are thoroughly evaluated. The starting date of the 
scientific assessment is generally recorded in most of the GCC States, except in UAE and Qatar, 
probably because the review process starts from the date of submission and ends at the date of 
granting the approval. Five regulatory authorities in the Gulf region have scientific committees 
as part of the scientific assessment process. Kuwait and Qatar do not have scientific committees 
and the quality of the review report depends on the assessors‟ experience and skills in evaluating 
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the registration dossier. The scientific assessment is not a target time in five GCC authorities 
while Oman and Saudi Arabia specified a time limit of 90 days and 180 to 245 days respectively. 
 
Queries to companies 
In this phase all the communications occur between the sponsor and the authority with regards to 
the registration of a new medicine in each GCC State. Questions and queries arising during the 
scientific assessment and quality control analysis stages are collected into a single batch to be 
sent to the sponsor by each of the seven GCC authorities. The sponsor‟s response time varies 
significantly between the seven GCC States with the shortest time limit being 30 days enforced 
by the Saudi Food and Drug Authority (SFDA) and the longest is approximately 365 days in 
Qatar. The clock-stop concept is perceived differently across the region. In Kuwait, for example, 
the authority does not enforce a limit for the sponsor‟s response time but if the sponsor fails to 
respond in two years, the authority ceases the registration process and returns the dossiers to the 
local agent and a new application is officially requested should the sponsor be still considering 
the product registration in Kuwait Bahrain and UAE, however, do not have a clock-stop system 
but they target a specified limit for the sponsors response time. 
Overall target time for registration 
While Bahrain Qatar and UAE were not setting a target approval time, the other four authorities 
have slight differences in their overall target approval times with the shortest one in Oman being 
120 days. 
 
Part 2: Total number of product approved in each Gulf states, median approval times for 
               the Gulf States by year 2008-2010 and the median approval times for the different 
              pharmaceutical companies 
In this study, three major areas were examined, for the period 2008-2010 namely, (1) Trends in 
submission and registration of new pharmaceutical products; (2) Changes in the approval 
timelines; (3) Approval times for Gulf, Arab non-Gulf, Asian and International pharmaceutical 
products in the GCC States. The number of approved products in any regulatory authority is 
affected by many factors. For example, the number of dossiers submitted to the authority and the 
number of reviewers in the review section (Hashan, 2005). The GCC States are no exception and 
like many other authorities the number of approved products varies from year to year influenced 
by these and other factors.  
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Total number of products approved in each Gulf state 
 
In general, the countries reviewed a similar number of products, but there was an increase in the 
number of approved products in 2010 in most GCC States compared to 2008 and 2009 with the 
exception of Saudi Arabia (Table 4.2). This may reflect an increased interest by the industry in 
the Gulf market or the authorities in the region were able to cope with an increased work load, 
translating into an increased number of products approved. The GCC regulatory authorities share 
common regulatory review practices that are critical in the establishment of a standardized 
review process for the GCC region. The differences identified in the five review processes were 
mainly due to the order of the steps carried out or the time spent in carrying out a certain 
procedure. As per Al-Essa (2011) the approval timelines in the GCC States depend on the type of 
products being registered, the quality of the submitted data and the level of interaction between 
the sponsor and the authority.  
 
 
In 2010, Kuwait registered the highest number of products among all the GCC countries with a 
total  of 210 products registered which is almost twice that of Saudi Arabia (92 products) (Table 
4.2). Bahrain had the lowest number of products registered in total for 2008, 2009 and 2010 at 
87, 149 and 174 products respectively. The analysis for each country is provided in the following 
paragraphs. Oman is the only country in the GCC with a more or less constant number of 
products registered between 2008 to 2010. Bahrain saw a steady rise in the number of registered 
medicines from 87 approved products in 2008, 149 in 2009 and 174 in 2010 (Figure 4.8). This 
steady increase in the registration of medicines in Bahrain was due to the decision from the 
Ministry of Health (MOH) in Bahrain to facilitate the procedures for the drug registration if the 
product is approved by advanced regulatory authorities such as EMA and USFDA or by one of 
the reference countries in the Gulf. 
 
Kuwait, on the other hand, saw a decrease in the number of registered medicines in 2009 and 
2010 of 198 and 210 respectively as compared to 416 in 2008. According to the Kuwait 
regulatory authority, the high number of approvals in 2008 was attributed to the pending files 
with minimum requirement which were finalised in 2008, Hence, an increase in total number of 
registered products in that year.  
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       Table 4.2  Number of approved products for Gulf Cooperation Council 
(GCC) States in 2008, 2009 and 2010 
Countries  Type of company 2008 2009 2010 
Approved 
products 
    
Approved 
products 
Approved products 
Bahrain 
  
  
  
Gulf 5 5 51 
Arab non-gulf 25 37 42 
Asian 7 2 19 
International    50 105 62 
Total 87 149 174 
     
Kuwait 
  
  
  
  
Gulf 81 51 43 
Arab non-gulf 94 38 46 
Asian 17 3 5 
International    224 106 116 
Total 416 198 210 
          
Oman 
  
  
  
  
Gulf 52 37 56 
Arab non-gulf 15 25 29 
Asian 15 5 12 
International    89 105 81 
Total 171 172 178 
     
Qatar 
  
  
  
  
Gulf 56 57 134 
Arab non-gulf 39 13 11 
Asian 1 0 0 
International    107 30 62 
Total 203 100 207 
     
Saudi   
Arabia 
 
 
Gulf 150 91 16 
Arab non-gulf 25 52 19 
Asian 0 0 0 
International    134 132 57 
Total 309 275 92 
 
In Saudi Arabia, the decrease in the number of registered medicines in 2010 as compared to 
2008 and 2009 was attributed to the transfer of the tasks from the Ministry of Health to the 
Saudi Food and Drug Administration in July 2010. During the transition period, the ministry 
refrained from accepting new registrations until the transfer was completed, hence the 
decline in the number of products registered. In Qatar, the decrease in the number of 
registered medicines in 2009 as compared with 2008 and 2010 was attributed to the limited 
number of registration committee meetings in 2009. Since the number of meetings was 
reduced, the number of products registered was also affected. 
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Figure 4.8 Number of approved products by the five regulatory authorities 
(2008-2010) 
 
Approval times in Gulf States 
 
There are differences in the milestones within the approval process among the GCC States. 
For example, the analysis step starts with the scientific assessment in Oman, Saudi Arabia, 
and Qatar (parallel procedure), but in Kuwait and Bahrain the analytical step comes after the 
scientific assessment (sequential procedure) and this could negatively impact the approval 
time. The GCC authorities also waive the analytical stage for products registered in Kuwait, 
Saudi Arabia, Oman, the GCC central drug registration (GCC-DR), and/or in countries with 
advanced regulatory systems such as the United States Food and Drug Administration or the 
European Medicines Agency (EMA). 
 
The median approval time for all approved products in the GCC States ranged from  69 days 
in Oman and Qatar in 2010, to 587 days in Saudi Arabia in 2008 (Figure 4.9). The Saudi 
Arabia median approval time was two to three times the regulatory approval time in other 
GCC States. This may be attributable to some products remaining in the approval process for 
a longer time, or because some steps in the regulatory approval required more time to 
complete or because they carry out a full review.  However, upon verification with the Saudi 
Arabia authority, the decrease in registration period for the three years (from 587 Day in 
2008, 515 in 2009 and 439 day in 2010) was due mainly to the decrease in the number of 
registration applications received by the MOH. With fewer files, the evaluation process and 
decision-making were carried out in a timely manner.   
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Figure 4.9    Median approval times for all products (2008-2010) 
 
 
Bahrain, recorded a decline in the registration period between 2008 and 2010. This decline in 
the registration period in the year 2010 (from 264 days in 2008 to 166 days in 2010) was 
attributed to the increase in the number of registration committee meetings and the increased 
number of reviewers. This expedited the approval process and reduced the registration 
process by 98 days.  
 
Qatar also experienced a decrease in the registration period for the three years; 143 days in 
2008, 87 Days in 2009 and 69 days in 2010. This was attributed to the increased number of 
reviewers, hence expediting the approval process. By taking into account products that had 
been approved by regulatory authorities in advanced countries such as the EMA and 
USFDA, the local approval process becomes more streamlined and shortened. Kuwait 
recorded a decline in the registration period for the same three years ranging from 346 days 
in 2008 to 300 days in 2010. Oman also recorded a decline in the median approval time from 
143 days in 2008 to 69 in 2010.  The increase in the approval time in 2008 was due to the 
development of the new regulations for approval of health and alternative products. These 
new regulations created an overload for the Quality Control Laboratory, increasing the time 
for the analysis of Pharmaceutical products. 
 
Approval time for Gulf, Arab non-Gulf, Asian and International    pharmaceutical 
products in the GCC States 
The approval times in the Gulf States varied based on the geographical location of the 
manufacturer. For local companies it is easier to contact the authority and faster to reply to 
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questions asked by the authority. International company products need a longer time for 
approval for many reasons, including priority given to local companies and cultural 
influences. Therefore, the following four figures examine the difference in the approval time 
for different types of companies in the GCC States. 
 
Gulf companies products 
 
The median approval time for the products from Gulf companies varied from about 70 days 
in Oman and Qatar in 2008, 2009, 2010 to more than 600 days in Saudi Arabia. The longest 
approval time was for Saudi Arabia at 609 days in 2008, as shown in (Figure 4.10). The 
regulatory review process for medicines in Saudi Arabia is carried out in the newly 
established autonomous “Saudi Food and Drug Authority” which commenced its activities in 
2008. The review process in Saudi Arabia comprises thirteen steps which are critical to the 
whole process (Al-Essa, 2012). As a result, the approval time decreased significantly over 
the period of this study. The Saudi Arabia authority ascertained that the reduction in approval 
time was partly due to fewer product registration applications received in 2008, 2009 and 
2010 from the GCC companies as well as the rapid responses from these companies 
regarding any clarifications.  The improvement in the approval time in Oman and Qatar in 
2010 was due to the positive effects of the Gulf Centralised Registration system. Qatar MOH 
for example requested the Gulf companies to register their products in the GCC Centralised 
system before they submit their products to the local procedure and this led to a reduction in 
the time needed to register the products. In Bahrain, the increase in the number of reviewers 
had a positive effect on approval times. But in Kuwait, the health authority thought the slight 
increase in approval times in 2008 and 2010 was mainly attributable to the delays in the 
companies‟ response to the authority‟s queries which affects the overall approval time. 
Bahrain, on the other hand, recorded an increase in the duration of medicine registration from 
Gulf pharmaceutical companies in 2008 (520 days), a decrease in duration recorded in 2010 
and no registration of any products from Gulf companies in 2009.The decline in the 
registration period in 2010 was due to the increase in number of the registration committee 
meetings and in the number of reviewers. On verification, there were no specific reasons 
recorded as to why there was no registration for any products from Gulf pharmaceutical 
companies in 2009. One of the probable reasons might have been that the Bahraini market is 
very small in size and hence not attractive for companies to register their products locally. 
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Figure 4.10   Median approval time for Gulf companies products (2008-2010) 
  
 
 
Arab non-Gulf companies products 
 
The median approval time varied from 91 days in Oman in 2008 to 567 days in Saudi Arabia 
in 2010. The approval time for Arab non-Gulf products in Saudi Arabia was four times that 
in the other GCC States (Figure 4.11). The increase in the median approval time to more than 
560 days in 2009 and 2010, respectively, was due to an accumulated backlog for the 
registration applications during the transition period for the newly established authority 
SFDA. Furthermore, priority was also given to products from local and Gulf companies at 
the expense of Arab non-Gulf companies. Saudi Arabia also cited that the slow responses 
from Arab companies further delayed the approval process. In Kuwait, the median approval 
time was 559, 437 and 450 days in 2008, 2009 and 2010 respectively and the increase in 
2008 was mainly due to lack of follow-up from the company to submit more documents or 
answer questions asked by the authority. The reduction by 90 days between 2008 and 2010 
was mainly due to an increase in the number of reviewers in the registration section. The 
approval time in Bahrain, Oman and Qatar varied from 90 days to 531 (Figure 4.11).  Qatar 
recorded a reduction in the duration of registration of medicines from Arab non-Gulf 
pharmaceutical companies and the median approval time is more constant over the 3 year 
period. This is attributed to an initiative by the Qatari MOH requesting the companies to 
register their products in the GCC Centralised system before they submit their products to the 
local system which led to the reduction in the approval time.  
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Figure 4.11 Median approval time for Arab non-Gulf companies products from 
(2008-2010) 
 
 
 
The increase in the approval time in Oman in 2009 and 2010 was mainly attributable to the 
delays of the company responses to the authority queries which affects the overall approval 
time. A significant drop in the registration timelines in Bahrain for the products from Arab 
non-Gulf companies was due to the decision from the Ministry of Health (MOH) to facilitate 
the procedures for drug registration for products approved by any reference authorities such 
as USFDA, EMA or SFDA. 
 
International  companies products 
 
The median approval time in 2008 for products submitted by International companies varied 
from 143 days in Qatar to 587 days in Saudi Arabia (Figure 4.12). The approval time for 
Saudi Arabia is two to three times that of the other countries, with 587, 473 and 434 days in 
2008, 2009 and 2010, respectively, which may reflect the fact that they carry out a full 
review. The mean fluctuated with an increase in 2008, mainly due to priority given to local 
and Gulf companies, which had a negative effect on the approval time for International   
company products. However, between 2009 and 2010, there was an increase in the median 
approval time, mainly due to products remaining in the approval process for a longer time. 
The median approval time for other GCC States varied from 70 days to 301 days, but it 
decreased with 143, 110 and 96 days in 2008, 2009 and 2010 in Qatar, due to the fact that the 
International companies submit complete dossiers. Furthermore, in Kuwait the reduced 
approval time was mainly because the NASs do not enter the quality control analysis stage as 
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long as the sponsor has provided complete pharmaceutical documents to ensure that this 
product is of the desired quality. EASs, however, are sent to the Quality Control laboratory 
for sample analysis and take the companies some time to follow up the queries.  
 
Figure 4.12 Median approval time for International   companies’ products  
(2008-2010) 
 
 
 
 
In Bahrain, there was an increase in the duration of the registration time for medicines from 
the Europe and the U.S. in the year 2009 (264 days) as compared to 164 days in 2008 and 
127 days in 2010. The Bahraini authority stated that this was due to some changes in the 
administration process which led to a delay in drug registrations in 2009. In Oman, there was 
a decrease in the median approval time for products from International companies from 217 
days in 2008 to 182 days in 2010. The reduction in approval time is due to the fact that more 
products from the International companies had been registered in GCC Centralised system 
which reduces the time needed to register the products locally. 
 
 
Asian companies’ products 
 
The median approval time for products submitted in 2008 by Asian companies varied from 
127 days in Qatar to 864 days in Oman (Figure 4.13). Saudi Arabia did not register any 
products from Asian companies during this period because these companies were unable to 
fulfill some of the registration requirements such as their product must first be registered 
with an advanced regulatory body such as EMA and USFDA. Similarly Qatar also did not 
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register any products from Asian companies in 2009 and 2010. Thus, only Oman, Kuwait 
and Bahrain registered products from Asian countries during these periods.  
 
Figure 4.13 Median approval time for Asian companies’ products (2008-2010) 
 
 
 
Bahrain registered an increase in the timelines of registration for Asian pharmaceutical 
companies in 2009 (664 days) as compared to 203 days in 2010. The Bahraini authority 
stated that the increase was attributed to several reasons, for example the low demand for 
Asian pharmaceutical products in Bahrain, the products were not registered with reference 
authorities or the products did not fulfill all the registration requirements such as bio-
equivalence studies. 
 
The approval time for Oman was 697, 864 and 216 days in 2008, 2009 and 2010, 
respectively. The mean fluctuated with an increase in 2008 and 2009 mainly due to the 
development of new regulations for the approval of health products and alternative medicines 
and the delay in the company responses to the authority queries. While Oman and Bahrain 
registered an increased in the median approval time for Asian companies, Kuwait recorded a 
decline in 2009 from 380 days in 2008 to 181 days in 2009. The Kuwaiti authority stated that 
this was due to the increased number of reviewers. However, in 2010 the approval time had 
doubled from that in 2009. 
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DISCUSSION 
 
The regulatory environment has changed in recent years, largely as a consequence of internal 
reviews designed to increase the efficiency and quality of the approval process. At the same 
time relationships have become more open both those between different national regulatory 
authorities and those between industry and the agencies perhaps due to the impact of 
restructuring and performance improvement initiatives. 
In order to make a consistent, timely and high-quality review decision the drug registration 
agency has to acquire the following key components in their quality assurance system: 1. 
Standard operating procedures; 2. Guidelines for the reviewers‟; 3. Review templates; 4. 
Training programs; and 5. Management review of individual files. 
This study investigated the pattern of the total regulatory approval time in GCC States in 
2008, 2009 and 2010 for pharmaceutical products from Gulf, Arab (non-Gulf), Asian and 
International companies. It revealed that the shortest median approval time was for the 
products from Gulf companies. In contrast, products submitted by Arab non-Gulf, Asian and 
International companies had the longest median approval times. The median regulatory 
approval time varied according to the geographical situation of the pharmaceutical 
companies. Several factors led to an improvement in the median regulatory approval time in 
the GCC States during the study period, such as the Gulf Central Registration which had a 
positive impact on submissions from the Gulf companies.  
 
1. Trends in the overall approval times in the Gulf States  
 
 
 The study data showed a downward trend in the median approval time for most of the GCC 
States, during 2008 to 2010. However, the approval time for all approved products in the 
GCC States during this period varied from about 60 days in Qatar and Oman (2009 and 
2010), and to about 609 days in Saudi Arabia (2008). 
 
  There are many factors which can affect and explain the differences in approval time in the 
GCC States. The main factor is the difference in the positions of milestones within the 
approval process, for example, the analytical step starts with the scientific assessment in 
Oman, Saudi Arabia, and Qatar (parallel procedure), but in Kuwait and Bahrain the 
analytical step comes after the scientific assessment (sequential procedure). The study 
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identified the negative influence of the sequential procedure on the products approval times. 
The speed and uniformity of the sample analysis can be achieved by fixing a time limit, 
which may improve the handling of the analytical procedure along with the required quality 
control tests in order to meet the target time. Furthermore, carrying out the quality control 
analysis in parallel with, rather than after the scientific assessment, would be a rational 
decision to avoid any impediment to patients‟ access to medicines.  
 
Bahrain and Qatar do not specify target approval times as there are several factors involved 
in their decisions. The major influencing factors are, the types of products being registered 
(i.e. whether they are NASs, EASs, or therapeutically important or life saving products), the 
quality of the submitted dossiers and the level of follow-up and interaction between the 
pharmaceutical company and the authority. The other three authorities showed slight 
differences in their overall target approval times with the shortest one in Oman being 120 
days. Regulatory approval times have also been influenced by the type of assessment carried 
out by different authorities. Bahrain and Kuwait conduct a verification reviews for all types 
of products registered in countries with competent authorities. Saudi Arabia performs a full 
review on all types of application while Oman and Qatar perform an abridged review for all 
products. It must be noted that all the GCC regulatory authorities require the submission of 
the Certificate of Pharmaceutical Product at one point during the registration process as this 
is the most important requirement for successful completion of the approval process in the 
five member states. The GCC states could take the Singapore system as an example to reduce 
the overall approval time by conducting verification review for all types of medicines which 
are previously authorized by at least two reference authorities, except for biological and 
biotechnology products. 
 
GCC states should seek to increase the level of funding to bring about the required expertise 
and resources to conduct a more extensive review of important medicines, including 
biological and biotechnology products. A clock stop is another important approach which is 
not fully enforced in the GCC authorities to control the overall approval time. EMA is 
obliged by the regulation to reach a decision within 210 days, although the clock is stopped if 
it is necessary to ask the applicant for clarification or further supporting data (EMA, 2009). 
In any case, the clock stop is an important practice that has several advantages for the review 
process, namely, 
1. It controls the approval time 
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2. It keeps the sponsor alert to the time limit and the consequences of delays of their 
    responses to the authority. 
3. It improves the interaction and follow-up practices between the sponsor and the authority 
4. It minimizes the backlog problem 
 
 2. The review times in the Gulf States 
 
The review of new drug applications by regulatory agencies around the world is an 
immensely complex process and the factors influencing regulatory behaviour are 
numerous. According to the Centre for Drug Evaluation and Research (CDER) of FDA, the 
staffing and disease politics (media coverage of diseases) play an important role in the drug 
approval process. An appropriate number of staff has been the dominant influence on 
review times for New Active Substances. It is essential to have a target time for the 
scientific assessment and to monitor the assessment time in order to prevent delays that 
may impact the final approval time. In the US FDA reviewers are under constant pressure 
to meet time goals. They  do not only review new drug applications (NDAs), but  also other 
key documents submitted by sponsors, some of which also have time goals attached. At the 
same time, reviewers must provide advice to sponsors and stay abreast of the latest 
scientific advances in their fields. The results of a study on the US FDA‟s review process 
for NDAs, revealed that the allotted six months priority review and ten months standard 
reviews were found to be inadequate due to concerns of time pressure on the FDA 
reviewers which ultimately required the agency to hire close to an additional 300 
employees within five years with funds from user fees (Rehnquist, 2003). 
 
The main factors (Barrocliffes et al. 1994, Donnelly  et al 1996) which may impact on 
review times are the harmonisation of technical requirements, increase in dialogue between 
industry and authorities, restructuring and reorganization of authorities, introduction by 
authorities of user fees and target review times.  This suggests that differences in review 
times between competent authorities may be related to the way in which the review is 
managed. The time taken from reaching a positive opinion by the scientific committee to 
the final approval varies considerably across the region taking less than 30 days in Kuwait 
and Oman and less than 90 days in Bahrain, Qatar and Saudi Arabia. This is the time 
period to complete the final administrative procedures before granting the registration 
approval in each country. It is important for the authorities to consider improving their 
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internal bureaucratic procedures that cause unnecessary delays in the authorization time 
without any justifiable reason related to the quality of the submitted registration dossiers. 
 
Most regulatory authorities have procedures for accelerated reviews like the fast track 
procedure in Europe, based solely on potential gain time from conditional licensing or from 
authorisation under exceptional circumstances. Hence the need for the product does not seem 
to be a determinant of the speed of the review.  The utilisation of abridged reviews, mutual 
recognition and assessment review sharing among regulatory authorities may enhance the 
efficiency of scientific reviews.  Initiatives such as increased dialogue, production of early 
guidelines and training of regulators may enable increased efficiency. The speed of review 
may depend on the need for the product, the quality of the dossier and the efficiency of the 
regulatory process. Still there is little evidence to show that the need for the product is a 
determinant of the review speed or the time to bring the product to the market. Accelerated 
reviews, fast track procedures and priority assessments constitute the efficiency of the 
regulatory agency (Lumley et al 1996). Facilities for accelerating the development of certain 
products for licensing under exceptional circumstances also are added measures in the 
regulatory process. Sometimes a fast track procedure means that under certain very 
specialized circumstances the regulatory authorities will assess a dossier ahead of time. The 
criteria should be solely those of a significant potential gain for public health. Adherence to 
strict time limits has been one of the quantitative measures for the success of a regulatory 
authority. This has been achieved partly through the introduction of a pre-submission phase 
and clear dialogue (sound scientific advice) with the applicant. Performance indicators like 
the Application Tracking Systems (ATS), monthly publication of decision tables, quality 
management systems, questionnaires, may accelerate the overall assessment and the drug 
registration process in the GCC states.  
 
3. The influence of the type of Companies on approval times 
 
Analysis of the 2008 data showed that, the approval time for the products of Gulf companies 
to be the shortest followed by Arab non-Gulf and International companies in most of the Gulf 
countries.  The main reason for this is the priority given to local manufacturers in the Gulf 
States. In addition, the rapid responses from these companies also help to expedite the 
approval processes. The local manufacturers have an unwritten priority in all regulatory 
review processes, as a part of governmental support to encourage local industry. Such 
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priority treatment reflects positively on approval times. The approval time for products from 
the Gulf companies was the shortest, compared to other types of companies. The median 
approval time in some authorities in 2010 was similar e.g. in Qatar there was no significant 
difference between types of companies nevertheless the approval time for local products still 
showed continuous improvement during 2008, 2009 and 2010 at 102 days, 86 days and 69 
days, respectively. The longest approval time was for products from Asian countries in Oman 
which was 864 days in 2009 and 395 days in Kuwait in 2010.  An unwritten review priority 
has always been given not only to products from the Gulf companies but also to products 
indicated for serious, life-threatening conditions in the GCC states. This is in line with the 
Canadian priority review for medicines and medical device applications intended for the 
treatment, prevention or diagnosis of serious, life threatening or severely debilitating 
illnesses or conditions. Their priority review is specifically applicable where no product is 
currently marketed in Canada and/or where a new product represents a significant increase in 
efficacy and/or significant decrease in risk such that the overall benefit-risk profile is better 
than that of existing therapies (Canadian Review process, 2006).  The longer approval time 
for the products from local companies in Saudi Arabia, compared to other GCC States, may 
be due to the sequential approval process followed in Saudi Arabia. However, the median 
approval time for products from Gulf companies in 2010 in Oman was about 79 days and 
Qatar it was 70. These shorter approval times may be due to the parallel approval procedure 
used in Oman and Qatar. It is important to note that the scientific assessments in Saudi 
Arabia are carried out by independent specialist academic staff which could lead to more 
difficult questions and consequently require more time to respond on the part of 
pharmaceutical companies, while in the other GCC States, the scientific assessments are 
carried out by internal pharmacists.  
 
In addition to the priority procedure, there are many other factors which affect the approval 
time of local companies positively, like the ease of establishing contact with key individuals 
in the authority and a rapid response to queries raised by the authority. Overall the median 
approval time is reduced radically for all products from all regions.  The main reasons for 
this decrease in approval time between 2008 and 2010 in the Gulf States are due to the 
positive effect of the Gulf Central Registration, a rise in the number of reviewers in some 
GCC drug authorities and the parallel procedure used in the regulatory approval review 
process. 
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SUMMARY 
 The findings from this study showed a downward trend in the median approval time 
for most of the GCC States between 2008 and 2010.  
 
 The main reasons for the decrease in approval time in the Gulf States are due to the 
positive effect of the Gulf Central Registration, the rise in the number of reviewers in 
some GCC drug authorities and the parallel procedure used in the regulatory approval 
review process. 
 
 Regulatory approval times in the GCC states have been influenced by the type of 
assessment carried out by different authorities.  
 
 Clock stop is not fully enforced in the GCC authorities to control the overall approval 
time.  
 
 The GCC states should seek to increase the level of funding to bring about the 
required expertise and resources to conduct a more extensive review of important 
medicines, biological and biotechnology products.  
 
 Performance indicators such as Application Tracking Systems, monthly publication 
of decisions and quality management systems, may accelerate the overall assessment 
and drug registration process in the GCC states.  
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INTRODUCTION 
 
The approval of medicines in different countries across the world has been and still is 
performed by regulatory agencies according to their national regulations, although, attempts 
to harmonise the regulations have been made for several years within the GCC region. The 
harmonisation of the regulatory review processes in the GCC States was initiated following 
the issuance of the GCC Health Ministers‟ Council Decree No. 8 in 1976 regarding the 
formation of a study group to report on how a centralised registration review system should 
be established to monitor the marketing of medicines and develop common guidelines for the 
participating authorities (Al-Essa, 2011).  
 
This was followed by a series of GCC Ministerial Decrees relating to the establishment of a 
centralised registration system which was not approved until the Kingdom of Bahrain 
submitted a proposal for the formation of a “Central Committee for the Gulf States” to 
register pharmaceutical companies and their products. This committee ensures that the 
pharmaceutical companies apply satisfactory standards to guarantee manufacturing of high 
quality, safe and effective medicines and to standardise their regulations with regards to 
medicines importation practices in the Gulf States.  
 
The Centralised Procedure for the registration of pharmaceutical companies and medicinal 
products has been established under the Executive Board of the Health Ministers Council for 
GCC States. The Executive Board is chaired by the Director General, who is responsible for 
supervising the work of the board and following up the resolutions and recommendations of 
the Health Ministers‟ Council, assisted by technical, administrative and financial 
departments.   
 
The Gulf Centralised Committee for Drug Registration (GCC-DR) was formed in May 1999 
and included Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, the United Arab Emirates with 
Yemen (joining in 2003). The GCC-DR consists of two representatives from each member 
state. The main role of the committee is to register pharmaceutical companies and their 
products through the joint coordination of the safety, efficacy and quality of medicinal 
products. 
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In order to adopt the Central Registration System, the following two phases were proposed. 
 
Phase 1:  In the year 2000, pharmaceutical companies in the Gulf States had to register their 
products using the local national system while at the same time it was mandated that they 
also use the centralised system.  During a period of two years the following was required: 
 The registration of research companies by the GCC-DR in accordance with the 
centralised registration. 
 The registration of new chemical entities, biological and new technology products. 
 A priority was given to the Gulf States companies to register centrally. 
 The registration of products which have not been through the centralised procedure but 
have been selected for the GCC international tender. 
 
Phase II:  The second phase took effect in 2002 following an evaluation of phase I and 
during this phase all the companies could submit their products through the GCC procedure.    
 During the eleven years (1999-2010) the GCC centralised system received 1,824 medicinal 
product applications and approved 1,165. This study has highlighted the different steps in the 
review process in the GCC-DR system and the way in which these influenced the overall 
timelines.   Information was obtained to identify the practices that accelerate or delay the 
marketing authorisation. Therefore this study mapped the key milestones and associated 
activities and evaluated the quality measures employed by the GCC-DR process. 
 
OBJECTIVES 
The objectives of this study were to: 
 Appraise the regulatory review process in the GCC Central Registration operation. 
 Evaluate the review times for New Active Substances (NASs) and Existing Active 
Substances (EASs) submitted to the GCC Centralised Registration (January 2006 to 
December 2010). 
 Identify the strengths and weaknesses of the centralised review process. 
 Propose strategies that could help the GCC-DR enhance the drug review process 
leading to improved patient access. 
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METHODS 
Information on the total number of applications and approvals together with the timelines 
from January 2006 to December 2010 were obtained directly from the Executive Board of 
the Health Ministers Council for GCC States. The data included the application submission 
date, the registration date and the overall review time.  The products were classified into four 
groups according to the location of the manufacturing companies (GCC, non-GCC Arab, 
international and Asian). The data also included information on different dosage forms 
(solids, semi-solids, liquids, injectables) and the therapeutic indications.   
 
THE GULF CENTRALISED PROCEDURE REVIEW PROCESS MAP AND 
MILESTONES 
Currently the Executive Board is responsible for receiving the registration files and the 
prescribed fee for the registration of pharmaceutical manufacturing companies and their 
products.  After receiving the files, the Executive Board forwards the files to all the member 
states for their evaluation. Every member state should review the files and provide their 
recommendations to the GCC-DR. The registration of the company is decided based on the 
recommendation of the inspection team.  If the company has been recommended to be 
registered, the GCC-DR issues the registration certificate; otherwise the company will be 
notified accordingly.  The inspection team consists of three members from three different 
member States.  The selection of members is carried out based on certain criteria where every 
member state would have an equal number of visits.  Upon completion of the visit, the head 
of the inspection team will prepare a visit report and it is signed by other members of the 
team and then the report is submitted to the GCC-DR.   Similarly, the GCC-DR forwards the 
registration files of the products to each individual Member State for evaluation.  The 
samples are sent for analysis to one of the four laboratories (Saudi Arabia, UAE, Kuwait and 
Oman) which are accredited by GCC-DR.  The registration of products is determined on the 
basis of the analysis reports. There are basically five steps for the regulatory authority in the 
Gulf Central Registration System. Some of these steps are critical and constitute a substantial 
part of the review process (Figure 5.1). The review process map indicates the main steps in 
the review and approval process and identifies the key milestones for monitoring and 
analysing timelines. Receipt and validation include administrative registration (reference 
number) and checks on legal requirements, the status of the company, manufacturer etc. as 
well as a „checklist‟ validation of the application content (e.g. technical sections, CPP status). 
The pharmaceutical  
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Figure 5.1: PROCESS MAP FOR GCC CENTRALISED REGISTRATION 
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companies are required to submit 16 samples of their product in addition to eight copies of 
the product dossier and one original copy which would remain with the Gulf Central 
Registration Office.  While two separate GCC States would be chosen through a computer 
program alphabetically according to the countries name, to act as rapporteurs, the other GCC 
States would keep the dossiers for documentation purposes. The rapporteurs are not chosen 
because of their expertise in a certain area of regulatory science, but to give equal 
opportunities to all the members states in a systematic manner of selection. Similarly, the 
reference laboratory chosen, to carry out the analysis, is based on the equity of the number of 
dossiers distributed between these laboratories and not on the ability of these laboratories to 
perform the analysis. 
 
Hypotheses 
This study examined the following hypotheses, 
1. There was a significant increase in the number of products registered from 2006-
2010. 
2. The highest number of products approved by GCC-DR is linked to those originating 
from the companies in the GCC region. 
3. There was a significant increase in the approval time between 2006-2010 in the GCC-
DR. 
4. The approval time for products from GCC pharmaceutical companies was shorter 
than for other companies. 
 
RESULTS 
 
Products considered and their characteristics 
During the five year period (2006 - 2010), the number of pharmaceutical products for human 
use successfully registered through the GCC Centralised Registration procedure was 413. For 
the purpose of clarity the results will be presented in four parts as follows: 
Part I    - Number of products approved in the Gulf Centralised Procedure. 
Part II   - Approval time in the Gulf Centralised Procedure.  
Part III  - Approval time for different dosage forms  
Part IV  - Approval time for different therapeutic groups. 
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 Part I:  Number of products approved in the Gulf Centralised Procedure 
(2006 - 2010) 
 
 A total of 413 Pharmaceutical Products (EASs and NASs) were registered by GCC-DR 
during the time period 2006-2010. The highest number was found in the year 2009 (130; 
32%) followed by the years 2007 (116; 28%), 2008 (91; 22%) and 2006 (60; 15%) (Figure 
5.2).   There was a substantial drop in the number of approved products  in 2010 (16;4%) 
which was due to the fact that the pharmaceutical companies failed to comply with the new 
GCC guidelines for the stability testing of active pharmaceutical ingredients (APIs) and 
finished pharmaceutical products (FPPs). The GCC countries come under climatic Zone III 
and IVa (hot and dry & hot and humid) the new guideline which was implemented  in 2009 
replaced the long-term testing condition of  25 °C ± 2 °C/60% RH ± 5% RH for climatic 
zone III and IV  with 30 °C ± 2 °C/65% RH ± 5% RH. The results showed an overall 
significant association (p<0.001) between the total number of registered pharmaceutical 
products and registration years. 
 
Approval of Existing Active Substances (EASs) and New Active Substances (NASs) in 
the Gulf Centralised Procedure (2006 – 2010) 
Out of the total of 413 products approved in the Gulf Central Registration between 2006 and 
2010, 317 products were EASs (Table 5.1) and 96 NASs (Table 5.2). 
 
Figure 5.2: Total number of pharmaceutical products approved in the Gulf 
Centralised Procedure (2006-2010) 
Statistical analysis of these data using a simple linear regression showed a significant association between the 
total number of registered pharmaceutical products and registration years (p<0.001). 
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Table 5.1: Number of EASs Approved in the Gulf Centralised Procedure from various 
regions, dosage forms and therapeutic classes 
Characteristics                Registration Year  
2006 2007 2008 2009 2010  
Region                Number of EASs  Total 
 Arab 7 9 12 20 3 51 
 Asian 6 2 7 3 0 18 
 Gulf 38 64 46 46 12 206 
 International 5 10 11 16 0 42 
Dosage Form            
 Injectables 16 4 14 9 0 43 
 Liquids 6 18 15 22 3 64 
 Semi-Solids 9 15 13 6 1 44 
 Solids 25 48 34 48 11 166 
Therapeutic Class            
 Anaesthesia 2 0 0 1 0 3 
 Cardiovascular system 14 8 20 15 1 58 
 Central Nervous system 4 8 9 9 3 33 
 Ear, Nose and Oropharynx 0 1 0 0 0 1 
 Endocrine system 2 2 0 17 3 24 
 Eye 0 1 1 3 0 5 
 Gastrointestinal system 4 6 3 3 1 17 
 Immunological Products and Vaccines 0 0 0 0 0 
0 
 Anti-infective 10 28 26 19 3 86 
 Musculoskeletal and Joint diseases 6 6 3 4 0 19 
 Malignant disease and immunosuppression 0 0 0 0 0 0 
 Nutrition and Blood 7 5 3 3 0 18 
 Obstetrics, Gynaecology and Urinary-tract 
disorders 0 0 0 1 2 
 
3 
 Respiratory system 3 8 7 6 2 26 
 Skin 4 12 4 4 0 24 
Total 56 85 76 85 15  
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Table 5.2: Number of NASs Approved in the Gulf Centralised Procedure from various 
regions, dosage forms and therapeutic classes 
Characteristics                 Registration Year  
2006 2007 2008 2009 2010  
Region                 Number of NASs Total 
Arab 0 0 0 0 0 0 
Asian 0 0 0 1 0 1 
 Gulf 0 2 0 0 0 2 
 International 4 29 15 44 1 93 
Dosage Form       
 Injectables 2 21 9 26 1 59 
 Liquids 1 2 0 2 0 5 
 Semi-Solids 0 0 0 0 0 0 
Solids 1 8 6 17 0 32 
Therapeutic Class        
 Anaesthesia 1 0 1 0 0 2 
 Cardiovascular system 0 6 7 11 0 24 
 Central Nervous system 0 1 2 2 0 5 
 Ear, Nose and Oropharynx 0 0 0 0 0 0 
 Endocrine system 1 3 0 10 0 14 
 Eye 0 1 0 0 0 1 
 Gastrointestinal system 0 1 1 0 0 2 
 Immunological Products and Vaccines 0 0 0 13 0 13 
 Anti-infective 0 0 0 2 0 2 
 Malignant disease and immunosuppression 0 2 3 0 0 5 
 Musculoskeletal and Joint diseases 0 0 0 1 0 1 
 Nutrition and Blood 2 17 1 4 0 24 
 Obstetrics, Gynaecology and Urinary-tract 
disorders 0 0 0 1 1 
 
2 
 Respiratory system 0 0 0 1 0 1 
Skin 0 0 0 0 0 0 
 Total 4 31 15 45 1  
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There were a similar number of EASs approved centrally in 2007 and 2009 (85; 27%) 
followed by 2008 (76; 24%), 2006 (56; 18%) and 2010 (15; 5%) (Figure5.3). Statistical 
analysis using a simple linear regression analysis showed that the increase in the number of 
registered EASs was statistically significant (p<0.001).   
 
The highest number of NASs  was registered in 2009 (45), whilst the lowest was in 2010 (1) 
(Figure 5.4). Out of the 96 NASs, 93 products (97%) were found to be from international 
companies. Statistical analysis using a simple linear regression showed a significant increase 
in the number of registered NASs (p<0.001). 
 
By individual regions, 208 (50%) medicines were identified as being approved from Gulf, 51 
(12%) from Arab non-GCC, 19 (5%) from Asian and 135 (33%) from international 
companies (Figure 5.5). Out of the total of 317 EASs approved in the Gulf Central 
Registration between 2006 and 2010, by individual regions, 206 (65%) drugs were identified 
as being approved from Gulf, 51 (16%) from Arab non-GCC, 18 (6%) from Asian and 42 
(13%) from international companies. 
 
Figure 5.3: Number of EASs approved in the Gulf Centralised Procedure 
                                                             (2006-2010) 
 
Statistical analysis using a simple linear regression showed a significant increase in the number of registered 
EASs (p<0.001). 
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Figure 5.4: Number of NASs approved in the Gulf Centralised Procedure 
(2006-2010) 
 
Statistical analysis using a simple linear regression showed a significant increase in the number of registered 
NASs (p<0.001). 
 
Figure 5.5: Approved pharmaceutical products (EASs & NASs) from GCC international, Arab 
non-GCC and Asian companies (2006-2010) 
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Part II: Approval times in the Gulf Centralised Procedure (2006 – 2010) 
 
The total approval time for the period studied (2006 - 2010) includes all the 413 EASs and 
NASs from different companies. During the five years, the median approval time ranged 
from 107 days in 2006 to 265 days in 2010. There was a significant increase in the median 
approval time between 2006 and 2010 which was due to several factors. These included the 
limited number of meetings by the GCC-DR. although the seven member states met four to 
five times a year to discuss the product review reports, on the other hand there was a steady 
increase in the number of registration applications. Another reason for the delay in 
registration was the assessment review process where two authorities are selected 
alphabetically to review a registration dossier. There was also a lack of a standard evaluation 
template for product assessment which leads to an increase in the correspondence which is 
sent to the sponsor in several batches and at different times. Statistical analysis using the non 
parametric test (Kruskal-Wallis test) across the five-year period showed that there was a 
significant increase in the approval time for pharmaceutical products (p<0.001) (Figure 5.6)   
 
Figure 5.6: Median approval time for all pharmaceutical products in the Gulf 
Centralised Procedure (2006-2010) 
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Statistical analysis using non parametric test (Kruskal-Wallis test) over the five-year period showed that there 
was a significant increase  in the approval times for pharmaceutical products (p<0.001). 
 
118 
 
Approval time of Existing Active Substances (EASs) in the Gulf Centralised Procedure 
(2006 - 2010)  
 
Approval time for the 317 EASs approved in the Gulf Centralised Procedure between 2006 
and 2010 varied from one year to the next. The lowest median approval time was for 2006 
(114 days) and the highest median for 2010 (265 days) (Figure 5.7). Statistical analysis using 
the non parametric test (Kruskal-Wallis test) across the five-year period showed that there 
was a significant upward trend in the median approval time for EASs (p<0.05). In general for 
the years 2006 to 2009 there is a wide range because in the centalised procedure there is no 
defined target time within which the company time is also not specified (no clock stop). 
However, in 2010 the range is significantly reduced because there were very few products 
approved as a result of the implementation of ICH stability guideline. 
 
Figure 5.7: Median approval time for EASs in the Gulf Centralised Procedure 
(2006-2010) 
 
 
Statistical analysis using the non parametric test (Kruskal-Wallis test) over the five-year period showed that 
there was a significant difference in the median approval time for EASs (p<0.05) 
  
Approval time for Existing Active Substances (EASs) by GCC, international, Arab non-
GCC and Asian companies (2006-2010)  
 
The median approval time for EASs varied for different cohorts of companies based on 
location, for example the shortest approval time was for Gulf company products (134 days) 
and the longest for those of international companies (346 days). The shortest approval time 
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for Gulf company products was due to the waiver of analysis requirements. A product is 
waived from analysis if it is registered in any one of the 4 GCC countries (Oman, Saudi 
Arabia, United Arab Emirates or Kuwait) where the Quality Control Laboratory for these 
States has the accreditation from the GCC. The median approval time for Arab companies 
was 227 and 332 calendar days for Asian companies. Statistical analysis using the non 
parametric test (Mann-Whitney U test) showed that there was a significant difference of 
approval time between international companies (median approval time=346 days ) and Gulf 
companies (median approval time=134 days) (p<0.001). 
 
Approval time for New Active Substances (NASs) in the Gulf Centralised Procedure 
(2006 - 2010) 
 
In the year 2009, the highest number of NASs was registered (45 products) with a median of 
288 days. In 2006, only four products were registered with median of 31 days. In 2007, 31 
NASs were registered with a median of 138 days. In 2008, 15 products were registered with 
median of 140 days. In 2010, the lowest number of products was registered (1 product only) 
with a registration time of 131 days. The results obtained from performing analysis of 
Kruskal-Wallis test showed that there was a highly significant upward trend in the median 
approval time for NASs products between 2006 and 2010 (p<0.001). This was due to several 
factors, including a limited number of meetings by the GCC-DR (only four to five times a 
year) and during this period there was a steady increase in the number of registration 
applications (Figure 5.8). The reason for the variation in approval times is similar to that 
expressed for EASs. This variation is not acceptable and could be mitigated by introducing 
target times.  
 
Part III: Approval time for different dosage forms for all Existing Active 
Substances (EASs) and New Active Substances (NASs) in the Gulf 
Centralised Procedure (2006-2010) 
 
From the 317 EASs  registered with the Gulf Centralised Procedure between 2006-2010, the 
lowest number constituted the injectable forms (14%) followed by the semi-solid dosage 
forms ( 20% ) with the highest represented by solid dosage forms (52%). Approval times  
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Figure 5.8: Median approval time for NASs in the Gulf Centralised Procedure 
                                                       (2006-2010) 
Statistical analysis using the non parametric test (Kruskal-Wallis test) showed that there was a significant 
difference in the median approval time for NASs between 2006 and 2010 (p<0.001). 
 
ranged from 138 days for liquids to 350 days for injectables (Figure 5.9). In general, when 
the dosage form is more complex, additional time is needed to approve the product. Special 
studies and more steps are needed to analyse some products such as solutions for IV infusion 
which need additional tests such as sterility and pyrogen testing. 
 
Figure 5.9: Median approval time for different dosage forms for EASs and NASs in the Gulf 
Centralised Procedure (2006-2010) 
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In terms of dosage forms, out of the 96 NASs registered in the Gulf Centralised Procedure 
(2006-2010), the lowest number registered was represented by the liquid dosage forms (5) 
with a median approval time 128 days. The highest number registered was represented by the 
injectable forms (59) with a median approval time 288 days. 
 
Part IV:  Approval times for Existing Active Substances (EASs) and New 
Active Substances (NASs) by therapeutic class, (2006-2010) 
 
 
The therapeutic class of 314 EASs was assessed and the lowest number was represented by 
ear, nose and oropharynx preparations (1 preparation) and the highest number represented by 
anti-Infective (86 preparations). The analysis of the approval time of EASs registered 
between 2006 and 2010 involved the four largest therapeutic groups, namely, 
 The cardiovascular system (CVS) 
 The central nervous system (CNS) 
 The gastro-intestinal system 
 Anti-infective 
 
The range of approval times for EASs analysed by therapeutic class varied from 206 days for 
central nervous system products to 162 for anti-infective products (Figure 5.10). The trend in 
approval times for EASs from different therapeutic groups was attributed to the GCC-DR 
assessment requirements depending on the nature of the products which may include the 
need for both clinical and bioequivalent studies and the prolongation of the analytical time.  
 
Ninety-six NASs were approved between 2006-2010 and the lowest number was represented 
by the eye, musculoskeletal and joint disease and respiratory system preparations (one 
preparation) whereas, the highest number was represented by cardiovascular and nutrition 
and blood preparations (24 preparations). The median approval times for NASs analysed by 
the main therapeutic classes ranged from 274 days for anti-infective products to 92 for 
gastro-intestinal products. The main factor for the variation in the approval time for different 
therapeutic groups was the nature of the products evaluated.   
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Figure 5.10: Median approval time for different therapeutic class for EASs and NASs in the 
Gulf Centralised Procedure (2006-2010) 
 
 
DISCUSSION 
This study investigated the pattern of total regulatory approval times in the Gulf Centralised 
Procedure over the period from 2006 to 2010. It also addressed the various factors which 
may have a positive or negative effect on the total approval times. It showed that the total 
number approved in the Gulf Centralised Procedure was 413 including both Existing Active 
Substances (EASs) and New Active Substances (NASs). The outcomes revealed that the 
largest number of medicines submitted for review and approved by GCC-DR occurred in 
2009. The study examined four hypotheses and their respective findings are discussed below. 
 
Hypothesis 1: There was a significant increase in the number of products registered 
from 2006 to 2010. 
 
The highest percentage of approved products was in the year 2009.  There was a considerable 
decrease in the number of approved products in 2010. This was due to the fact that the 
pharmaceutical companies failed to comply with the new GCC guideline for stability testing 
of active pharmaceutical ingredients (APIs) and finished pharmaceutical products (FPPs). 
The new guideline was a major challenge to most of the pharmaceutical companies leading to 
the rejection of those which failed to meet the new stability study specifications. Other 
factors influencing the number of approved products in 2010 were that the Saudi FDA began 
to evaluate all the products in addition to the two rapporteurs from the Gulf States designated 
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to review the products. This resulted in a large number of queries raised from the Saudi Food 
and Drug administration (SFDA) which substantially delayed the review process and there 
was a significant decrease in the number of products approved in 2010. However, despite this 
change in 2010, this hypothesis was accepted.  
 
Hypothesis 2: The highest number of products approved by GCC-DR is linked to those 
originating from the companies in the GCC region. 
 
The number of products approved during the period of the study varied for different 
companies based on their geographical location. The highest percentage of products 
approved was from the Gulf companies, followed by Arab companies, international 
companies and finally the Asian companies. However, the highest number of products 
approved from GCC companies could be due to several factors including; that the GCC 
manufacturers increased their efforts to obtain the GCC-DR approval in order to facilitate 
entry into the international tender which is the common purchase route by GCC states. This 
has an impact on the number of submissions and approvals in GCC-DR. Other factors that 
might have also contributed to the increased number of products approved by GCC-DR from 
GCC companies was the decision to waive the requirement to submit full time stability 
studies during the first submission. The GCC manufacturers need to submit only one year 
full time stability data during the first submission. However, non-GCC manufacturing 
companies need to submit full time stability studies for the whole shelf life. This is because 
the GCC States are making efforts to support and improve their local manufacturing 
capabilities and the production capacity for the local population. The lower number of 
products approved by GCC-DR was from non-GCC manufacturing companies due to the 
strict GCC regulations that require evidence of registration in countries with developed 
regulatory systems. Therefore this hypothesis was accepted. 
 
Hypothesis 3: There was a significant increase in the approval time between 2006-2010 
in the GCC-DR. 
 
During the five year period of the study (2006 – 2010), the median approval time   
significantly increased due to several factors which included the limited number of meetings 
by the GCC-DR and the increased number of applications for registration.  Other factors that 
delayed the registration were the assessment review process where two authorities are 
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selected alphabetically to review the registration dossier. In addition, the lack of a standard 
evaluation template for product assessment leads to an increase in the correspondence which 
is sent to the sponsor in several batches and at different times. It is recommended to have one 
standard assessment template and rather than selecting the reviewing authorities 
alphabetically, the dossier should be sent to all countries and all assessments combined into 
one final report on which the final decision in the GCC-DR could be based. A clock-stop 
system is not enforced in the Gulf Centralised Procedure and this delays the company 
response to queries from the GCC Central registration committee. The implementation of a 
clock-stop will ensure the sponsor meets the deadline and would allow more time for the 
reviewers to complete the assessment of the submitted data. The sample analysis stage is an 
essential part of the review process that impacts on the overall approval time. It is completed 
after the scientific assessment as the outcome of the sample analysis affects the final approval 
decision. Carrying out the quality control analysis in parallel, rather than after the scientific 
assessment, would avoid the impact in the overall registration time. The queuing process is 
straightforward and allows appropriate handling of the registration dossiers in an organised 
manner. However, the lack of regular monitoring of queue time could lead to a backlog. 
Managing the priority review is another important issue that needs recognition by GCC-DR 
and should be dealt with according to set guidelines and SOPs that clearly specify the 
conditions under which products can be taken out of the queue for such review. Therefore, 
adequate resources and electronic handling of the queuing process should be provided to 
support accurate follow-up of the pending dossiers, priority reviews and fast-track products. 
On the basis of these finding this hypothesis has been accepted. 
 
Hypothesis 4: The approval time for products from GCC pharmaceutical companies 
was shorter than for other companies. 
 
The approval time for pharmaceutical products varied for different cohorts of companies 
based on their location, for example the shortest approval time was for the Gulf company 
products and the longest for international companies and this was due to the waiver of 
analysis requirement. The analysis is waived for a product if it is registered in any one of the 
four GCC countries (Oman Saudi Arabia, United Arab Emirates or Kuwait) where the 
Quality Control Laboratory has the accreditation from the GCC. There are other factors 
which have a positive effect on the approval time for Gulf companies but have a negative 
effect on the international, Arab non-GCC and Asian companies.  
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This includes the geographical proximity of the company to the authority which leads to an 
effective interaction and thus a faster response to any question asked by the authority. 
Additionally, most locally manufactured products are EASs and do not need very much 
consultation during the scientific review compared to NASs. 
 
 However, a priority procedure is a common practice in many authorities, the rapid approval 
time is also due to  the GCC States  making efforts; particularly (Oman, Saudi Arabia, UAE, 
and Kuwait) to improve their local manufacturing capabilities and the production capacity for 
the local population (Al-Essa, 2011). The data supported this hypothesis and therefore it was 
accepted.   
 
For the first time this study has examined the centralised regulatory review process in the 
Gulf region and identified which steps within the process take the most time. In addition, it 
has highlighted the factors which may improve or delay the approval process resulting in 
accelerating patients' access to medicines. Furthermore these results may improve the 
registration process thereby saving time and resources.  
 
SUMMARY 
  
 There was a significant upward trend in the regulatory approval times in the Gulf 
Centralised Registration process between 2006 and 2010.  
 The limited number of meetings per year led to a delay in the feedback for the 
submitted files to GCC-DR by the companies.   
 Further correspondence after registration should be dealt with by individual local 
health authorities rather than centrally. 
 The reference laboratory chosen to carry out the analysis is based on equity of the 
number of dossiers distributed between these laboratories, not on the ability of these 
laboratories to perform the analysis and that can lead to an increase in the analysis 
period. 
 There was no clock-stop system and this delayed the company response to queries 
from the GCC Central registration committee. 
 The re-registration (renewal) of pharmaceutical companies and their products led to a 
reduction in the number of new product applications reviewed by GCC-DR in 2010. 
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 The lack of a standard assessment template for product evaluation leads to a number 
of requests for additional data at different stages of registration. A standard template 
could possibly avoid such delays and lead to more consistent outcomes.  
 Using information technology and e-mails could speed up the registration process 
rather than the manual exchange of the product registration files between the 
Executive Office and the member states.   
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CHAPTER 6 
 
 
 
 
 
 
 
 
 
 
 
An Evaluation of the Gulf States Views and 
Experiences with GCC Centralised Procedure 
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INTRODUCTION 
The historical implementation of the central registration system was subject to several 
criticisms with challenges from both the pharmaceutical industry as well as government. The 
GCC-DR received 1,824 medicinal product applications out of which 1,165 (64%) 
applications were approved during the eleven years from 1999 to 2010. The pharmaceutical 
industry was apprehensive about whether the GCC-DR system would be a hindrance to the 
timely approval of medicines in the region while the government officials were concerned 
about losing sovereignty to the centralised authority (Hashan, 2005). The collaborative 
efforts between the member countries however proved to be effective and substantiated the 
support of the GCC-DR system for each GCC country improving the regulatory approval 
processes and operation efficiencies at the national level. 
Two members from each of the seven GCC countries represent the GCC Central Drug 
Registration (GCC-DR) Committee with the current procedure in force and two member 
countries are chosen to review a registration dossier. The selection of those countries is 
unbiased and purely based on alphabetical order and all the GCC countries are equally 
responsible for evaluating the quality, safety and efficacy of medicines.  Thus, all seven GCC 
countries consisting of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE and Yemen are 
provided with copies of the product registration dossier for their individual assessments. The 
member countries meet four to five times a year to discuss the product review reports issued 
by the reviewers from each country and an approval decision is made by common agreement.  
The only studies that have addressed the GCC region was the one reported by Hashan in 
2005 and later by Al-Essa in 2011. They reported that there are three common phases in the 
GCC regulatory review process: submission, evaluation, and authorisation. The similarities 
and differences in the key milestones and activities in the GCC states made it possible to 
propose a new process, which could underpin the degree of standardisation required for a 
strong regulatory body that facilitates an effective drug approval process for the region (Al-
Essa,2011). These are the key components essential for the development of a strategic plan 
for strengthening drug regulations in the Gulf region. This chapter evaluates the experiences 
and opinions of all seven Gulf States regulatory authorities with the GCC Central 
Registration Process. 
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OBJECTIVES 
The main objectives of this study were to: 
 Evaluate the regulatory views and experiences of all seven Gulf States with respect to the 
Centralised Procedure. 
 Appraise the barriers and opportunities to the full implementation of the Gulf Centralised 
Procedure.  
 Make recommendations to improve the Gulf Centralised system as well as to identify its 
future strategy based on the views of the national regulatory authorities. 
 
METHODS 
There is a lack of information and research on the GCC Centralised Registration Procedure 
and therefore, with this limited information, there is a need to develop suitable measurement 
tools in order to obtain the relevant data required for this study. The development of the 
assessment instrument was carried out over 5 phases; 
Phase 1 – Identify target population and item generation 
Phase 2 – Development of themes and item reduction  
Phase 3 – Development of the first version of the instrument, Gulf Assessment of                   
                Centralised Procedure (GACP) 
Phase 4 – Pilot study 
Phase 5 – Development of the final version of the GACP 
This final version of the study instrument was sent to the seven Gulf States and followed up 
after one month. 
RESULTS  
This section presents the results from the development of the GACP and the views of the 
seven GCC regulatory authorities. For the purpose of clarity the results will presented in two 
parts: Part I - The development of the study instrument (GACP); and Part II - The views of 
seven Gulf states about the Centralised Procedure. 
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Part I:   The Development of the Study Instrument (GACP)  
Phase 1 – Target population and item generation 
An informal interaction and dialogue was held with the members of the GCC-DR which 
consist of two individuals (The head of the agency the head of the registration department) 
from each of the seven member states in the Gulf region. This allowed the generation of 
items for the development of the GACP. In addition, the relevant literature was also reviewed 
to inform this phase of the development.   
Phase 2 – Development of themes and item reduction 
There were a total of five themes emerging from the item generation phase based on 
the objectives of the study. The first version of the questionnaire comprised 5 sets of 
questions pertaining to the following headings;  
Theme 1- Value of centralised procedure consisting of seventeen sub-themes. 
 Theme 2- Utilization of resources consisting of five sub-themes; 
 Theme 3- Regulatory expertise consisting of eight sub-themes; 
 Theme 4- Importance of CP consisting of five sub-themes; 
Theme 5- General observations consisting of seven sub-themes. 
Phase 3 – Development of the first version of the instrument: Gulf Assessment 
                 of Central Procedure (GACP) 
 
Any item that was mentioned by only one individual was not included in the themes and sub-
themes unless these were country or regulatory authority specific items. Having selected the 
themes and sub-themes, these were put in an appropriate structured questionnaire. These 
were then reviewed by an expert panel using four appropriate parameters; namely; language 
clarity, completeness of the statement, appropriate relevance and scaling. Account was also 
taken with regard to the length of the items and their readability.   
Phase 4 - Pilot study 
The purpose of the pilot study was to assess the practicality, feasibility, applicability and 
relevance of the study instrument to assessing the Gulf Centralised Procedure. Having   
developed a structured questionnaire it was sent to the head of agency in two GCC States; 
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namely Oman and the UAE.   Feedback on the first version of the questionnaire was obtained 
from Oman and UAE Drug Control Authorities. The pilot study clearly indicated that such a 
study into the GCC Central Registration Procedure was essential to bring about 
standardisation and harmonisation of procedures. This would inevitably improve the 
registration processes for both the applicants as well as the approving authorities.   
Based on the feedback from the pilot study, the following item was deleted. 
Part 1 – Question 1.1.7: Do you think your agency has the necessary expertise for the 
Centralised Procedure and are you willing to contribute? 
The following item was added in Part 1 of the questionnaire. 
Part 1 – Question 1.1.8: Is your agency willing to contribute to the revision of these 
guidelines? 
Finally at the end of the questionnaire, six simple questions were added to enable feedback 
and opinions about the questionnaire that was used to obtain the information from each of the 
Drug Regulatory Authorities in the GCC. This feedback was critical in order to design more 
effective assessment instruments for future studies (Figure 6.1). 
Phase 5 – Development of the final version of the GACP 
Following the pilot study and implementation of the changes suggested by the participating 
regulatory authorities, the development of GACP was completed. Thus, the final version of 
the instrument consists of 42 items grouped into five major categories. In addition it includes 
an introductory page collecting the respondents' personal details (Figure 6.2). The final 
version of the questionnaire was sent to all seven Gulf States with a clear guideline on the 
aims and objectives of the study and a confidentiality note that would ascertain the 
confidential procedure for the collection of data to prevent the identification of individual 
respondents. Generally the structure of the questionnaire did not differ from that used in the 
pilot study. Only minor adjustments and refinements were carried out to make the final 
questionnaire more user friendly and easily understood by the respondents. 
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Figure 6.1 
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Figure 6.2 
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The final version of the questionnaire was well received by all the Drug Regulatory 
Authorities in the region. They successfully completed the questionnaire and submitted the 
completed documents in good time. Their full co-operation was significant for the success of 
this study. 
Part II:  The views of seven Gulf States about the Centralised Procedure  
The regulatory authorities who are responsible for the regulation of pharmaceutical products 
in the seven Gulf States participated in the survey and a 100% response rating was achieved. 
(Table 6.1).  
 
Table 6.1 - List of the seven participating authorities in the Gulf Cooperation Council (GCC) 
States  
Position Agency Country 
Director, Pharmacy & Drug Control Ministry of Health Bahrain 
Drug Registration and Release Superintendent Drug and Food Control - 
Ministry of Health 
Kuwait 
Director General of Pharmaceutical Affairs & 
Drug Control 
Directorate General of 
Pharmaceutical Affairs and 
Drug Control- Ministry of 
Health 
Oman 
Head of Drug Registration Section  Drug Control Department- 
Supreme Council of Health 
Qatar 
Executive Director of Licensing Department - 
Drug Sector 
Saudi Food and Drug 
Authority 
Kingdom of Saudi 
Arabia (KSA) 
Head of Registration and Pricing Department 
 
Drug Control Department - 
Ministry of Health 
UAE 
Member of the board council Supreme board of drugs and 
medical appliances 
Yemen 
 
Section 1 - Value of the Centralised Procedure (CP) 
The complete responses from all GCC member states indicated that the Centralised 
Procedure (CP) had indeed contributed to an effective system for authorising medicinal 
products for the GCC. This was ascertained from their views that the GCC-DR achieved its 
main objective, by providing the best possible scientific opinion for the CP. They also agreed 
that the CP has appropriate guidelines for regulatory review in the GCC-DR and that the 
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quality of the CP decision-making is satisfactory to good as compared to the national system. 
The CP which has been put in place since 1999 is clearly still functioning well as six of the 
member countries indicated that the quality of the CP Decision-Making process is good. 
Only Saudi Arabia rated the quality of processes as satisfactory.  
This signifies that all GCC member countries support the centralised procedure in registering 
pharmaceutical products. With the strong support for the CP, four member countries 
(Kuwait, Saudi Arabia, UAE and Yemen) indicated that the CP should be extended to other 
products to include herbal products, health products and medical devices while Bahrain, 
Oman, and Qatar reported that CP procedure should not be extended to other products 
(Figure 6.3). 
Figure 6.3 The products which could potentially be registered under the Centralised Procedure 
 
 
The suggested range for the approval timeline for products reviewed in the Centralised 
Procedure should be between 6-12 months as indicated by four of the member countries 
(Oman, Saudi Arabia, UAE, and Yemen) while Bahrain, Kuwait and Qatar indicated that it 
should be 3-6 months (Figure 6.4). The latest data available (2010) indicated that the median 
approval time for the Centralised Procedure was nine months (chapter 5). 
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Figure 6.4 Proposed approval timeline for products in Centralised procedure 
 
 
 
Responses for GCC authorities with regard to improving the CP  
 
Registration process and timelines  
The long approval time could be the main obstacle in advocating the CP as the main route for 
registration of products in the region. As a result, five of the member countries (Bahrain, 
Kuwait, Oman, Saudi Arabia and UAE) agreed that the CP process could be shortened, 
although two (Yemen and Qatar) indicated otherwise (Figure 6.5). Bahrain and UAE 
indicated that the CP approval time can be reduced by following the exact rules and 
regulations in the guidelines by all sectors. In addition, if the verifications were carried out at 
the time when the applications were submitted, the time line could be reduced. UAE also 
added that another way would be for the reviewing country to send the applications with 
preliminary assessment before the committee meets for their discussion as the committee 
sees the assessment for the first time at their meeting. To reduce the timeline further, Oman 
stated that the member states should not demand more requirements in order to avoid 
delaying the whole process; but they should encourage the sponsors to respond expeditiously 
to any such requests and by increasing the number of meetings. Kuwait stated that adopting 
mutual recognition from mature regulatory authorities would shorten the approval time. 
Saudi Arabia, on the other hand, advocated parallel national approvals in the Gulf could also 
expedite the process. 
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Figure 6.5 – Responses for the GCC authorities with regard to improving the GCC Centralised Procedure  
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Bahrain, Oman, Saudi Arabia and UAE, agreed that certain aspects of the registration 
procedure could be simplified to reduce the duration of the CP process. Bahrain stated 
that this could be done by developing a written policy for fast track registration, while 
Saudi Arabia and UAE advocated the implementation of electronic communication along 
with an online submission. Oman stated that the countries must consolidate all the 
requests for additional information to be sent to the sponsors as one single batch instead 
of in several batches and at different times.  
 
Centralised Procedure guidelines 
Bahrain, Kuwait, Oman, Qatar, and Yemen agreed that the CP has appropriate guidelines 
for the regulatory review in GCC-DR while UAE and Saudi Arabia report that currently 
the guidelines are not adequate. Bahrain, Kuwait, Qatar, Saudi Arabia, and UAE, 
indicated that some current guidelines need to be revised or updated. The areas 
recommended include GMP inspections, generics registration, contract manufacturing 
and biological / biosimilar registration. These guidelines should also be revised on a 
regular basis according to international requirements. All the member countries with the 
exception of Yemen indicated that they would be willing to contribute to the revisions of 
CP guidelines. 
 
GMP Inspections 
All member countries indicated their concerns about GMP inspections. Six of the member 
countries reported on the quality of expertise for GMP inspectors as well as the quality of 
the reports. UAE cited other causes which included the inconsistency of the inspections 
and decision-making with regard to classification of defects and time given for corrective 
actions and their follow-up. 
 
The effectiveness and efficiency of the GCC-DR 
Only Qatar and Oman indicated that the organisation and administration of the GCC-DR 
are effective and efficient. Bahrain, Kuwait, Saudi Arabia, UAE, and Yemen reported that 
the organisation and administration of the GCC-DR is not effective and efficient. Bahrain, 
Saudi Arabia, UAE and Yemen cited the voting system as the contributing factor to the 
ineffectiveness which in turn affects the efficiency of the GCC-DR system. Kuwait cited 
that choosing the countries to conduct the evaluation affected the effectiveness and 
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efficiency. In addition, Kuwait indicated that there is political pressure in some Gulf 
States for special consideration to be given to local manufacturers. Bahrain also added 
that the SOP for the voting system, which requires total agreement between all member 
states, should be written into the policy document. 
 
Contribution to GCC-DR 
Four member states (Bahrain, Kuwait, Qatar and Yemen) considered that every agency 
made an adequate and appropriate contribution to GCC-DR while the remaining three 
member states (Oman, Saudi Arabia and UAE) believe that all agencies did not make an 
adequate contribution. 
 
Assessment of Centralised Procedure 
In general the GCC Drug Regulatory Authorities are satisfied with the GCC-DR 
assessment procedure, implementation of the regulatory guidelines and the availability of 
the scientific and technical expertise as is shown in Figure 6.6. 
 
Figure 6.6 – Member states assessment of the Centralised Procedure  
 
However, only two member countries (UAE and Yemen) stated that the quality of the CP 
decision-making is better that of their national system (Figure 6.6) while four members 
(Bahrain, Kuwait, Oman and Qatar) indicated that it is about the same as their national 
system. On the other hand, Saudi Arabia indicated that the quality of the CP decision-making 
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is worse than that of their national system and this is certainly a cause of concern that needs 
to be further investigated. 
GCC-DR Secretariat activities 
The GCC-DR secretariat activities were also evaluated to ascertain the quality and 
deficiency, if any, within the organisation. Five member countries (Bahrain, Kuwait, Oman, 
Qatar and UAE) indicated that the level of interactions between the GCC-DR Secretariat and 
the GCC-DR Committee was good to excellent. Only two member countries (Saudi Arabia 
and Yemen) stated that it was only satisfactory. However, all member states, with the 
exception of Qatar, indicated that the GCC-DR Secretariat‟s support to the GCC-DR 
Committee should be increased (Figure 6.7). 
 
Figure 6.7– Level of interaction between GCC-DR Secretariat and the Committee 
  
 
The member states added that the Secretariat‟s support could be enhanced by increasing the 
number of staff and improving the follow up system between the members. They also 
recommended that there should be expert pharmacists at the Secretariat‟s office to validate 
the submitted files and this would ensure that the approval process is streamlined. This view 
was also reiterated by another member country who stated that the Secretariat needed to 
include one or two pharmacists who have enough experience in drug registration and GMP 
inspections. Furthermore, since it is an administrative issue, more scientific staff are needed 
to organise the dossiers distribution, follow up the status of the companies, and communicate 
with other GCC countries members. 
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Section 2 – Utilization of Resources 
The key issues explored here centred on the allocation of resources to various activities 
carried out at the national or centralised level. All member states indicated that limited 
resources did pose moderate problems for their agency in relation to their activities with the 
Centralised Procedure. However, only Kuwait, Qatar, Saudi Arabia and UAE indicated that 
they did not lack the expertise required for the assessment of the Centralised Procedure 
applications. Bahrain, Oman and Yemen stated that they did lack the necessary expertise and 
that they would be able to overcome this issue by increasing their budget and engaging the 
resources required. 
Further information was gathered on how the GCC States evaluated their allocation of 
resources depending on the various CP activities. Only Oman, Saudi Arabia and UAE 
conducted GMP inspections at both national and centralised level (Figure 6.8). Generally 
there is an increasing trend for the conduct of GMP inspections at a centralised level.  
Figure 6.8 – Number of GMP Inspections conducted by GCC (2008 - 2010) 
 
Based on the data collected from Oman, Qatar and Saudi Arabia (Figure 6.9), it could be 
ascertained that the number of product evaluations at a national level is more than those 
carried out under the CP. This indicates that most pharmaceutical companies prefer to receive 
approval at a national level rather than through the CP. This is further reinforced by the fact 
that half of the states indicated that the current CP evaluation system would not be 
sustainable due to the lack of resources, together with the current expertise and the heavy 
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national workload. There are a total of 250 internal and external reviewers available in the 
GCC. However, this number varied from state to state with Saudi Arabia having the largest 
number (121) while Yemen has the lowest number (11). With an increasing number of 
products to be evaluated, the number of reviewers within the GCC may not be sufficient to 
process the number of new products, thus resulting in the long delay experienced by the 
pharmaceutical companies.  
From the data collected via the questionnaire (Figure 6.8). UAE conducted a total of seven 
GMP inspections at a national level for 2008 and 2009. Oman conducted a total of 29 GMP 
inspections at a national level between 2008 and 2010 whereas Saudi Arabia conducted 66 
such inspections for 2009 and 2010.  It is obvious that there is an increasing trend in the 
conduct of GMP inspections at a national level over the three year period (2008 to 2010). 
More GMP inspections were carried out centrally in which the total inspections completed by 
Kuwait, Oman, Saudi Arabia and UAE for the three year period was 280. There is also an 
increasing trend towards central GMP inspections conducted by the four GCC countries from 
56 in 2009 to 147 in 2010 which is an increase of more than 100%. 
 
Figure 6.9 – Number of Products evaluated by Oman, Qatar and Saudi Arabia (2008 - 2010) 
 
Product evaluations in Oman, Saudi Arabia, Qatar and at national and central registration 
reached a total of 1957 for the period 2008, 2009 and 2010 (Figure 6.9). The highest number 
of product evaluations was carried out in the year 2008 with a total of 762 or about 40% of 
the total number. Saudi Arabia has the highest total number of products evaluated (841), 
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followed by Oman (662) and Qatar (422). This survey also indicated that four member states 
did not provide the data for products evaluated by them between 2008 to 2010 for the central 
registration. The data for Saudi Arabia was combined with that of the national data as it was 
not differentiated when the data was first collected. There is no data available from Bahrain, 
Kuwait, UAE and Yemen for centralised product evaluation. In general, it could be 
ascertained that the number of products evaluated at a national level is more than those 
conducted within the Centralised proceed.  
 
Limitation of resources for product evaluation 
All member countries indicated that limited resources posed moderate problems for their 
agency in relation to the activities within the Centralised Procedure. However, Kuwait, Qatar, 
Saudi Arabia and UAE indicated that they did not lack the expertise required for the 
assessment of the Centralised Procedure submissions although Bahrain, Oman and Yemen 
indicated that they did lack the necessary expertise.  The member states which indicated that 
the lack of expertise would be a problem in the future stated that they would seek additional 
budget and utilise external reviewers. All member states also indicated that they have a unit 
or person within their authority that coordinates CP activities. The entity varies from state to 
state depending on the size of the organisation and the related activities.Bahrain, Kuwait, 
Oman and Yemen indicated that the current system is not sustainable while the remaining 
Qatar, Saudi Arabia and UAE indicated that it is. The countries which indicated that the 
current system is not sustainable cited the lack of resources as the main factor. The lack of 
expertise is another key concern as well as the national workload as the third factor (Figure 
6.10). 
 
Part III:  Regulatory Expertise 
This section of the report examines the regulatory expertise residing within the national 
agencies that would enable the evaluation of different parts of the registration applications. 
Table 6.2 provides a summary of all the data pertaining to the internal and external expertise 
available in each agency. 
 
 
 
141 
 
Figure 6.10 – Factors that affect the sustainability of the Centralised Procedure 
 
 
Generally local internal specialised reviewers are available within each agency and these 
account for almost three times the number of external experts. The highest number of internal 
experts are involved with the quality data review (30%) while the lowest number is involved 
in the review of the biological data (4%) (Table 6.2). Saudi Arabia has the largest number of 
internal reviewers totalling 77 while Yemen has the lowest number (11). Oman, UAE and 
Yemen rely entirely on internal reviewers. However, there is a direct correlation between the 
number of experts, the number of products evaluated and GMP inspections carried out by 
these member states (Table 6.3). 
 
Saudi Arabia reported the highest number of evaluators totaling 121 (internal and external) 
and they managed to complete 841 product evaluations at national and central levels (2008, 
2009 & 2010) as shown in Table 6.3. With their reviewers, Saudi Arabia was able to carry 
out 65% of the total GMP inspections carried out at national level. Product evaluations in 
Oman, Qatar and Saudi Arabia at national and central registration reached a total of 1,957 for 
the period 2008, 2009 and 2010.  
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Table 6.2 – Number of internal and external personnel in different areas of expertise within the Gulf States 
Gulf States 
Quality 
data                                                
Safety data                                                   
Efficacy 
data  
Pharmacovigil-
ance data    
Bioequivalence 
data                                    
Biological/ 
Biosimilar 
data                         
Vaccines data                                               
GMP 
inspection                                           
Others (if 
any) state
Total  
Int Ext Int Ext Int Ext Int Ext Int Ext Int Ext Int Ext Int Ext Int Ext Int Ext 
Bahrain 
8 5 0 0 0 0 1 0 6 1 0 0 0 0 9 0 0 0 24 6 
Kuwait  
8 0 4 0 10 0 0 0 4 0 2 0 0 special 
committee 
2 0 0 0 30  
Oman 9 0 2 0 2 0 2 0 1 0 1 0 2 0 5 0 0 0 24 0 
Qatar 
3 1 3 1 3 1 1 1 0 0 1 0 1 0 0 0   12 4 
Saudi 
Arabia  
25 2 9 1 9 1 6 13 1 3 2 0 2 0 17 15 6 9 77 44 
U.A.E 3 0 2 0 2 0 1 0 2 0 2 0 3 0 1 0 2 0 18 0 
Yemen 3 0 0 0 0 0 0 0 1 0 0 0 0 0 7 0 0 0 11 0 
Total 59 8 20 2 26 2 11 14 15 4 8 0 8 0 41 15 8 9 196 54 
% of 
Reviewers 
30 15 10 4 13 4 6 26 8 7 4 0 4 0 21 28 4 17 100 100 
* Int = Internal 
* Ext = External 
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Table 6.3 – Relationships between capacity and workload for each Gulf State  
(2008, 2009 & 2010) 
Gulf 
States 
Internal 
evaluators 
External 
evaluators 
Total 
Percentage 
% 
Total 
Product 
Evaluation 
at National 
& CP Level 
Percentage 
% 
Total GMP 
Inspections 
done at 
National 
Level 
Percentage 
% 
Bahrain 24 6 30 12 NA NA NA NA 
Kuwait  30 NA 30 12 NA NA NA  NA 
Oman 24 0 24 10 662 34 29 28 
Qatar 12 4 16 6 422 22 NA  NA 
Saudi 
Arabia 
77 44 121 48 841 44 66 65 
U.A.E 18 0 18 7 NA NA 7 7 
Yemen 11 0 11 4 N A NA NA  NA 
Total 196 54 250 100 1925 100 102 100 
NA – Not Available 
 
Section 4 – Importance of GCC-DR 
Despite the large number of products being evaluated at a national level, the GCC 
member states agreed that the GCC-DR system provides salient advantages to them in 
terms of the availability of specialised expertise, training, sharing of 
pharmacovigilance data and harmonisation of guidelines. The most valued service is 
the collaboration with other national agencies and the provision of guidelines for 
harmonisation of the central and national processes. (Figure 6.11). 
Figure 6.11 – The value of professional functions to the GCC-DR system by the 
Gulf States 
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Generally, Bahrain, Qatar and UAE indicated that all the services rendered by the 
GCC-DR system are of high value to their respective agencies while Kuwait, Oman 
and Yemen indicated that they are of moderate value. Only Saudi Arabia indicated 
that the services provided by the GCC-DR system are of little value. The most valued 
service is the collaboration with other national agencies and the harmonisation of the 
guidelines.  
Expertise  
 
In addition, the member states added that by continuously engaging with the GCC-DR 
evaluators through discussions and debates, national evaluators would be challenged 
to acquire more information and knowledge about the subject of debate and in so 
doing expand their experience. These active intellectual exchanges are essential since 
those applications which would be evaluated and registered centrally would be then 
registered automatically by the individual GCC States. 
Training  
 
With regards to training, the respondents stated that such training could be of higher 
value if the frequency for shared workshops is increased and becomes an essential 
part of each GCC-DR committee meeting attended by reviewers, evaluators and 
committee members. Many shared workshops at a GCC level enriched the expertise 
of the evaluators who attended. In addition, through such workshops there is a great 
potential for the companies to participate at GCC level and opens up the opportunity 
to share knowledge and expertise for all participants. To facilitate the training efforts, 
it was suggested that training plans be prepared periodically at GCC-DR level. 
Collaborations with other agencies  
 
 The member states indicated that the exchange of information, experience and plans 
should be initiated between all national agencies in the region on a regular basis.  This 
is clearly beneficial and natural when the committee members are meeting on a 
regular basis and have the opportunity to share information. Networking among 
member states becomes easier with better established teamwork and this facilitates 
communication and enhances further collaborations.  
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Sharing of Pharmacovigilance Data 
 
The member states indicated that the sharing of pharmacovigilance data is most 
important because at least three member states do not have reviewers in this area. 
They added that the potential benefit of the GCC-CP is not fully exploited. If it was, 
then the CP will be of very high value to all member countries. It needs more 
resources and a specialised unit at the central level equipped with the right software 
and supported by unified systems at the country levels. In addition, the respondents 
suggested that there should be a system for sharing scientific data between all national 
agencies 
Guidelines Harmonisation  
 
The member states indicated that the GCC-CP is a great opportunity to harmonise 
guidelines and requirements. The GCC States recognised the importance of expediting 
these guidelines as eventually the GCC registered products will have the option to be 
marketed in their country. If guidelines are not harmonised this would mean 
inconsistency in the product quality and the guidelines would also avoid duplication 
of effort. All members reiterated that similar registration requirements and 
circumstances permit the adoption of guideline harmonisation. In addition, they stated 
that the regular updating of guidelines is essential. 
Section 5 – General Observations 
All the national agencies in the GCC indicated that the integrity of the evaluation 
results and better scientific opinion are the key to the success of the centralised 
evaluation system (Figure 6.12). Hence, it can be ascertained that the CP has achieved 
its mandate to provide a better and efficient registration system in comparison to the 
national system. The GCC agencies provided details of the main advantages and 
disadvantages of the CP system in comparison to the national system. Their 
recommendations to improve the CP system included streamlining and harmonising 
the approval process. 
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Figure 6.12 – A comparison between the centralised and the national systems 
 
Kuwait, Oman, Qatar, UAE and Yemen indicated that the centralised evaluation 
system mostly provided a better scientific opinion than the national system. Bahrain, 
on the other hand indicated that the centralised evaluation system always provides a 
better scientific opinion than the national system while Saudi Arabia indicated that it 
was rarely better (Figure 6.12). 
All the GCC States with the exception of Saudi Arabia indicated that the current 
centralised system mainly provides consistent evaluations in comparison with national 
evaluation. Hence, this is clear evidence that the integrity of the evaluation results and 
better scientific opinions are the key to the success of the centralised evaluation 
system.  
All GCC member countries agreed on having a standard price for specific medicines 
throughout the GCC States as shown. However, Qatar was against this, citing the 
reason that there would be differences in the proportions of sales and consumption of 
medicines between the states and this leads to different profit margins. All GCC 
member countries agreed to support the continuity of national registration in parallel 
to the centralised procedure while Yemen did not agree to support such a motion due 
to limited financial capabilities in comparison to other six member states and for this 
reason the Centralised Procedure is a cost-effective option for Yemen. 
 
 
146 
 
Major advantages of the CP system compared to the national system 
 
The major advantages of the centralised procedure as compared with the national 
system are shown in table 6.4. Generally, respondents agreed that the first key 
advantage of the CP system is the availability of external expertise to complement the 
internal reviewers. This enhances the quality of the report and more information is 
focused on the registration to ensure that product evaluation is carried our according 
to the standards. In this manner, the quality of the product registration is assured 
across the GCC States. 
Major disadvantages of the CP system compared to the national system 
The main disadvantage of the system is the long approval process together with the 
differences in recommendations between the national and the centralised procedure. 
The inflexibility of the system and the limited number of meetings per year further 
delays the whole process thus making the CP system not as attractive as national 
registration for companies (Table 6.5). 
Practicality and Applicability of the GACP 
An evaluation of the GCC states experiences in participating and completing the 
questionnaire for this study was carried out. Generally all the participating states 
found the questionnaire easy to complete and understand and they found the 
questionnaire relevant and clear. Six states found the length of the questionnaire about 
right while only Kuwait indicated it was too long. Three states (Oman, Qatar and 
Yemen) indicated that they took 30 minutes to complete the questionnaire, Bahrain 
took only 20 minutes while Kuwait and UAE took about 120 minutes. Saudi Arabia 
could not ascertain the amount of time taken to complete the questionnaires. 
Table 6.4 – Summary of the major advantages 
1. Better quality scientific evaluation since more than one state is studying the file 
2. More scope for exchange of knowledge, ideas and experiences 
3. Drug regulatory coordination 
4. The burden and workload is divided 
5. Better GMP Inspections 
6. Guidelines consensus and harmonisation 
7. Exchange of Pharmacovigilance reports 
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Table 6.5 – Summary of the major disadvantages 
1. The delay in registration process in comparison to the national system 
2. Conflict of some of the recommendations and/or designs with national system 
3. The lack of ability to contact the applicant directly to verify or clarify issues 
4. The inability to track the full history of the application as the process of review and 
follow up is fragmented 
5. Lack of a standardised assessment template 
6. The limited number of meetings 
7. Increase in the number of applications lead to rushed evaluation by the countries 
8. Difficulty in activating some of the recommendations 
DISCUSSION 
This study was carried out to examine the regulatory views and experiences of all 
seven Gulf States with respect to the Central Registration Procedure as well as 
identifying the barriers and opportunities to improve the CP.  Several challenges face 
the GCC health authorities to successfully operate the GCC-DR system. The seven 
states identified the need for regulatory reforms during the last 12 years, and this has 
enabled the improvement of their national system which has enhanced patients‟ access 
to high quality medicines throughout the region. The central registration system has 
faced several criticisms both from the pharmaceutical industry who were 
apprehensive about whether the GCC-DR system would be an obstacle to the timely 
approval of medicines in the region as well as government officials who were 
concerned about losing sovereignty to the centralised authority (Hashan, 2005). 
However, the effective collaborative efforts between the member states substantiated 
the support of the GCC-DR system from each GCC authority with an improvement to 
regulatory approval processes and operational efficiencies at the national level. 
The most significant finding from this study is that the National Drug Regulatory 
Authorities in the GCC believe that the Centralised Procedure (CP) has contributed to 
an effective system for authorising medicinal products in the GCC. This is ascertained 
from their views that the GCC-DR CP achieved its main objective of providing the 
best possible scientific opinion for the CP. They also agreed that the CP has 
appropriate guidelines for the regulatory review in the GCC-DR and that the quality 
of the CP decision-making is satisfactory to good as compared to the national 
systems. Apart from obtaining better quality scientific evaluations, since more than 
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one state is studying the application dossiers, the CP allows more scope for the 
exchange of knowledge, ideas and experiences among the National Drug Regulatory 
Authorities in the GCC. This results in better drug regulatory coordination within the 
GCC. As a result of this study it could be ascertained that product evaluation at a 
national level is more frequently carried out than at the CP as most pharmaceutical 
companies prefer to have their products reviewed at a national level. As an outcome 
of this more than three of the states indicated that the current CP evaluation system 
would not be sustainable due to the lack of resources and the heavy national 
workload. 
This lack of resources presents moderate problems for the GCC States in relation to 
their activities within the Centralised Procedure. The GCC States recognise the 
importance of resources, both human and financial, for the development of strong 
regulatory systems. However, the lack of resources can be compensated to some 
extent by effective collaboration among countries and information sharing (WHO, 
2008). Furthermore, the GCC authorities are able to allocate financial resources due to 
their strong economic status, but the availability of human resources and expertise 
remains a challenge for the development of a robust drug regulatory system. 
There are a total of 250 internal and external professional evaluators available in the 
GCC. However, this number of evaluators varied from country to country with Saudi 
Arabia having the largest number (121) and Yemen having the lowest with only 11. 
With the increasing number of products to be evaluated, the number of specialised 
experts within the GCC may not be sufficient to process product registration, which 
will result in further delays for pharmaceutical companies. Increasing the number of 
external experts in the GCC States may be the best solution for this problem to reduce 
the workload on the internal reviewers but this may have a possible impact on the 
quality of the review.  
Pharmaceutical companies have mixed feelings about whether they can gain faster 
marketing authorisation through the national regulatory systems or the regional 
centralised system. The goal of any pharmaceutical company is to complete the 
registration requirements and gain access to the national GCC markets in the shortest 
possible time.  In the end, two approval routes, national and centralised exist side-by-
side in the GCC region. For the centralised system to dominate, member states should 
seek ways to increase their collaborative efforts to bring their systems closer towards 
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standardisation that would facilitate the regional registration process and maintain 
patients‟ access to safe and effective medicines within a reasonable time frame. The 
long approval timeline in the CP approval process is a major obstacle to advocating a 
central approval procedure. The majority of GCC States agreed that the CP process 
should be shortened and they indicated that the timeline for the Centralised Procedure 
could be reduced by: 
 All member states following the GCC guidelines.  
 The verifications of the registration documents being carried out at the time of 
submission. 
 The reviewing agency sending the applications with preliminary 
remarks/deficiencies before the committee meets for their discussions.  
 The member states not demanding additional data to avoid delaying the whole 
process. 
  Increasing the number of GCC-DR meetings.  
  Taking in to account the prior approval by mature regulatory authorities. 
 
One way forward is to consider the verification model for the assessment of a new 
registration dossier. This model can be used for applications for products that are 
registered in a reference country with established mature regulatory authorities 
(McAuslane et al., 2009). If not, a more specialised review can be considered for 
products which are not registered elsewhere. Singapore, for example, conducts a 
verification review for all types of medicines which are previously authorized by at 
least two reference authorities, except for biological and biotechnology products. 
 
The member States also agreed that certain aspects of the registration procedure could 
be simplified to reduce the duration of the CP process, these aspects are to: 
  Implement electronic communication together with online submissions.   
  Send all the requests for further information or clarification questions to the 
companies at one time instead of in several batches.  
 Have a written policy for fast track registration such as life-saving anti-cancer 
and anti-HIV drugs. 
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Despite the large number of products being evaluated at a national level, the GCC 
member states agreed that the GCC-DR system provides significant advantages in 
terms of the availability of specialised expertise, training, sharing of 
pharmacovigilance data and harmonisation of guidelines. The most valued service is 
the collaboration with other national agencies and the provision of guidelines for 
harmonisation of the central and national processes.  
The GCC agencies agreed that the key advantage of the CP system is the exchange of 
knowledge and information between the member States. This enhances the quality of 
the report and more attention is focused on the registration to ensure that the product 
evaluation is carried out according to set standards and thus the quality of the product 
registration is assured across the GCC States. In addition, the inflexibility of the 
system and the limited number of meetings per year further delays the whole process 
thus making the CP system less attractive for companies to obtain their product 
approval.  
 
SUMMARY 
 
 This study has demonstrated that the GCC-DR Centralised Procedure achieved 
its main objective by providing the best possible scientific opinion.  Appropriate 
guidelines for the regulatory review in GCC-DR was of considerable value while 
the quality of the CP decision-making ranged from satisfactory to good as 
compared to the national system.  
 
 All member countries indicated that limited resources did present moderate 
problems for their agency in relation to their activities with the Centralised 
Procedure. 
 
 There are more products being registered at a national level than at the CP. 
Despite the preference to evaluate products at a national level, these agencies 
agreed that the Centralised Procedure (CP) had indeed contributed to an effective 
system of authorising medicinal products for the GCC by providing the best 
possible scientific opinion for the quality of the CP decision-making as compared 
to the national system.  
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 The main disadvantage of the system is the long process to obtain the approval. 
The inflexibility of the system and the limited number of meetings per year 
further delays the whole process thus, making the CP system less attractive for 
companies. 
 
 The member countries recommended that the GCC-DR streamlines and 
harmonises the CP approval process with national systems in order to improve 
the effectiveness and efficiency of the Centralised Procedure. 
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An Evaluation of the Pharmaceutical 
Companies Experiences with the GCC 
Centralised Procedure 
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INTRODUCTION 
The primary aim of drug regulation is the protection of public health.  Hill (2004) 
suggested that for some the balance between controlling pharmaceuticals in the 
interests of ensuring public health and encouraging the development of 
pharmaceutical products has shifted in favour of the innovative industry. However, 
others perceive regulation as an obstacle to the availability of medicines in national or 
regional markets and this has placed a significant demand on regulators to expedite 
reviews and evaluations to approve medicines (Hill, 2004). Nevertheless, medicines 
regulation is the foundation of any country‟s national drug policy that ensures a viable 
pharmaceutical industry as well as a high standard drug approval process.   
The establishment of the International Conference on Harmonization (ICH) between 
the United States, Europe and Japan in 1990 reflected a need felt by the research 
based industry and certain governments to streamline the approval process for the 
registration of new medicines (Mallia-Milanes, 2010). The term harmonisation refers 
to the standardisation of technical requirements for medicines regulation, of which the 
requirements relate to quality, safety and efficacy of medicines and this can differ 
from one country to the other.  Since its inception, ICH has evolved, through its 
Global Cooperation Group (GCG) to respond to the increasingly global phase of drug 
development. The GCG was originally formed as a subcommittee in 1999, in response 
to the growing interest in ICH guidelines beyond the ICH regions and one such 
harmonisation was that of GCC, the Gulf cooperation council.   This collaborative 
mechanism ensures ensure a more transparent and streamlined process for the 
marketing authorization of pharmaceutical products in the GCC region.    
The Gulf centralised registration process is facing several challenges which lead to 
delays in patients‟ access to medicines with the need to re-register products in 
individual countries after central registration. In addition there is a requirement to 
register the manufacturer prior to submitting the product file to the Central 
Registration Office. Currently there is the need to establish effective methods for 
sharing the workload amongst the regulatory authorities in the GCC states. A paucity 
of studies at the GCC level, probing into the views and experiences of individual 
pharmaceutical companies with the GCC central registration system, has made its 
improvement a constant challenge. Hence, this study is envisaged to explore the 
importance of the system and identify challenges and critical success factors to 
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enhance the effectiveness and efficiency of the central registration procedure.  
Patients benefit from the timely access to safe and effective therapies while 
pharmaceutical companies are able to market the product sooner and generate 
revenues for further research and development.   
 OBJECTIVES 
The objectives of this research were to: 
 Evaluate the experiences and views of pharmaceutical companies with respect to 
the central registration review process. 
 Appraise the barriers and opportunities to the implementation of the Gulf 
Centralised Procedure.  
 Make recommendations to improve the Gulf Centralised system as well as to 
identify its future strategy based on the views of the pharmaceutical companies. 
 
METHODS  
With limited information and the lack of data on the GCC Central Registration 
Procedure, there is a need to develop suitable measurement tools in order to obtain the 
relevant information required in this study. In Chapter 6, an assessment tool for the 
evaluation of the Centralised Procedure by the Drug Authorities in the GCC was 
developed and the findings reported. In this Chapter, the emphasis will be on the 
pharmaceutical companies and evaluating their experiences in obtaining approval for 
their products. The development of the assessment instrument was completed over 5 
phases;  
Phase 1 – Identify target population and item generation 
Phase 2 – Development of themes and item reduction 
Phase 3 – Development of the first version of the instrument, Companies Assessment                           
     of Centralised Procedure (CACP) 
Phase 4 – Pilot study  
Phase 5 – Development of the final version of the CACP 
This final version of the study instrument was sent to 100 pharmaceutical companies 
(50 generic and 50 innovative) and followed up after one month. 
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RESULTS 
This section presents the results from the development of the CACP and the views of 
pharmaceutical companies. For the purpose of clarity the results will be presented in 
two parts: Part I - The development of the study instrument (CACP); and Part II - The 
views of the pharmaceutical companies about the Centralised Procedure 
Part I:  The Development of the Study Instrument (CACP)  
Phase 1 – Target population and item generation 
An informal interaction and dialogue was held with a number of pharmaceutical 
companies at a consultation meeting organised by the GCC-DR in the spring of 2010. 
This allowed the generation of items for the development of the CACP. In addition 
these items were cross-referenced with the Gulf States instrument in order to ensure 
that relevant items were also retained for the CACP. 
Phase 2 – Development of themes and item reduction 
There were total of five themes emerging from the item generation phase based on the 
objectives of the study. The first version of the questionnaire comprised five sets of 
questions pertaining to the following headings;  
Theme 1- General Introduction consisting of eight sub-themes;  
Theme 2- Centralised Registration Procedure consisting of eight sub-themes;  
Theme 3- Interaction with GCC-DR consisting of six sub-themes; 
Theme 4- Scientific Opinion consisting of nine sub-themes;  
Theme 5- General observations consisting of eight sub-themes.  
The General Information included their preference for using the system, national vs. 
centralised, data on the number of products submitted and registered through the 
centralised procedure, along with their experience and opinion of the system itself.  
Theme 2 deals with the guidelines, quality of scientific opinions, appeal procedure, 
implementation of the common technical document submission format and 
harmonisation of the procedure.  Interaction of the company with GCC–DR with 
respect to the quality and timing of information received, their relationship with 
individual member countries, influence of the pharmaceutical companies on the 
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GCC–DR formed Theme 3  Scientific opinion in terms of regulatory expertise was 
included in Theme 4, and Theme 5 contains general observations from pricing to 
recommendations to improve the procedure, their views on the present system and 
future strategies.   
Phase 3 – Development of the first version of the instrument, Companies 
Assessment of Central Procedure (CACP)      
The selected themes and sub-themes were put into an appropriate structured 
questionnaire. These were then reviewed by a social science expert using four 
appropriate parameters; namely; language clarity, completeness of the statement, 
appropriate relevance and scaling. Account was also taken with regard to the length of 
the items and their readability.   
Phase 4 – Pilot study 
The purpose of the pilot study was to assess the practicality, feasibility, applicability 
and relevance of the study instrument to assessing the Gulf Centralised Procedure 
from the companies‟ perspective. The structured questionnaire was sent to five 
targeted companies (two innovative and three generic).  
Feedback from the first questionnaire was obtained from these companies. This pilot 
study clearly indicated that such a project into GCC Central Registration Procedure 
from the pharmaceutical companies‟ perspective was essential to bring about 
standardisation and harmonisation of the approval process. This would inevitably 
improve the registration system for both the applicants as well as the approving 
authorities. Based on the respondents feedback minor changes were made to the 
questionnaire. These changes included adding refinement to questions 2.1 and 2.2 in 
Part 2 and repositioning questions 3.3 and 3.4 in Part 3 of the questionnaire. Finally, 
six simple questions were added to the questionnaire to obtain the views of the 
respondents about the practicability, applicability and relevance of the CACP. This 
feedback was critical in order to design a more effective assessment instrument for 
future studies (Figure 7.1). 
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Figure 7.1 
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Phase 5 – Development of the final version of the CACP 
Following the pilot study and implementation of the changes suggested by the 
participating companies the development of CACP was completed. Thus, the final 
version of the instrument consists of 39 items grouped into five major categories. In 
addition it includes an introductory page collecting the respondents' personal details 
(Figure 7.2). The final version of the questionnaire was sent to 100 companies who 
had registered their products through the either centralised registration procedure 
and/or national registration systems. The questionnaire was sent with a clear guideline 
regarding the aims and objectives of the study with a statement assuring them of the 
confidentiality of the study. 
Part II: The views of the pharmaceutical companies about the 
Centralised Procedure 
An analysis of the target audience was carried out by listing all pharmaceutical 
companies who had interactions with the national registration system and/or the CP in 
the GCC region. This list of the companies registered with the CP was obtained from 
the GCC-DR office in Saudi Arabia. The profile of each company was analysed to 
ascertain their suitability and their willingness to provide information for the study. 
Fifty generic and 50 innovative companies were selected for the study from the list of 
registered companies, half of them with experience registering their products through 
the CP while the other half had the experience of registering their products through 
the national system.    
Characteristics of the study participants:  
The CACP was distributed to 100 pharmaceutical companies out of which 30 
responses were received (30%) (Appendix 1). The remaining, who did not respond, 
could be categorised into four groups: 
1- Unwilling to participate  
2- Lack of experience 
3- Lack of response, and 
4- Sensitivity of the information required  
159 
 
 
  Figure 7.2 
161 
 
 
161 
 
 
162 
 
 
163 
 
 
164 
 
165 
 
The CACP scores: 
In order to answer the main evaluation questions covering the experience of these 
companies with GCC-DR Central Registration Procedure the results are presented 
under five sections. 
Section 1 – Companies general views about the Centralised procedure 
In this section, the companies‟ experiences in registering their products through the 
Centralised Procedure were examined. Their preference for using this system, national 
versus centralised was determined. Data on the number of products submitted and 
registered through the centralised procedure, along with their experience and opinion 
of the system itself were also recorded.  Generally, more than half of the companies 
who responded preferred the national registration procedure to the Centralised 
Procedure (Figure 7.3) The majority of the pharmaceutical companies preferred to 
register their products through the national system than the centralised system. Eleven 
innovative companies preferred the national system rather than the CP while six 
generic companies choose the national system instead of the CP. Nineteen companies 
had submitted their products for registration under the centralised system, while more 
generic companies (12) had submitted their products to the CP than the innovative 
companies (Figure 7.3).  
Figure 7.3 – Number of companies and their preferred pharmaceutical registration 
system 
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Only the 19 companies who had the experience of registering their products through 
the CP were able to provide critical information on the strengths and weaknesses of 
the CP registration system. The main reasons for choosing the centralised registration 
system over the national system are illustrated in Figure 7.4. This shows that 14 
pharmaceutical companies were able to meet the requirements to GCC tender 
specification, convenience (12 companies) and timeliness of registration, 
cost/resources required and ease of subsequent CP registration. One of the 
respondents indicated that the central registration team is more accessible, easier to 
communicate with, flexible and understanding about the companies‟ issues. It is also 
faster in approval than the national authority. Another respondent indicated their 
choice of product registration system would be dependent on their company‟s strategy 
and the nature of the product. 
Figure 7.4 – Reasons for companies preference in using the Centralised 
Procedure for product registration 
 
*Other Factors 
1. Central registration team more accessible, easier to communicate with flexible and 
understanding about the companies’ issues. Faster in approval than the national and is a 
respectable authority. 
2. Depending on the company strategy and  the nature of the product 
 
Figure 7.5 shows the reasons why pharmaceutical companies did not prefer the 
centralised system. Eight of the companies stated that their product strategy was 
aligned to the registration in selected GCC states, hence the preference for national 
registration. The timeline for registration and the experience with the national systems 
registrations resulted in a total of seven responses. The rest cited the cost and resource 
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requirement and subsequent pricing of products as well as a concern over possible 
rejection by GCC-DR. One of the companies highlighted that for highly specialised, 
orphan, and important products, they preferred to go via the national procedures, since 
they found it more transparent and easier to communicate with the regulatory 
authorities. The CP is a strategic option, but due to a limited number of GCC-DR 
annual meetings, the companies cannot take the risk for important products that are 
required to be available in the countries faster, since CP may take a longer time 
compared with national registration. 
Figure 7.5 – Reasons why companies did not prefer the Centralised Procedure 
 
*Other Factor 
Due to the limited number of GCC-DR annual committee meetings, the company cannot take the risk 
for important products registration that must be made available in the countries quickly, since it may 
take a long time to receive GCC-DR comments. 
 
The number of products submitted for approval to the Centralised Procedure by 13 
companies varied between 29 to 75 submissions annually (Figure 7.6). The year 2010 
saw a substantial increase in the number of applications by almost 3 times as 
compared to the previous year (2009). This could be an indication that the companies 
realised the benefits of obtaining an approval from the GCC-DR to market their 
products to the seven member states seamlessly. The total number of products 
submitted from 2006 to 2010 was 212 while the total products registered were 210 for 
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the four years (2006 to 2009). An upward trend can be seen in product submissions 
and product registrations under the CP system. This clearly indicates that though there 
were challenges in processing the products for approval at GCC-DR level, it certainly 
is gaining recognition as a viable option. Twenty companies believed the quality of 
decision-making of the Centralised Procedure to be good or excellent while seven 
companies stated that it was only satisfactory.  
This is an indication that although there are issues with the centralised registration 
system, the quality of its decision-making is still satisfactory for most companies 
(Figure 7.7). Although some companies had no experience of registering their 
products through the CP they were still able to provide their opinion about this 
system.  
Figure 7.6 – Number of products submitted and approved through the Centralised 
Procedure 
 
 
Twenty companies stated that it took them more time to register their products 
through the centralised system.  The pharmaceutical companies also stated that the 
limited number of meetings by the Central Committee was one of the main causes of 
the delay in product registration; thus their preference for national registration. The 
delay in product registration is also attributed to the fact that the submission of the 
documents for review and approval by the Committee has to be done earlier before 
the summer hiatus if the companies wish to complete the procedure in good time. 
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Figure 7.7 –The quality of decision-making of the Centralised Procedure 
 
However, unlike the national registration procedure in which both the product and the 
pricing registration could be done concurrently, the company has then to wait for the 
product approval centrally before proceeding with the pricing approval locally.   
Further delays in product approval and registration in the CP were caused by long 
technical documents evaluation, distribution of the files for the reference countries for 
evaluation and analysis feedback and a long queue for submission and review by the 
committee. The issue of sequentially processing for national registration after the 
Centralised Procedure added a further delay to the approval process and it could take 
between 1.5 to 2.5 years for approval to be attained for each product. Furthermore, 
with so many issues to be discussed in the CP Committee meetings coupled with the 
limited number of meetings per year meant approval and registration issues would 
take a longer time to be resolved, hence lengthening the approval process. More 
delays are caused when evaluators waited until after the CP meetings to pass their 
comments and requests for additional information instead of asking for this 
immediately on reviewing at the first stage. 
Twenty-seven companies indicated that the timelines for registration in the 
Centralised Procedure could be shortened and twenty of these companies also stated 
that by having more GCC-DR meetings this could be achieved.  Others believed that 
having additional technical expertise and conducting parallel processing of the 
laboratory tests and the CP registration could also shorten the process however, 
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Parallel processing was induced in 2011. Figure 7.8 summarises how certain aspects 
of the registration procedure could be simplified. Twenty of the companies also 
indicated that certain aspects of the registration procedure could be simplified. The 
majority of these respondents believed that electronic submissions and automation of 
some of the processes could assist in simplifying the Centralised Procedure as a whole 
and hence shorten the whole process. Others indicated that the technical evaluation 
could be simplified by relying on documents submitted to GCC since these were the 
same documents already submitted and approved in the US/UK and other reference 
countries. Finally, 16 of the companies indicated that the current registration fee for 
the Centralised Procedure is reasonable while 11 of the companies stated that it is too 
high. Hence, the cost factor from the registration perspective is not the key reason 
why companies preferred the national registration system to the Centralised Procedure 
to obtain approval for their products.  
Figure 7.8– Companies’ suggestions on how certain aspects of the registration procedure 
could be simplified 
 
*Others 
1. The pricing procedure in the individual GCC states should be in parallel with the CP 
Registration.  
2. The communication with the companies could be via email or other means of electronic 
transmission. 
3. Stop the site inspection if the site was in a reference country and has the appropriate GMP 
and manufacturing license (same as the national registration).  
4. Have one registration certificate for all GCC states from GCC-DR (once registered, no need 
to submit again per each country to gain approval). 
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Section 2 - Centralised Registration Procedure 
The companies experiences in submitting and registering products under the CP is 
reviewed in this section. Generally the companies were satisfied with the quality of 
the guidelines and scientific advice as well as their opinions on the implementation of 
the Common Technical documents, pharmacovigilance procedures, and transparency 
of the Centralised Procedure. In addition, the majority of the companies also agreed 
that the CP led to the harmonisation of national procedures in the GCC legislation. 
Half of the companies indicated that the Centralised Procedure guidelines were easy 
to understand (eight generic and seven innovative companies), 10 companies (six 
innovative and four generic companies) stated that the guidelines were not always 
clear and another three companies indicated that they were generally unclear (Figure 
7.9). Those who stated that the guidelines were not always clear further provided their 
explanation for their choice. They pointed out that there were no guidelines for all 
registration requirements (e.g. available guidelines are for Stability Studies and 
Bioequivalence study only). Variations to the guidelines were also not available. The 
biotechnology products registration guidelines were very short and ambiguous and 
many of the requirements, that the committee asked for, were not included. In 
addition, they commented that the committee sometimes went outside the guidelines 
and asked for additional requirements found in other international guidelines 
(oscillating between EU and FDA, especially with stability and Bioequivalence). 
They also stated that the patient information leaflets (PIL) requirements were not clear 
and many times the committee asked for amendments for the PIL that was 
internationally recognized. Hence, they were not provided with clear criteria in this 
matter. Finally, they added that the registration certificates for manufacturing sites 
were not harmonized with regards to the nomenclature of the production lines which 
created confusion when required to register a product from such a site later. 
Quality of GCC-DR Scientific Opinions 
The majority of the companies indicated that the quality of the GCC-DR scientific 
opinions ranged between good to excellent while five companies stated that it was only 
satisfactory (Figure 7.10). It can be concluded that the pharmaceutical companies in 
general were satisfied with the quality of the GCC-DR scientific opinions despite the 
hassle and the issues faced in getting their products registered through the Centralised 
Procedure. 
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Figure 7.9 – Companies’ view on the Centralised Procedure guidelines 
 
Figure 7.10 – Companies’ views on the quality of the GCC-DR scientific advice, 
efficiency and effectiveness of the centralised pharmacovigilance procedures and the 
transparency of the Centralised Procedure 
 
Similarly, the majority of the companies also stated that the current appeal procedure 
was
 
 sufficient in the case of a negative opinion issued by the GCC-DR, although, 10 
companies felt otherwise. They further added that there should be meetings between 
the GCC-DR and the companies so that these companies could explain the reasons for 
the appeal which may not have been understood by the committee previously. 
Therefore, these views should be considered by the member states.  Also, the GCC 
needs to take in to account the registration certificates issued from the mature 
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regulatory authorities such as FDA and EMA. Other respondents also stated that the 
GCC-DR had no experience in dealing with appeal cases and hence there was neither 
any clear timelines nor clear answers provided to the companies as justification for the 
rejection. This made it very difficult for the companies to convince all the members of 
the committee of their positive opinion or challenge the rejection decision. There were 
also no response received by the companies in case of a negative opinion by the GCC 
and the submission of their appeal document.  
Seven companies indicated that the implementation of the common technical 
document format would be a barrier to their company‟s submission of product 
registrations through the Centralised Procedure.  Nevertheless, they also stated that to 
work in the same CTD format for all the GCC countries individually in addition to 
GCC-CP, would encourage many manufacturing companies in the region to obtain the 
approvals from GCC-CP. However, the resources, specialised personnel and hands-on 
training are not enough. At present, not all the member states are at the same level for 
receiving and processing CTD applications. Most medium size and Arab companies 
did not have any idea about such a format and they would need a considerable time 
before they could fulfil these requirements. This would be very difficult for these 
companies and would be costly to submit the same documentation but in a “different” 
ICH format. Moreover, such a requirement has been applied without prior notice or 
time allowance. As a result, it may take a much longer time to get the final approval. 
Some form of flexibility should be accepted as there are old and rare products which 
do not have a CTD dossier. This new requirement would also mean that there would 
be additions in the required documents. Some of these documents and tests may 
require more time to be prepared, thus, this would delay the process of registration. 
 
The efficiency and effectiveness of the GCC centralised pharmacovigilance 
procedures 
 
The majority of the companies who responded were satisfied with the efficiency and 
effectiveness of the GCC centralised pharmacovigilance procedures as the GCC-DR 
had continued to be vigilant and monitor Adverse Drug Reactions (ADR) of 
medicines speedily. In addition, currently the companies believe that the current GCC 
guidelines for pharmacovigilance are not clear, even though the Saudi FDA guidelines 
are well recognised. However five companies (Figure 7.10) indicated that although 
the efficiency and effectiveness of the GCC centralised pharmacovigilance procedures 
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were poor, they were not aware of any pharmacovigilance systems in the region being 
implemented. However, the five companies had strict internal systems related to 
safety, PV and Risk Management Plans (RMP).  
 
The transparency of Centralised Procedure 
Five companies indicated that the transparency of the Centralised Procedure was 
excellent because the GCC-DR was open in their communications; it was easy to meet 
the central organization team member who was willing to simplify the issues and had 
great understanding with a high level of transparency. On the other hand half of the 
companies stated that although the CP transparency was good as there were clear 
guidelines, refinement was needed in the follow-up of the application process. 
Overall, 70% of the companies disagreed that the Centralised Procedure should be 
made compulsory for certain range of products. However, six companies agreed that 
the Centralised Procedure should be made compulsory for the following range of 
products: 
 Prescription only Medicine 
 Narcotics and controlled drugs  
 Medicinal, Herbal and Heath products 
 Biotechnology products especially coming from non stringent countries.  
 Vaccines  
 Life saving medicines and products that are crucially required in these markets 
Finally, 18 companies agreed that the Centralised Procedure has contributed to the 
harmonisation of the legislation throughout the GCC while eight of the respondents 
did not agree. 
Section 3 - Interaction with Gulf Central Committee for Drug Registration 
(GCC-DR) 
Generally, the companies were satisfied with the level of interaction with the GCC-
DR in terms of the quality of the information received and the relationship between 
the authorities.  The majority of them also agreed that the pharmaceutical industry can 
influence the GCC-DR Centralised Procedure through sharing of knowledge and 
experiences and promoting closer collaboration.  
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Based on the same data, more than 15 companies were satisfied with the timing of the 
registration procedure at GCC-DR while six companies indicated that the timing of 
the registration was poor. Nineteen companies indicated that their relationship with 
the Registration Department of the GCC-DR was good or excellent and 22 companies 
indicated that they were satisfied with the relationship (Figure 7.11). 
 
Figure 7.11 – Companies’ view of the level of interaction on the quality of information 
received, timing of the registration procedure and their relationship with the 
Registration Department of the GCC-DR 
 
 
 
Although many companies refrained from commenting on their relationship with the 
GCC-DR because of its sensitivity, however they indicated that the relationship could 
be improved. Some of the ways in which this could be improved are summarised in 
Figure 7.12. Three companies suggested that the increased sharing of knowledge 
through training, seminars and workshops would promote more interactions between 
the companies and the GCC-DR especially in discussing changes to regulations and 
procedures. This would significantly improve the relationship between companies and 
the GCC-DR and could contribute to providing healthcare benefits to GCC states.   
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Figure 7.12 – Companies’ views on some of the ways to improve the relationship 
between the companies and the GCC-DR 
 
Ten companies suggested that there should be an increased number of meetings as 
well as improved communication between the GCC-DR and the pharmaceutical 
companies. Through openness and regular communication with the companies and 
having open dialogue and meetings to determine companies needs, the relationship 
between the two organizations would be improved. This would also promote 
consistency in decision-making and provide transparency and clear justifications 
should there be any rejections in the future. 
One of the companies indicated that the number of GCC-DR staff is low as compared 
to the considerable amount of work they have to carry out; therefore the quality of the 
relationship is adversely affected. Hence, increasing the number of GCC-DR staff is 
essential to ease the workload and improve their relationship with the companies. 
Others suggested that the GCC-DR must work as the centre for all GCC 
Pharmaceutical companies. They should promote regular activities such as running 
conferences and training courses in different fields of pharmaceutical manufacturing, 
case-studies, training on registration guidelines in GCC and in other regulated 
markets. Also, it should include distributing statistics on GCC pharmaceutical 
companies and medicines, improving knowledge on pharmaceutical technology 
among pharmaceutical companies and linking with other international conferences on 
medicines and related issues. In addition, they suggested that by providing electronic 
online services, the companies would be able to track the progress of their product‟s 
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registration status and comments, anytime, anywhere. This would greatly facilitate 
communication with the GCC-DR and expedite information requests. Twenty 
companies agreed that the pharmaceutical industry can influence the GCC-DR 
procedure and that it could be done in the following manner; 
 Through sharing of knowledge, experiences and interaction, the 
pharmaceutical companies could provide support at any level through their 
worldwide experience with authorities and regulators. As an important partner 
in the registration process, the companies would be able to provide the GCC-
DR with effective and efficient services and quality products.   
 The pharmaceutical companies could contribute to drafting and refining the 
guidelines and GMP inspection systems to make them more effective and 
efficient.  
 They could assist the GCC-DR in streamlining the procedure in order to 
improve and expedite the registration process.  
 They also added that private accredited laboratories could be engaged to help 
facilitate the procedure and by giving priority to the registration of new 
products from local industries. 
Section 4 - Scientific Opinion 
Twenty companies indicated that the scientific opinions from the CP were relevant 
with respect to their regulatory expertise. Generally, they were satisfied with the 
quality and safety data, bioequivalence studies and vaccines data provided by the 
GCC-DR experts for the pharmaceutical products registration and approval process. 
Generally, half of the companies indicated that the quality of the assessment provided 
by CP experts for safety, efficacy, pharmacovigilance, bioequivalence studies, 
biological/biosimilar, vaccines data and GMP inspections were good or excellent 
(Table 7.1) with only six companies indicating that the assessment for efficacy data, 
pharmacovigilance data, biological/biosimilar and GMP inspections were poor. There 
was also a high percentage of companies (36%) who did not provide their responses 
for this question which probably indicated that they may not have had the appropriate 
experience in these areas.  
 
 
 
178 
 
Table 7.1   – Companies’ opinion regarding regulatory expertise within the GCC-DR  
Review Expertise Excellent Good Satisfactory Poor Total 
Quality data 5 16 3 0 24 
Safety data 5 13 5 0 23 
Efficacy data 5 14 3 1 23 
Pharmacovigilance data 2 6 8 3 19 
Bioequivalence studies 6 7 6 0 19 
Biological/biosimilar 2 8 1 1 12 
Vaccines data 3 7 1 0 11 
GMP inspections 9 10 1 1 21 
Section 5 - General observations 
The majority of the companies believe that the CP has a more efficient registration 
system as compared to the national system and indicated the main advantages and 
disadvantages of the CP system based on their experiences. Three companies 
indicated that the current centralised evaluation system always provides a better 
scientific opinion/outcome than the national system, while five companies stated that 
this occurs frequently. Nine companies indicated that the GCC-DR sometimes 
provided better scientific opinion/outcome than the national system while three 
companies stated that this happened rarely. However, more than half of the companies 
agreed that the current centralised evaluation system did provide better scientific 
opinion/outcome than the national system (Figure 7.13). 
Nine companies agreed that the current centralised system provided consistent 
evaluations in comparison with the national evaluation while ten companies indicated 
that this happened sometimes and only six companies stated that this happened rarely 
(Figure 7.13). Clearly, attaining a standard consistency of the evaluation reports 
continuously is critical to the quality and efficacy of the centralised GCC-DR 
procedure. Half of the companies did not agree with the idea of having a standard 
price for specific medicines throughout the GCC states and the reasons for their 
disagreement are shown (Figure 7.14). The most critical aspect, as cited by 14 
companies, is the difference in economic aspects of the various GCC states as 
differences in the cost of living and demographics would impact the volume of the 
products, hence the price of the medicines. 
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Figure 7.13 – A comparison of the companies’ views of the national versus the 
centralised system with respect to scientific opinion and consistency of evaluations 
 
 
 
 
 
Figure 7.14 – Companies’ views as to why a standardised pricing is not appropriate 
 
 
 
It is therefore a complex task to set a standard price for specific medicines throughout 
the GCC states. Finally, 80% of the companies stated that they would support the 
continuity of a national registration in parallel to the Centralised Procedure while 20% 
of the companies would not. 
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Advantages of the Centralised Procedure compared to the National System 
Fourteen companies who responded to the survey clearly indicated that one decision 
from the GCC-DR has a considerable advantage as the product could be promoted 
faster, easier and is highly recognisable in the seven GCC states.  The advantages of 
the Centralised Procedure as compared to the national system are as follows; 
a. Harmonisation of procedures 
One approval procedure, one set of documents for the entire approval process 
and one file with the same format for one submission. The procedure is much 
simpler and less complicated. This would save time and effort and promote 
transparency.    
b. One decision for all seven countries 
In this way medicinal products can be available to all GCC States at the same 
time once they have been approved by GCC-DR. This facilitates the 
registration of manufacturing sites in one step. Hence, it would reduce the 
burden on internal company resources to prepare “dossiers” for additional 
registration.  
c.   Others  
 Collective and diversified opinions from the different GCC states add 
more value to the CP decision.  
 Products registered at the GCC level will add value to the company 
and it will open new markets for its products, 
 The implementation of CTD format in the central and national levels.    
 Proceed with other countries with less documentation. 
 If there are no major objections from the committee, then the approval 
is faster  
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Disadvantages of the Centralised Procedure compared to the National 
System 
The major disadvantage of the CP as compared to the national system is that it is a time 
consuming and costly process, followed by the inconsistency of the process and the 
insufficient number of meetings. The companies also stated that the need to re-submit 
product files at a national level after approval at the Centralised Procedure is another 
disadvantage. Sometimes more details are required in terms of the assessment of products 
by the national system compared to the Centralised Procedure. The companies are also 
concerned about the possible rejection by GCC-DR that would affect other GCC 
countries national registration. They stated that although the products are acknowledged 
by national authorities as final approval in one or more of the member states, they still 
need to go through the full CP process. By not using communication such as electronic 
mail, the GCC-DR further delays any correspondence with the companies which could 
facilitate the registration processes. In addition, the companies also indicated that inter-
committee politics may affect certain decision-making outcomes which are not 
standardised.  
 
The three major disadvantages of the Centralised Procedure as compared to the national 
system are as follows; 
 
Time consuming procedure and costly process - The procedure of registration 
involves a very lengthy period both at the quality control laboratory for analysis as 
well as at the committee level. Feedback is not clear and there is no direct 
communication with principal companies. Coupled with the high registration fee, the 
long registration process is the key disadvantage of the Centralised Procedure. 
 
Inconsistency of the process – The absence of guidelines leads to inconsistency in 
the opinions and some radical differences occur at national level. Many of the 
documents submitted to the GCC are requested again at a national level after GCC 
approval. Some states do not accept registration without prior GCC-DR approval. 
National authorities do not approve the product for distribution even after attaining 
GCC-DR registration through the CP system. 
 
Quarterly meetings - Once a quarter committee meetings is not sufficient to 
process the application. Hence, the long delay in the approval process. 
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Practicality and Applicability of the CACP 
 
An evaluation of the companies‟ experiences in participating and completing the 
questionnaire for this study was carried out. Twenty-two companies (88%) found the 
questionnaire easy to complete while 12% of the companies found it difficult (Figure 
7.15). Twenty-four (96%) of the respondents found the questionnaire easy to 
understand while only one company found it difficult to understand. Nineteen (76%) 
of the respondents found the questionnaire relevant while only 3 companies  (12%) 
found the questionnaire not relevant. One of the companies stated that the 
questionnaire was not always relevant. Twenty-three (95%) of the respondents found 
the questionnaire clear while only one company stated that the questionnaire was not 
clear. Twenty-one 83% of the companies participating in this study found the length 
of the questionnaires about right. Only 17% of the companies indicated that the 
questionnaire was too long. Nine (30 %) of the companies took about 30 minutes to 
complete the questionnaire while 35% took more than 30 minutes and the remaining 
35% took less than 30 minutes. Thirteen percent of the companies took only 10 
minutes to complete the questionnaire which was the shortest time while 5 (21%) of 
the companies took more than an hour and the longest time taken was 120 minutes.  
 
Figure 7.15  Summary of responses on the questionnaire 
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DISCUSSION 
An efficient review allows the regulatory authorities to fulfill their public health 
mission to ensure that safe and effective medicines are made available to patients in a 
timely manner and allows for the efficient use of resources. Patients benefit from the 
timely access to safe and effective therapies while pharmaceutical companies are able 
to market their products sooner and generate revenues (Booz Allen Hamilton, 2008). 
The regulatory challenge is to allow access to the safest and most effective 
pharmaceutical products in the shortest possible time with the highest degree of 
certainty (Alder, 2001).  In the GCC states, pharmaceutical companies can choose 
whether to register new products via each regulatory authority individually or via the 
central registration system and the length of the expected review time will influence 
this decision. Therefore, evaluating the pharmaceutical industry‟s views about the 
advantages and disadvantages of the GCC-DR system and how this has impacted the 
speed of the marketing authorisation time of their products in each Gulf State was 
essential. 
Pharmaceutical companies were able to provide critical information on the strengths 
and weaknesses of the CP registration system. Based on this experience, only 13 
companies surveyed preferred the CP registration system, of which nine were generic 
companies. The main reasons for choosing the centralised registration system over the 
national system include: 
 The ability of the pharmaceutical companies to meet the requirement of GCC 
tender specification. 
 The convenience of the system,  
 An improvement of patients‟ access to safe and effective medicines in the GCC 
region.  
 The central registration team is more accessible and easier in communication,   
 The companies‟ strategy and economic-related factors. 
The pharmaceutical companies which preferred the national system stated that their 
product strategy was aligned to the registration in selected GCC states for the 
following reasons and hence their preference: 
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 Timeline of registration.  
 Experience with national system. 
 Concern over possible rejection by GCC-DR.   
 More transparent and communication easier with local national regulatory 
authorities.   
  Limited number of GCC-DR annual meetings.   
 
However, despite the majority of the companies‟ preferences for a national 
registration, the companies indicated that the CP has a better and efficient registration 
system as compared to the national system. The companies agreed that the CP 
provides better scientific opinion/outcome than the national system and that the CP 
provides consistent evaluations as compared to the national system. The companies 
indicated that through harmonisation of the processes, which would entail one 
approval procedure, one set of documents for the entire approval process and one file 
with the same format for one submission, the procedure is much simpler and less 
complicated. 
This saves time and effort and promotes transparency.  Furthermore, a medicinal 
product can be available to all GCC states at the same time once it has been approved 
centrally. This also facilitates the registration of manufacturing sites in one step and 
hence, reduces the burden on internal company resources.  However, the time 
consuming procedure and costly process coupled with unclear feedback and lack of 
direct communication between the GCC-DR and the companies are some of the major 
issues that hampered the CP registration system. The absence of guidelines leads to 
inconsistency and therefore some radical differences occur at national levels. Many of 
the documents submitted for the GCC-CP are requested again at a national level and 
some GCC countries do not approve the product for distribution even after attaining 
GCC-DR registration. Moreover, committee meetings held only four times a year is 
insufficient to address all the product registration issues which results in further 
delays. 
Although more than 60% of pharmaceutical companies stated that it took more time to 
register their products through the centralised system, they still felt that the GCC-DR 
Centralised Procedure is the way forward for several reasons: 
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 By registering their products at GCC level they would have gained access to 
seven markets in the GCC states.  
 The CP leads to the harmonisation of the procedures at the national level and 
better quality scientific opinions. 
  The current centralised system provides consistent evaluations in comparison 
with   national evaluation.  
The majority of these respondents indicated that electronic submission and 
automation of some of the processes could assist in simplifying the Centralised 
Procedure and hence shorten the whole process. Others indicated that the technical 
evaluation could be simplified by relying on documents submitted to the GCC since 
these were the same documents already submitted and approved in the US/UK and 
other reference countries. 
Pharmaceutical companies in general were satisfied with the quality of the GCC-DR 
scientific opinions despite the hassle and the issues faced in getting their products 
registered through the Centralised Procedure. In addition, the pharmaceutical 
companies were satisfied with the efficiency and effectiveness of the GCC centralised 
pharmacovigilance procedures as the GCC-DR, through this procedure, has monitored 
Adverse Drug Reactions (ADR) of medicines rapidly.    
All the companies indicated they were satisfied with the level of transparency of the 
Centralised Procedure. They cited that the GCC-DR were open in their 
communication, and it was easy to meet the central organization team member. They 
were willing to simplify the issues, had great understanding and there was a high level 
of transparency in the GCC executive office. However, there is still room for 
improvement in the follow-up of the application process. Generally, the majority of 
the companies indicated that they were satisfied with the relationship that they had 
established with the Registration Department of the GCC-DR. They suggested that 
increasing the sharing of knowledge through training, seminars and workshops could 
promote more interactions between the companies and the GCC-DR authority 
especially in discussing changes to regulations and procedures. This will significantly 
improve the relationship between companies and GCC-DR authorities and can 
contribute more in providing healthcare benefits to GCC States. The companies also 
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suggested that there should be an increase in the number of meetings and communications 
between the GCC-DR committee and the pharmaceutical companies. Through openness 
and regular communication with the companies and having open meetings to define 
companies needs, the relationship between the two organisations would be improved. 
This would also promote consistency in decision-making and provide transparency and a 
clear justification should there be any rejections in the future. In addition, they suggested 
that providing electronic online services would greatly facilitate communications with the 
GCC-DR and expedite information requests. Pharmaceutical companies also agreed that 
the pharmaceutical industry can influence the GCC-DR procedure through knowledge 
sharing, interactions and collaboration as a partnership basis. Through such activities, the 
pharmaceutical companies could provide support at any level through their worldwide 
experience with authorities and regulators. The pharmaceutical companies could 
contribute in drafting and refining guidelines and the GMP inspection system to make 
them more effective and efficient. They could also assist the GCC-DR in streamlining the 
procedure in order to improve and expedite the registration process.  
Finally, the GCC authorities are facing an increasing number of pharmaceutical 
companies who are demanding more efficient, effective and transparent regulatory 
services. This places a significant pressure on the Gulf States to improve the quality of the 
regulatory review process as well as to expedite the marketing authorization of 
pharmaceutical products without affecting the quality of the new medicines. The GCC-
DR challenge in the beginning was to convince companies to consider submitting their 
dossiers to the centralised procedure. The submission process is voluntary as GCC-DR 
cannot implement a compulsory system until the required level of standardization in the 
regulatory review systems has been reached. However, pharmaceutical companies still 
have mixed feelings about whether they can gain faster marketing authorization through 
the national regulatory systems or the regional centralised system (Al Essa, 2011). After 
all, the goal of any pharmaceutical company is to complete the registration requirements 
and gain access to the national GCC markets in the shortest possible time. In the end, two 
approval routes, national and centralised, are permitted to exist side-by-side in the GCC 
region. But for the centralised system to dominate, member states should seek ways to 
increase their collaborative efforts to bring their systems closer towards standardization 
that would facilitate the regional registration process and maintain patients‟ access to safe 
and effective medicines within a reasonable time frame. 
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SUMMARY  
 The pharmaceutical companies who responded to the survey were able to provide 
critical information on the strengths and weaknesses of the CP registration 
system.   
  In general pharmaceutical companies were satisfied with the quality of the GCC-
DR scientific opinions despite the difficulties and the issues faced in getting their 
products registered through the CP. 
 The participant companies were satisfied with the efficiency and effectiveness of 
the GCC centralised pharmacovigilance procedures as the GCC-DR, through this 
procedure, rapidly monitors adverse drug reactions.  
 All the companies indicated they were satisfied with the level of transparency of 
the CP as the GCC-DR were open in their communication, it was easy to meet the 
central organisation team member, they were willing  to simplify the issues and 
had great understanding. 
 The GCC-DR has a significant advantage as the product could be promoted faster, 
easier and is highly recognisable in the seven GCC States.  
 The major disadvantage of the CP as compared to the national system is the time 
and the expense involved in the process, followed by the inconsistency of the 
process and the insufficient number of meetings. The companies also stated that 
the need to re-submit product files at a national level after approval at the 
Centralised Procedure is a further disadvantage.  
 The study confirmed that although more than half of the 30 pharmaceutical 
companies preferred the national registration system as compared to the GCC-DR 
Centralised Procedure, they agreed that the CP is the way forward for the future 
as it will bring about harmonisation of the registration process, quality scientific 
opinions and faster access to the GCC market. 
 
 
 
 
 
 
188 
 
CHAPTER 8 
 
 
 
 
 
 
The Gulf Centralised Procedure- A 
Comparison between the Experiences of 
Regulatory Authorities and Pharmaceutical 
Companies: a Proposed new model   
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INTRODUCTION 
 
The Centralised Procedure was designed to improve the operation of the „Single 
Market‟ for medicinal products, the avoidance of duplication of scientific evaluation 
and the reduction of the administrative burden. Apart from these, product safety 
enhancement and harmonisation are also important for this region. However, the 
situation in the Gulf Centralised Registration procedure is complex because each state 
has its own government, constitution, legislation, regulatory requirements and 
healthcare systems, as well as differences in history and medical practices.  
 
Today regulatory authorities are thinking in terms of Global and Regional themes, for 
example the European Medicines Agency (EMA), the African Regulatory 
Harmonization Initiative (AMRH), and the International Conference on 
Harmonisation (ICH) for Europe, Japan and USA. However, such efforts are not risk-
free due to the influence of regional groups in pursuing harmonisation of drug 
registration. In addition, more stringent registration requirements may displace 
substandard medicines from the market. 
 
The Ministers of Health in most of the Gulf States have expressed their doubts about 
the ability to secure the expertise required for registration while at the same time there 
is the fear of losing their sovereignty to the centralised authority (A. Rahman, 2005). 
The successful development and registration of a medicinal product requires effective 
dialogue between the pharmaceutical industry and the health authorities. For the 
pharmaceutical industry, good communication with the health authorities is essential 
during the entire lifecycle of a medicinal product, which include the registration 
procedure and the subsequent maintenance phase (Heidenreich, 2004). The main goal 
of both the pharmaceutical industry and the health authorities is to establish a positive 
benefit/risk ratio and an appropriate benefit/risk management system for medicinal 
products. Pharmaceutical companies should contact the health authorities at an early 
stage in the development in order to achieve this goal. Early and frequent dialogue 
between these two stakeholders can build a good relationship between the future 
assessors of the marketing authorisation applications and the responsible managers of 
the company. This may rule out problems and issues with the development of the 
product and thus reduce the risk of an application been rejected.  
191 
 
The result will be more rapid access to essential priority medicines, including 
important new treatment options such as generic fixed-dose combinations of assured 
quality and affordable prices by the communities and patients in Gulf States. National 
drug regulatory authorities need to be better equipped to register medicines in a cost 
effective and timely manner and this will lead to increased efficiencies across GCC 
Countries. Capacity building will enhance the quality of the registration decision, 
whilst streamlined processes and improved information management lead to effective 
medicines control. As a result drug regulatory authorities may enjoy substantial 
savings and increased patient reach with generic equivalents (in the context of high 
volume and high value essential medicines. Beyond this, Governments could enjoy 
additional economies of scale via pooled procurement which is only possible when 
the same medicine is registered across all participating countries. 
OBJECTIVES 
The main objectives of this comparison were to: 
 Identify the similarities and differences between the experiences of regulatory 
authorities and pharmaceutical companies with the Gulf Centralised 
Procedure.  
 Develop a new model for the  GCC-DR based on evaluation and the outcome 
of the centralized procedure.  
 Propose a business plan which would enable the implementation of the new 
model  
 
METHODS 
An assessment of the Centralised Procedure was carried out with two groups of 
stakeholders in the GCC. The first study Gulf Assessment of Centralised Procedure 
(GACP) evaluated the experience and opinions of all seven Gulf regulatory authorities 
with the GCC Centralised Registration. The second study Companies Assessment of 
Central Procedure (CACP) evaluated the experiences and views of pharmaceutical 
companies with respect to the centralised registration review process. In this chapter, 
a comparative analysis between the GACP and the CACP is presented to highlight the 
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issues and challenges faced by these stakeholders as a prelude to the 
recommendations to be made to the GCC-DR. Information from chapter 5, 6 and 7 
was used to develop the new GCC-CP model and proposed  business plan which 
would help to implement the new model. 
RESULTS AND DISCUSSION 
 
The results of this comparison will be presented in three parts:  
Part I:  The Similarities  and Differences between the Experiences of the Drug 
             Regulatory Authorities and the Pharmaceutical Companies. 
Part II: The proposed model for GCC-CP. 
Part III: The proposed business plan which would help to implement the new GCC- 
            CP model. 
 
Part I - The Similarities and Differences between the Experiences of 
the Drug Regulatory Authorities and the Pharmaceutical Companies  
 
At the introduction of the GCC-DR system in 1999, government officials were 
concerned about losing sovereignty to the centralised authority (Hashan, 2005). The 
central registration system has faced criticism for some aspects and approval for 
others from both the member states of the centralised authority and the 
pharmaceutical companies dealing with the system. An interesting development 
which contributed to the improvement of the GCC-CP was the appointment of 
“Cameron McKenna and Andersen Consulting” to audit the EMA's centralised and 
decentralised drug registration procedures. An EMA audit survey mandated a review 
of that agency's activity within six years of its inception.  
The report of this survey namely the Evaluation of Community Producers for the 
Authorisation of Medicinal Products was published in October 2000. It was based on 
interviews with and/or questionnaire responses from trade associations, national drug 
registration authorities, professional and patient associations, national ministries with 
interests in drug approval and pharmaceutical companies. The audit report contained 
the following summary of survey responses: 
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1) The centralised and decentralised procedures are both perceived to have 
contributed to the creation of a harmonised community market for 
medicinal products. 
2) There is some criticism of particular aspects of both systems. However, in 
general, the two systems provide a strong foundation for future progress to 
a harmonised and efficient regulatory environment. Because of their 
different attributes, there is a strong desire on the part of both applicants 
for marketing authorisations and the competent regulatory authorities to 
maintain the parallel systems. 
 
The survey examined many aspects of both the centralised and mutual recognition 
procedures. The auditors did not limit their research to the EMA's activities, but they 
investigated member states' response to EMA decisions. This audit survey examined 
the level of satisfaction with the Centralised Procedure. Of the 32 companies that had 
obtained marketing authorizations by this route, 88% were satisfied with the system 
and 3% was very satisfied. These results are identical to the outcomes of this study. 
The member states regulatory authorities of EMA were more enthusiastic about the 
Centralised Procedure with 73% being satisfied while 20% were very satisfied with its 
operation. These results from Europe also mirrored the outcomes of this study in the 
Gulf States. 
 
A well coordinated, reliable centralised regulatory framework effectively reduces the 
administrative burden and duplication of scientific evaluations by participating 
member states.  The companies believe that if this procedure was streamlined, was 
faster and transparent it could be the system of choice. As the documents for a 
medicinal product are submitted as a common single registration, this results in cost 
saving and an efficient follow up opportunity in all the seven Gulf States. At the 
beginning of 2014, the GCC-DR will initiate the CTD electronic submission (as NeeS 
[Non-eCTD electronic Submissions] format), which is currently implemented by 
internationally recognised agencies and as from January 2015 only the eCTD format 
will be accepted. This approach is useful in that it assists the pharmaceutical 
companies in understanding the rules of the submission process and thus helps both 
the industry and the authority to make better decisions (TGA, 2009). The findings 
from this study highlight the ten years achievement of the Centralised procedure and 
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its future potential as identified by the health authorites as well as the pharmaceutical 
companies. The pharmaceutical companies shed some light on the advantages and 
disadvantages of the centralised system which were similar to the views of the 
national regulatory authorities of the member states, although in some ways they were 
different. Both the regulatory authorities and the pharmaceutical companies agreed 
that the centralised procedure is an effective system for authorizing the marketing of 
medicinal products in all of the GCC countries in one procedure and is the way 
forward, but there is room for improvement in the procedure and the follow ups. 
 
With regard to submission preference the majority of the pharmaceutical companies, 
which took part in this study, prefered the review at a national level mainly due to 
their experience with the national regulatory authorities, therefore making it easier to 
gain market authorization. The long duration of the CP process contributes to the 
preference for the national submission as well as the fear of rejection by a centralised 
authority. The preference of the pharmaceutical companies to apply to national 
authorities is confirmed by the responses of the national regulatory authorities which 
stated that the number of national applications was greater than those submitted to the 
centralised authority adding to the workload of the national regulatory authorities in 
addition to their CP workload. 
Despite the preference of the pharmaceutical companies for national submissions, 
they find the registration at the CP to be better and more efficient. Ease of 
communication has been reported for both the national procedure and CP although 
there is no direct access to CP by the pharmaceutical companies. Most of the national 
regulatory authorities of the member states concur with the fact that the duration of 
the process to obtain market authorisaiton through the centralised procedure should be 
shorter to make it more appealing to applicants. The duration of the centralised 
procedure could be shortened by several means which include increasing the number 
of CP committee meetings per year which has been clearly recognized by both the 
pharmaceutical companies and the national regulatory authorities. The lack of 
resources, mainly human expertise on the side of national regulatory authorities, 
contributes as well to the delays even though there is effective collaboration and 
sharing of information between the national regulatory authorities. Recruiting external 
experts can aid the national regulatory authorities with the shortage of human 
expertise but there is a fear that this will impact the quality of the review. The demand 
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for additional requirements by different national regulatory authorities adds to the 
delay and length of the process. The most effective way is to optimise the process of 
evaluation by the centralised authority by finding a more appropriate model. 
According to the regulatory authorities‟ views, standardisation of the system would 
also be a means to improve and facilitate the regional registration process and 
maintain the supply of safe and effective medicines within a reasonable time frame. 
The national regulatory authorities in the Gulf have found the shared experience, ideas 
and knowledge at the centralised meetings to have enriched their own experience and 
knowledge which is reflected in their performance at the national level. The clear 
outcome of this collaboration and joint effort between the national regulatory 
authorities produces an improved scientific opinion and a higher quality of decision-
making. Pharmaceutical companies have also indicated their agreement with this 
where they found consistent evaluation of submission and a better scientific opinion 
received from the centralised authority than from the national regulatory authorities 
leading to a more efficient system. 
One major aspect of CP approval reported by both the pharmaceutical companies and 
the member states is the centralised pharmacovigilance procedures and reporting 
system which are efficient and effective. In addition, member states of the centralised 
authority find the GCC guidelines to be sufficient and appropriate for their intended 
purpose. On the other hand, pharmaceutical companies, submitting to the centralised 
authority, struggle due to the absence of appropriate guidelines leading to 
inconsistency. Also there are differences when accessing the market at a national level 
such as re-requesting documents already submitted for the CP or not even approving 
the product for distribution after attaining GCC-DR registration.  
Certain aspects of the registration procedure can be modified in order to move 
forward and improve the quality of the experience. Both the national regulatory 
authorities of the member states and the pharmaceutical companies have agreed that 
the use of electronic on-line submissions to the centralised authority, as well as 
electronic communication between the member states, is one way to expedite the 
process. This is the current method implemented in the recognised established 
authorities worldwide such as EMA and FDA. Further, a recognition of the 
assessment by established mature regulatory authorities through implementation of 
the verification procedure is a means of improving the process and easing the burden 
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of the high workload on the national regulatory authorities and for the pharmaceutical 
companies as well. Harmonisation of requests and clarifications sent to the 
pharmaceutical companies is yet another way agreed by both the pharmaceutical 
companies and the national regulatory authorities. The national regulatory authorities 
identified the need for training, seminars and workshops to improve the experience of 
their expert staff. Pharmaceutical companies have suggested the same where the 
additional interactions between pharmaceutical companies and the national regulatory 
authorities would improve the overall knowledge of the national regulatory authorities 
especially as the pharmaceutical companies have worldwide experience. Also it would 
further enhance the relationship and communication between them. The 
pharmaceutical companies even suggested helping to draft, improve and refine 
guidelines including GMP. One of the key concerns, as highlighted by the companies, 
is the limited number of committee meetings per year. The quarterly meetings to 
validate the pharmaceutical products are clearly insufficient to meet the increasing 
demands for product registration and approval. The companies recommended that the 
frequency of the GCC – DR committee meetings needs to be at least 8 per year or 
every 45 days. In addition, sub-committees could be formed with more frequent 
meetings to handle specialised matters such the registration of life saving products.  
The companies recommended that the comments and opinions of the countries, where 
the products have been registered nationally, should be considered when products are 
being evaluated by the GCC-DR. In this way, the approval process would be 
expedited and this would facilitate faster approvals at a national level after the 
products have been approved by the GCC-DR. Over half of the companies supported 
the GCC-DR procedure while five companies out of thirty prefered the national 
registration system. The main reason companies move toward local registration is 
because of the delay and queuing at CP.  Nevertheless, the companies agreed that if 
the GCC-CP improves it will increase its acceptability of the marketing authorisation 
issued centrally in other markets. They also suggested the use of University 
laboratories to speed up „product testing‟ against additional fees.  
The only way to improve support for the GCC registration is to give some advantages 
over the national registration for companies who choose this route. It is very 
important to note that most companies are seeking to establish a single registration 
system, either national or centralised, for their products. Dealing with two registration 
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systems in the same region is impractical.  For all these reasons, companies usually 
adopt the most economically viable registration system that meets their corporate 
objectives. In conclusion, figure 8.1 summarises the key issues to be consider in the 
new proposed GCC model. 
 
Figure 8.1: Key issues to be consider in the new proposed GCC model  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part II - The proposed model for GCC-CP 
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and from product to product. However, it is possible to complete the review process 
within a reasonable time frame if the data are available and adequate. Many countries 
have legislative maximum times allowed for the review of a dossier. For example, the 
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days taken by the US FDA (CIRS, 2013). Several challenges faced the GCC health 
authorities to successfully operate the centralised system. Therefore, they encountered the 
need for regulatory reforms during the last 12 years, in order to improve their individual 
systems and to unify their procedures to expedited improved patients‟ access to high 
quality medicines throughout the region. The GCC-DR challenge in the beginning was to 
convince companies to consider submitting their dossiers via this procedure. The 
pharmaceutical companies still have mixed feelings about whether they can gain faster 
marketing authorization through the national regulatory systems or the regional 
centralized system. After all, the goal of any pharmaceutical company is to complete the 
registration requirements and gain access to the national GCC markets in the shortest 
possible time.   
 
It is crucial for the GCC states to identify the most prevalent driving forces for improving 
the centralised procedure and to attract the pharmaceutical companies to use this system. 
From the results of this study and the information in chapter 5, 6 and 7 a model can be 
proposed based on the current GCC-DR centralised procedure (Figure 8.2) and taking 
account of the comments in part I of this chapter. The model‟s main features are as 
follows: 
 Maintain the main structure of GCC-DR centralised procedure. 
 Amend the parts that are time consuming in the current GCC-DR centralised 
procedure. 
 Allow all member states to participate in the review process and the conclusions 
reached in a timely manner. 
 Adopt an electronic system of review for the proposed model to overcome 
infrequency of meetings and the possibility of all member states participating in 
the review process in a remote manner. 
 Adopt electronic communication with applicants for deficiencies for improved 
review process. 
 Adopt a clock-stop timing for the review process based on the automation of the 
review process. 
 
 This model (Figure 8.3) is based on the current GCC review process. It maintains the 
main features of the approval process namely receipt & validation, management of the 
overall dossier review cycle, registration approval by heads of authorities and upholding 
the independence and sovereignty of member states within the approval process. 
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However, the proposed model eliminates the steps in the approval process which are time 
consuming and present redundancy in the process. The main step to be eliminated relates 
to the questions raised by member states following the review. Clearly this step raises the 
question as to why member states would raise questions that are not highlighted by the 
two reviewing authorities. This at best produces doubts regarding the review capabilities 
of certain member states while at worst raises doubts about the GCC review process in 
general. On one hand each member state must be allowed the possibility to state their 
views regarding the application, while on the other hand there is a need to achieve review 
time efficiency. To realize such a target the model proposed is as follows: 
A. Receipt phase: Receipt of the application is carried out in accordance to the 
published GCC guidelines for NAS‟s and EAS‟s. The applicant should request a 
submission date for the application which would be provided by the GCC office. It is 
of importance that the applicant would provide a statement that the application being 
submitted has observed all the relevant GCC guidelines. This statement has a 
functional effect on the clock-stop as it is quite frequently observed that applicants 
submit partially completed dossiers, especially the local industry, making promises to 
bring missing or complete data at a later date. The applicant must be held accountable 
in such cases and this can only be done according to local laws if such documents are 
provided, otherwise the receiving officer will usually be held responsible. 
Furthermore, the statement will serve as time zero for the “clock-stop”. The receipt 
process should be conducted at the GCC Executive Office and performed by GCC 
staff. This phase is actually maintained as the current practice of application receipt at 
the GCC office. 
B. Validation phase: The validation phase may be critical for agencies like Health 
Canada, US FDA or EMA, when many dossiers are submitted by the applicant 
whereby the submission is screened to ensure that the data are complete and of 
suitable quality for review. In this phase for the GCC-CP the requirements are 
checked against the requested formal requirements. This should include the 
administrative registration (reference number) and checks on legal requirements, the 
status of the company, manufacturer etc. as well as a „checklist‟ validation of the 
application content (e.g. technical sections, CPP status). 
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Figure 8.2  The current GCC-CP registration system 
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Figure 8.3 The proposed model for GCC-CP 
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Further checks on patent compliance are necessary and any contractual 
arrangements such as contract manufacturing or licensing agreements are also 
checked. The allocated clock-stop time for both processes of administrative and 
legal formalities should be 30 days. The validation processes are carried out at the 
GCC office. In effect the validation process should make sure that the submitted 
application is in compliance with the formal requirements as stated in module 1 of 
the CTD specifications together with further checks that all the required technical 
data is provided. This phase is maintained as the current practice of application 
validation by the GCC office. 
 
C. Review phase: The scientific assessment stage is the major part of the review 
process and requires considerable amount of evaluation of data relevant to the 
safety, efficacy and quality of the pharmaceutical product. Therefore, it is 
essential to focus the attention on providing the appropriate skill sets and the 
facilities as well as establishing guidelines, SOPs, training and continuing 
education programmes and the electronic handling of the review process to 
implement the desired good review practices (GRPs). In the new proposed model 
the scientific review should be overhauled to allow all member states to 
participate in the review process in a one-step approach. This necessarily means 
that steps (C), (D) and most of (E) of the current GCC model of practice are 
merged into one step in the proposed model. In this phase, two committees are 
established from all member states. Therefore each member state is represented in 
each of the two committees to ensure the active participation of all states. The two 
committees are as follows: 
 
a. Clinical committee: this committee should consist of experts from the 
member states and should be responsible for reviewing the clinical 
requirements for both NAS‟s and EAS‟s dossiers. In effect this committee 
is concerned with safety and efficacy/modules 4 and 5 of the approved 
GCC CTD standard. 
 
b. Technical committee: this committee should consist of experts from the 
member states and should be responsible for reviewing and approving 
API‟s and excipients in the formula as well as the finished product. This 
committee is very similar to the EDQM committee in the EU in addition 
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to the technical review committee in respective EU member states. This 
committee would focused on module 3 of the GCC CTD standard. 
 
The clinical and technical committees cover all aspects with regard to the safety, 
efficacy and quality of the product while any legal aspect that may relate to the 
product would have already been checked during the application validation 
process. The clinical and technical committees approach to the product‟s review 
compared to the two step approach of the current model would lead to 
considerable time saving and review process efficiency and transparency. Each 
member state would be able to state their approval or concerns during the review 
process in that particular committee. A letter of deficiency relating to that 
committee would be issued to the applicant with a time limit for the applicant to 
respond. The committee‟s meeting time can be organised in a manner to allow for 
the review of new applications while keeping about 30% of the meeting time for 
replies to issued letters of deficiencies. The committees should meet at least once 
a month to keep the process efficient and timely. The allocated clock-stop time 
for both committees concurrently is 150 days. The tasks performed in the 
committees are done primarily by members of staff from health authorities of the 
member states and not from the GCC office staff. 
c. Laboratory analysis: the required laboratory tests should be performed 
concurrently with the application review process of both clinical and 
technical committees. The allocated clock-stop time for the laboratory to 
complete the required tasks is 120 days which is well within the 150 days 
clock-stop time allocated for both clinical and technical committees. This 
should be the default and implies that the work of both clinical and 
technical committees and the laboratory is harmonized and synchronized 
to complete the work within the 150 days time limit. 
D. Approval phase: Once the two committees grant approval for their part as well as 
the laboratory decision to approve the product, their respective decisions are 
transferred to the head of authorities meeting to give the approval to issue the 
registration certificate. If, for any reason, the heads of the authorities are 
concerned regarding any aspect of the application they will issue a letter of 
concern to the appropriate organisation which might be the GCC management 
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staff, specified committee(s), the laboratory or the applicant. Once the concern is 
answered then an instruction to issue the registration certificate is mandated. The 
heads of authority‟s approval is to check that the approval process steps and an 
adequate review is observed. This may represent a quality assurance task 
performance to guarantee good review practices at the GCC office. The allocated 
clock-stop time for this phase should be 30 days and the tasks are entrusted to the 
heads of health authorities of the GCC member states. The heads of authorities in 
this case should be considered as the approval council (head of agencies) and they 
should meet, every month. The allocated clock-stop time for this committee is 30 
days. This takes into account the meeting frequency of this committee making 
sure that once the applications passes all requested formal and substantive 
requirements the application‟s final approval by the heads of authorities shall be 
compliant with the clock-stop. Once the approval is granted by the approval 
council then the GCC office should issue the registration certificate for the 
product under application. 
 
In order for the above proposed model to function the following are required: 
a. Clear guidelines for the review process are laid down by the council of 
heads of authorities. Good review practices should be mandated in such 
guidelines. The GCC should elect one authority to host a training academy 
for all aspects related to the sciences and skills needed by the GCC and 
member states staff involved in the review process. 
b. Electronic management (Computerisation) of the whole process of the 
review including an electronic review system which allows committees to 
hold meetings, while each committee member is in their office, utilising 
modern computer software and communication tools and devices. Using 
modern meeting techniques will result in cost savings, process efficiency 
and significant review time saving. Further electronic process 
management will enable external experts to participate in meetings of the 
various committees if required without the need to make travel 
arrangements giving expert support to the work of the GCC reviewing 
process. 
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This new model would allow the GCC to adopt a clock-stop approach to the review 
process. The GCC‟s main bottle neck is the “questions to the applicants” raised by 
non-reviewing member states. This proposed model eliminates such a bottle neck 
through the participation of all member states in the reviewing committees. The time 
saving should allow GCC to promise 210 calendar days for NAS‟s and of course 
fewer days for EAS‟s is expected, but at worst would be the 210 days.  
 
However, adopting the clock-stop dictates that the applicant‟s expected response time 
and date is indicated to the applicant. Failing to meet the response date by the 
applicant should allow the GCC to remove the application from the review process 
after warning, in order to reduce the review pipeline. Clear guidelines for the clock-
stop concept and the use of such a concept should be clearly documented and 
announced. 
 
The laboratory analysis requirement should be performed in a manner that eliminates 
delays in the analysis process. This is based on member states laboratories declaring 
their readiness to meet the clock-stop requirement and availability of time for 
analysis. Even though each of Kuwait, Oman, UAE and KSA Quality Control (QC) 
laboratories are well equipped for conducting analysis of pharmaceutical products, 
member states should agree on accreditation criteria for QC laboratories in order to 
officially identify that these laboratories are able to meet these accreditation criteria.  
In addition, each member state with the ability to meet the accreditation criteria 
should also be able to accommodate 120 days clock-stop to complete the assigned 
task. Analysis tasks are assigned to laboratories that declare their ability to meet the 
clock-stop requirements and tasks are given to member states laboratories in order to 
give analysis tasks to member states laboratories in a fair manner. This would allow 
all participating laboratories equal opportunities to contribute to the process of 
product approval in the GCC system. In this way, laboratory tasks, assigned in this 
model, would eliminate the long analysis time and undue waiting experienced 
currently.  
 
 
215 
 
Part III - A proposed business plan underpinning the implementation 
of the new GCC-CP model 
 
Quality management practices are an integral part of several established drug 
regulatory authorities (eg. EMA, FDA) including governance configuration and its 
business processes. These practices help to ensure that the agency operates to 
consistently high levels of quality, efficiency and cost-effectiveness. In terms of 
financial resources, it is worth investigating the impact of different budget structures 
on performance across authorities (Anderson, 2007).  
 
The agency charges a fee for processing applications from companies that want to 
bring a medicine to the market. It also charges fees for services related to the 
marketing of medicines in the EU in areas such as scientific advice, inspections, 
renewals and variations and the establishment of maximum residue limits. The total 
budget of EMA was 194.4 M€ in 2009 (EMA, 2010) and it is expected to be 239.1M€ 
in 2013. The budget process allows the EMA to cover its needs, mainly by fee 
revenue which is subject to fluctuation.   
 
The pharmaceutical industry considers EMA fees fair and appropriate „to the services 
provided‟. On the other hand the US FDA's federal budget request for fiscal year (FY) 
2012 totalled $4.36 billion (El Boghdady et al, 2012). About $2 billion of this budget 
is generated by user fees and pharmaceutical firms pay the majority of these fees, 
which are used to expedite drug reviews. Even though the procedures and 
classifications differ considerably between EMA and FDA, the majority of 
stakeholders consider both agencies provide high quality evaluations for their 
products. It is noteworthy that the European pharmaceutical market size is 2/3 of the 
US pharmaceutical sector. 
 
 The EMA fee structure (EMA, 2010) appears complex in comparison with the FDA 
fee structure; there are specific cases for three different types of variations, such as 
type Ia, Ib, and II, beyond extension, additional fees for specific strengths or 
presentations, as well as referral fees. Several fee waivers favouring generics, 
biosimilars, orphan and paediatric products, small and medium sized enterprises exist 
in the EMA structure.  
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On the other hand, the FDA levies establishment fees (US$, 457,200) every year from 
the authorised drug manufacturers. In a similar fashion, FDA also gives fee waivers 
like EMA, in special cases.  Spending on medicines will reach nearly $1,100Bn in 
2015 (IMS, 2012). The U.S. share of global spending will decline from 41% in 2005 
to 31% in 2015, while the share of spending from the top five European countries 
(Germany, France, UK, Italy and Spain) will decline from 20% to 13% over the same 
period. In contrast to EMA, the FDA fee requirements include application fees for 
previously filed applications or supplements , fees for designated orphan drugs or 
indications ( both for prescription products or for a supplement) . 
The FDA user fee programmes support the safe and effective review for human and 
animal medicines, biological products, medical devices and the review of other FDA-
regulated products. User fees also allow FDA programs to achieve enhanced 
premarket review performance. Other FDA user fees support the regulation of tobacco 
products, the inspection of mammography facilities, the certification of color 
additives and the certification of FDA-regulated products exported from the United 
States. New user fees enacted by the FDA Food Safety Modernization Act support 
essential food safety activities. The budget includes inflationary increases for FDA 
user fee programmes, as authorized by law. 
 
The Prescription Drug User Fee Act (PDUFA), enacted in 1992, authorizes FDA to 
collect fees from companies that produce certain human drugs and biological 
products. Since the establishment of PDUFA, user fees have played an important role 
in expediting the drug approval process. On July 9, 2012, the President sanctioned 
the Food and Drug Administration Safety and Innovation Act (FDASIA), which 
includes the reauthorization of PDUFA through to September 2017. PDUFA V will 
provide for the continued timely review of new medicines and biologic license 
applications in the US. The new law ensures that FDA will continue to receive a 
source of stable and consistent funding during fiscal years 2013-2017 and allow the 
agency to fulfill its mission to protect and promote public health by helping to bring to 
market critical new medicines for patients.  
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Government support in the form of a budget is the method of financing employed in 
most of the GCC States, however, only Saudi Arabia and Yemen are self-financed by 
fees. Governments are committed to support the GCC authorities financially and 
prioritise funding of the regulatory review process. In any case, arrangements should 
be made so that the financial sustainability is maintained for continuous and effective 
implementation of the various drug regulatory functions (Ratanawijitrasin, 2002).  
The quality of the review process, the technological and scientific skills 
improvements remain a limiting factor without Governmental support (Hashan, 2006). 
The range of fees, however, varies significantly from country to country according to 
the funding structure and the services provided by each authority. The relatively high 
registration fees charged by the Saudi Food and Drug Authority (SFDA), compared to 
the other GCC authorities, are related to the autonomous support of the SFDA for its 
own practices, facilities and services through the direct access to the fees, rather than 
being collected by the central government revenue as in the other GCC States which 
may or may not be returned to the authority undertaking the work (Hill and Johnson, 
2004).  
The Yemen regulatory authority is an autonomous authority as well and therefore the 
registration fees are slightly higher than those charged by the rest of the GCC States, 
but considerably lower than SFDA probably to attract pharmaceutical companies to 
the local market in Yemen. It is agreed by all the GCC authorities that in order to 
improve the regulatory review process, the authorities need to increase their resources 
such as the number of experts, developing the information technology structure and 
establishing training and continuous education programmes.  
 
Without appropriate funding, the authorities will always face difficulties in improving 
their regulatory systems. It can clearly be seen (Table 8.1) the parity among member 
states' fees ranging from no fees in Qatar to as high as USD 25,341 in Saudi Arabia. 
This wide difference in the range of the requested fees at national level from each 
member state will cause those with higher national fees to resist the GCC Centralised 
Procedure.  
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Table 8.1: Registration fees in the GCC States 
 
*The proposed fees structure calculated according to the ratio of current national fees to the  total fees for all member states in 
addition to 10% as administration fees. (The basic  fees in EMA for a single strength= 274,400 Euro) (FDA New Drug 
Application (With Clinical Data) fees for 2014 fiscal year (FY) =$2,169,100).         
 
 It is recommended that if the proposed model is implanted then each member state 
should decline their national fees in favour of GCC-CP fees and that the GCC-CP fees 
should be shared amongst member states where each share is calculated according to 
the ratio of current national fees to the total fees for all member states in addition to 
10% as administration fees. For this model to be feasible in the future, the overall fees 
of the GCC-CP must be increased. The increased fees would allow member health 
authorities to benefit from these application fees and for tasks they perform during the 
application approval process. Further to the above, the fees for analysis should be 
awarded to the assigned QC laboratory of the member state performing the analysis 
task. Training is a key element for capacity building for the success of the proposed 
model. Training should be carried out to achieve higher performance with improved 
efficiency for member states for the review of GCC-CP applications. The training fees 
should be awarded to the member state hosting the training activity. The comparison 
of the views from pharmaceutical companies and regulatory authorities has identified 
the most important outcome as the desire for improving the GCC centralised 
procedure model.  
 
 
 Bahrain Kuwait Oman Qatar Saudi Arabia UAE Yemen GCC-
CP 
Proposed 
GCC-CP 
fees 
 
Company 
Registration 
5 BD 
= 
USD 13.3 
250 KD 
= 
USD 
887.2 
100 OR 
= 
USD 
259.7 
 
 
NO 
FEE 
 
(ONLY 
INSPECTION 
FEE) 
1000 
DH 
= 
USD 
272.3 
3000 
USD 
10000 
SR 
= 
USD 
2,667.5 
(ONLY 
INSPEC-
TION 
FEE) 
 
 
Products 
NASs   
5 BD 
= 
USD 
13.3 
100 KD 
= 
USD 
354.9 
75 OR 
= 
USD 
194.8 
 
 
NO 
FEE 
95,000 SR 
= 
USD 
25,340.8 
1000 
DH 
= 
USD 
272.3 
1500 
USD 
10000 
SR 
= 
USD 
2,667.5 
 
 
USD 
30,4444* 
 
 
Products 
EASs  
5 BD 
= 
USD 
13.3 
100 KD 
= 
USD 
354.9 
75 OR 
= 
USD 
194.8 
 
 
NO 
FEE 
40,000 SR 
= 
USD 
10,669.8 
1000 
DH 
= 
USD 
272.3 
1500 
USD 
10000 
SR 
= 
USD 
2,667.5 
 
USD 
14,305* 
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SUMMARY 
  Agencies and companies agreed that the centralised procedure had 
contributed to an effective system for authorising medicinal products in the 
GCC by providing the best possible scientific opinion for the quality of CP 
decision-making as compared to the national system.  
 Enhancing sufficient resources like qualified and trained experts together with 
technical facilities would improve the quality of the GCC regulatory 
performance. 
 It is crucial for GCC states to identify the most prevalent driving forces for 
improvement to the GCC centralised procedure such as on-line submissions 
and an increase in the number of committee meetings in order attract 
pharmaceutical companies to use this system. 
 Quality management practices are an integral part of several established drug 
regulatory authorities and its business processes. These practices help to 
ensure that an Agency operates to consistently high levels of quality, 
efficiency and cost-effectiveness. 
 The overall fees of the GCC-CP should be increased in order to allow member 
health authorities to benefit from application fees and for tasks they perform 
during the application approval process. 
 The comparison of the views from pharmaceutical companies and regulatory 
authorities has identified the most important outcome as the desire for 
improving the GCC centralised procedure model.    
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CHAPTER 9 
 
 
 
 
 
General Discussion 
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A systematic examination of pharmaceutical regulation and its environment across 
countries can help shed light on a country situation, provide a new perspective on the 
constraints facing it and suggest options for improvement. A comparative approach is 
used in this study, on the grounds that countries can benefit from learning from one 
another. There are three basic reasons for conducting systematic comparisons between 
countries (Booz Allen Hamilton, 2006).  
 
 Strategy development: comparing different ways of managing similar 
problems can provide both positive and negative lessons, i.e. guidance on what 
to do and what not to do. Comparing cross-country experiences is a useful way 
of developing policy instruments for problem-solving in a particular country. 
 
 Understanding: comparing public policies can help improve understanding of 
how government institutions operate within their environment and suggest 
possibilities for improvement. 
 
 Interdependence: the interdependence of nations as reflected in international 
agreements, regional political-economic groupings, bilateral treaties and 
collaboration is constantly increasing. Accordingly, problems that occur in one 
country can spill over into other countries more easily and rapidly today than 
at any other time in history. Similarly, policies adopted in one country often 
have important implications for others. In other words, knowledge about what 
has occurred in other countries can help a country prepare for new challenges 
of its own. 
 
Making a positive decision about a pharmaceutical product requires careful weighing 
up of the potential benefits and harms and the scientific complexity of such decision-
making should not be underestimated (Hill, 2004). From the authority‟s perspective, 
success is the licensing of quality medicines to enable patients to have access in a 
reasonable time frame without compromising safety and/or efficacy (Hashan, 2005). 
Therefore, a thorough review is carried out by the assessors with particular emphasis 
on the quality, safety and efficacy studies. The use of ineffective, harmful, poor 
quality medicines can result in therapeutic failure, deterioration of the disease being 
treated, resistance to medicines and sometimes death. It also undermines confidence 
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in the health review system, health professionals, pharmaceutical manufacturers and 
distributors (Rago and Santoso, 2008). The complexity and challenges of the drug 
registration system should not be overlooked. It is simplistic to believe that speeding 
up the registration process will improve patients‟ access to quality, safe and effective 
medicines. This is the industry‟s argument but neglects to take into account important 
issues such as the quality of the review. Given the pressures that arise from the 
legitimate business interests of the multinational pharmaceutical manufacturers, there 
needs to be support for regional activities designed to ensure the quality in the 
registration systems. This includes ensuring that there is adequate capacity to cover 
the required resources and appropriate guidelines at a country level to assess and 
control the quality of medicines. 
Information sharing and harmonisation reduces workload and improves overall 
regulatory performance. Harmonization is the value added that directs expert 
knowledge and resources to functions that improve public and personal   health and 
facilitates access to essential medicines. Formation of effective networks among 
national regulatory authorities participating in various harmonization initiatives 
facilitates sharing of scarce resources; eliminates duplication of activities; saves 
money for all; supports cooperation, collaboration and international understanding; 
facilitates in building regulatory capacity and enhances public trust in regulatory 
efforts. 
 
The Gulf States faced significant challenges in dealing with their established 
regulatory bodies who were reluctant to give up their independence to the newly 
established GCC Central Drug Registration (GCC-DR) system (Al-Essa, 2011). The 
idea of implementing a central registration system came originally from the 
industrialised world, especially from the success stories of the European Medicine 
Agency which encouraged gulf regulatory organisations to structure the central 
registration system. The centralised process of the European Union drug regulatory 
agencies under one roof resulted in the development of EMA which has attained 
improved trust, transparency, communication and mutual recognition through the 
unification process. The European approach to national and central procedures differs 
greatly from that adopted in the GCC. The difference is conceptual and structural 
which is reflected in the procedural aspects and furthered the outcome of the 
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European approach. The missing link in the comparison between the European 
approach and the GCC approach is the following: 
 
1. The European system was initiated based on the need for mutual recognition 
between some member states. This lead to the mutual recognition procedure 
between some member states such as UK, France, Germany, etc. The system 
was further refined to the centralised procedure covering all member states. In 
this evolution the European approach presented a coherent system for review 
of medicinal products with standards acceptable to all member states. The 
system has inherent flexibilities for applicants to choose the national route for 
submission or the centralised procedure. Furthermore, the system allowed 
applicants to switch from the centralised procedure to the decentralised 
procedure. On the other hand, the GCC system evolved from the need for 
communal procurement of medicinal products not from mutual recognition 
needs. The foundation of the system is based on the GCC tendering procedure 
rather than communal review system. The review standards and consequently 
review quality leads to a non-harmonized system between member states. It is 
this non-harmonized system that led to the difficulties expressed clearly by 
GCC member state staff. In order to overcome this difficulty most member 
states are advocating national harmonization with GCC-DR. 
 
2. The European system of review and approval leads a formal grant of 
marketing authorization for applicants without the need for follow up 
submission by member states. In this regard the centralised procedure in 
Europe represents a viable alternative to submission in multi-states in the EU 
while the GCC-DR does not offer the same opportunity and applicants need to 
go through the national procedure as well as following the central procedure 
approval. 
 
3. For a review system to be effective all elements of the review system must be 
clearly defined through guidelines and procedure. One of the most important 
elements in any review system is the pricing guideline and procedure. The 
GCC-DR does not include the pricing element which is of course emanating 
from the intended purpose of the GCC-DR being the unified route for 
tendering in the GCC procurement of medicinal products.  
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4. The European Medicines Agency (EMA) has established systems of training 
its own staff and extends it to the training of scientific experts. Training takes 
into account entry level of review staff up to the continuous training of senior 
reviewers. Even non-employed personnel have their own training (EMA, 
2011). The main purpose of the training is to ensure the review process is 
measured from different aspects namely effectiveness, efficiency, long-term 
effectiveness on EU citizens, impact on EU internal market and on different 
stakeholders (EMA, 2010). Training is the main tool to ensure a quality review 
and the absence of a GCC-DR training system directly affects the quality of 
the review procedure and consequently impacts all other features of the GCC-
DR system.  
 
From the above it becomes evident that a comparison between EMA and GCC-DR is 
not an objective assessment. Certain elements will look common between both central 
procedures by virtue of them being central procedures e.g. the participation of 
reviewers from all member states. However, for the EMA the criteria for a reviewer 
appointment is based on review skills attested by EMA for any national member state, 
while in the GCC-DR it is a formal procedure based on member state‟s discretion. 
The anomalies between GCC-DR and EMA could render the comparison misleading. 
 
The quality of the review process is a comprehensive and multifaceted concept 
(Brown et al., 2002). Previous studies have concluded that it is not sufficient to 
measure regulatory performance in terms of the speed of the approval process alone. 
Maxwell (2004) indicated that: “Concern about quality of care must be as old as 
medicine. But honest concern about quality, however genuine, is not the same as 
methodical assessment based on reliable evidence”. Maxwell also identified six key 
dimensions of the quality, and these are (1) Accessibility (is the service accessible in 
terms of distance, time, and social barriers?) (2) Effectiveness (does the service 
produce the desired outcome?) (3) Efficiency (does the service produce the desired 
outcome with the least waste/at low cost?) (4) Equity (indicating the quality of access 
to services) (5) Relevance to need (is the service appropriate to the needs of its users?) 
(6) Acceptability (what is provided and the manner in which it is provided) (Moss, 
2004). The quality of the regulatory review process, from the construction of the 
dossier to the final regulatory decision must also be examined (McAuslane and Cone, 
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2006). The importance of implementing and maintaining Good Review Practices 
(GRPs) are critical measures that need to be considered by the Gulf States to provide 
consistency and to improve efficiency, clarity, and transparency of the review 
process.  It is important to adopt GRPs as standard processes through formal training 
of the review staff (US FDA, 2009).  
The GCC authorities were found to be carrying out a number of activities to bring 
about continuous improvement in their regulatory review process. Various reasons 
were stated for introducing quality measures into their activities but the most common 
ones were to ensure consistency and efficiency and to minimize errors in the system 
(Al-Essa, 2011). Therefore, quality systems should be regularly reviewed to ensure 
that they are working effectively (Mallia-Milanes, 2010).    
The purpose of this research has been to evaluate the regulatory review process in the 
GCC central registration and its impact on patients‟ access to medicines in the GCC 
States. The focus of chapter three was on evaluating the regulatory review process in 
Oman in order to identify areas of improvements in the system. Chapter four analysed 
the approval time over the period 2008-2010 in the GCC States. The evaluation of the 
review times for New Active Substances (NASs) and Existing Active Substances 
(EASs) in the GCC Centralised Registration system (January 2006 to December 2010) 
was the focus of chapter five while chapters six and seven assessed the views and 
experiences of the GCC regulatory authorities and pharmaceutical companies in order 
to identify the strengths and weakness of the current GCC centralised procedure. 
Finally, the similarities and differences between the experiences of regulatory 
authorities and pharmaceutical companies with the Gulf Centralised Procedure and a 
proposed new model for the GCC-DR was the focus of chapter eight.  
The research began by thoroughly assessing the trend in the regulatory approval times 
in Oman for the period 2006 to 2010. The findings showed that although there is an 
increase in the approval time for all pharmaceutical company products, the median 
approval time for the five year period was 117 days. This is within the time limit (4 
months) which is fixed by the health authority for the overall registration time. Oman 
is facing significant challenges reflecting the rapid advancement of regulatory 
services with limited resources possibly influencing patients' timely access to 
medicines. These challenges gave the regulatory agency no choice but to review and 
update its regulatory practices. The ability to regulate medicines effectively is 
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determined by a number of factors including the availability of guidelines, good 
written procedures and the provision of the appropriate resources to fulfill the 
regulatory needs. The lack of resources can be compensated to some extent by 
effective collaboration among countries and information sharing (WHO, 2008). The 
Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC) budget 
is not separated from the MOH, so development is minimized, due to priority within 
the government system. Increase in the registration fee and its use to develop the 
authority could help to improve the quality of the review.  
  
Another important aspect that needs to be highlighted in Omani regulatory practices is 
the use of the verification model for the assessment of a new registration dossier. This 
model is acceptable for the majority of applications if they are registered in countries 
with recognized regulatory authorities. If not, it is critical to consider a thorough and 
more specialized review for products which are not registered elsewhere and for 
biotechnology and biological products. Singapore, for example, conducts a 
verification review for all types of medicines which are previously authorized by at 
least two reference authorities (e.g FDA, EMA), except for biological and 
biotechnology products (Health Science Authority (HAS, 2011).  
 
In a further study a downward trend was demonstrated in the median approval time 
for most of the GCC States during 2008 to 2010. However, the approval time for all 
approved products in the GCC States during this period varied from about 60 days in 
Qatar and Oman (2009 and 2010), and to about 609 days in Saudi Arabia (2008). 
There are many factors which can affect and explain the differences in approval time 
in the GCC States. The main factor is the difference in the positions of milestones 
within the approval process, for example, the analytical step starts with the scientific 
assessment in Oman, Saudi Arabia, and Qatar (parallel procedure), but in Kuwait and 
Bahrain the analytical step comes after the scientific assessment (sequential 
procedure).   
 
Regulatory approval times have also been influenced by the type of assessment 
carried out by different authorities. Bahrain and Kuwait uses a verification review for 
all types of products registered in countries with competent authorities. Saudi Arabia 
performs a full review on all types of application while Oman and Qatar perform an 
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abridged review for all products. The GCC states should seek to increase the level of 
funding to bring about the required expertise and resources to conduct a more 
extensive review of important medicines, including biological and biotechnology 
products. A clock stop is another important approach which is not fully enforced in 
the GCC authorities to control the overall approval time. The EMA is obliged by the 
regulation to reach a decision within 210 days, although the clock is stopped if it is 
necessary to ask the applicant for clarification or further supporting data (EMA, 
2009). 
 
Furthermore, this research project investigated the pattern of total regulatory approval 
times in the Gulf Centralised Procedure over the period from 2006 to 2010. It also 
addressed the various factors which may have a positive or negative effect on total 
approval times. During the five year period of the study (2006 – 2010), the median 
approval time significantly increased due to several factors which included the limited 
number of meetings by the GCC-DR and increased number of applications for 
registration.  Other factors that delayed the registration were the assessment review 
process where two authorities are selected alphabetically to review the registration 
dossier. In addition, the lack of a standard evaluation template for product assessment 
leads to an increase in the correspondence which is sent to the sponsor in several 
batches and at different times. It is recommended to have one standard assessment 
template and rather than selecting the reviewing authorities alphabetically, the dossier 
should be sent to all countries and all assessments combined into one final report on 
which the final decision in the GCC-DR could be based. Other factors that could 
speed up the registration process is an increase in the number of the committee 
meetings and using information technology and e-mails in the communication 
between the Executive Office and the companies.   
 
The findings from this study also highlight the ten years achievement of the 
Centralised procedure and its future potential as identified by the health authorites as 
well as the pharmaceutical companies. Although, both the regulatory authorities and 
the pharmaceutical companies agreed that the centralised procedure is an effective system 
for authorizing the marketing of medicinal products, the pharmaceutical companies still 
have mixed feelings about whether they can gain faster marketing authorization through 
the national regulatory systems or the regional centralized system. After all, the goal of 
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any pharmaceutical company is to complete the registration requirements and gain access 
to the national GCC markets in the shortest possible time (AL-Essa, 2011).  
In the end, two approval routes, national and centralized, are permitted to exist side-by-
side in the GCC region. But for the centralized system to dominate, member states should 
seek ways to increase their collaborative efforts to bring their systems closer towards 
standardization that would facilitate the regional registration process and maintain 
patients‟ access to safe and effective medicines within a reasonable time frame. It is 
recommended that the comments and opinions of the countries, where the products have 
been registered nationally, should be considered when products are being evaluated at 
GCC-DR.  In this way, the approval process would be expedited and this would facilitate 
faster approvals at a national level after the products have been approved by the GCC-
DR. The only way to improve support for the GCC registration is to give some 
advantages over the national registration for companies who choose this route. It is very 
important to note that most companies require a single registration system, either national 
or centralised, for their products. Dealing with two registration systems in the same region 
is thought by some to be inefficient.    
 
The GCC as a conceptual framework for harmonization among the member states has 
been extended to areas like pharmaceutical procurement. In this regard the centralised 
procedure was established as a step in the overall harmonization efforts of member states. 
The GCC-DR is gaining momentum and importance for the private sector as reflected in 
the responses of companies. Furthermore, the GCC-DR is contributing in a positive way, 
especially in smaller member states although efficiency needs to be improved. Efficiency 
can be clearly linked to the quality of decision-making during the review process and all 
member states considered the GCC-DR review to be of the same quality as the national 
review or better except for Saudi Arabia who considered the review quality as worse than 
national review. Member states sought to find a solution to improve the review process by 
utilising a standardised review template. This would avoid efficiency issues due to 
requests for additional data. In addition raising the scientific and review skills of 
participating staff from member states in the central procedure and by adopting clear 
SOPs for the review process would be of benefit. Furthermore, harmonization of national 
review guidelines and procedures within the GCC-DR would be an advantage as well. 
Needless to say the positive influence of such harmonization will result in efficiency at 
both national and central procedure level. For all these reasons, companies usually adopt 
the most economically viable registration system that meets their corporate objectives. 
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The GCC-DR system can be better executed by the formulation of policies and guidelines 
that are practical, concise and clear. A healthy interaction between regulatory agencies 
and pharmaceutical companies at an early planning stage may boost the overall central 
drug registration process. A competent registration process which is rooted in 
transparency of procedures and unbiased scientific opinions would lead to a smooth drug 
registration process among the GCC States.  
 
Limitations of the study 
 
As with any research there were a number of limitations including the following:        
 
 For the evaluation of regulatory review times in the Gulf States it was not possible to 
obtain information of the review system or timelines for UAE or Yemen. This was 
despite several e-mails and follow-up phone calls. Although for the sake of 
completion it would have been ideal to have received data from both these States, it 
did not have a detrimental effect on the overall conclusions. 
  
 The evaluation of the GCC Centalised regulatory review process only focused on 
approved products. It would have been an advantage in reviewing the timelines to 
have access to those products that were rejected, however, these were not available in 
an electronic form and so would have necessitated identifying these manually. Again, 
this would not have influenced the evaluation of the efficiency and overall 
performance of the GCC-DR. 
 
 
 The evaluation of the pharmaceutical companies experiences with the GCC 
Centralised Procedure was limited by the response rate of 30%. This was despite an 
extensive follow-up of the companies who did not respond or who had limited 
experience with the centralised system. In such circumstances, the problem is not so 
much ending up with a low number, but rather the differences between responders 
and non- responders. 
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Recommendations 
As a result of this research there are a number of recommendations that can be made. 
There is defiantly scope for improvement whether at national level or at the GCC-DR. 
Although many, if not most, of the desired improvements are a common to all 
member states some of them are specific to each member state. Common 
recommendations for all member states include the following: 
 Adoption of harmonized regulations 
Member states in the GCC-DR have collaborated to produce regulations that 
govern the approval process at the GCC-DR. The regulations are in effect the 
result of a common acceptance of the required standard for marketing 
authorization of pharmaceutical products. It is logical for each member state to 
adopt, at a national level, such regulations which would be the basis for greater 
harmonization within the GCC-DR and among member states should mutual 
recognition be contemplated between two or more states. 
 
 Training programmes 
 
Common training programmes are needed  for reviewers in all member states. 
Such training programmes should provide the required knowledge and skills 
for reviewers. In order for such programmes to be effective, acceptable criteria 
for the attainment of training objectives must be agreed as well. This could be 
at a national, inter-state or common for all GCC states. Only qualified trainees 
should be allowed to progress to be official reviewers. Almost all developed 
health authorities have similar programmes for training employees to be 
reviewers and this is an essential element for any health authority. 
 
 Electronic process management 
 
The adoption of computer based systems for task management is often absent 
in most Gulf States despite the fact that they have adopted electronic 
governance in their countries. Computerization is seen in almost all aspects of 
life in the Gulf States and it is surprising that computer systems are not yet 
used in many Gulf States for the regulatory review process. Computerizations 
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of process management remain one of the most challenging tasks for most, if 
not all, GCC states. This task is assisted in that all member states and the 
GCC-DR have adopted the CTD (Common Technical Document) standard for 
dossier submission. Furthermore, the eCTD (electronic Common Technical 
Document) standard is already published by ICH and should allow the Gulf 
States to manage the computerization of the review process in an enlightened 
manner. 
 
 Qualifying programs for Quality Control Laboratories (QCL) 
 
In order to harmonize the standards for analytical procedures in each member 
state, common standards must be agreed by member states for each state QCL. 
This should be followed by appropriate training for all QCL staff and adopting 
of common accreditation criteria. 
 
 Batch analysis 
 
Like all Arab states, the GCC states perform release analysis for all submitted 
products for approval. Further, the QCL performs release analysis for every 
batch marketed. This places a burden on QCL in any country and prevents the 
QCL from performing their main task of assuring the product‟s quality in the 
market place. The GCC states need therefor to agree on the required function 
of the QCL in member states which should be similar to the European 
approach to QCL in European regulatory authorities. 
 
 Further recommendations are also suggested for the GCC-DR. 
 Adopt a new model for the regulatory review  
 
As already outlined a new model is proposed for the GCC-DR. Irrespective of 
whether the proposed model is acceptable or not, a new process model is 
needed to improve the performance of the GCC-DR. Any model must take 
into account the effectiveness and efficiency needs of the GCC-DR. 
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 Proceed to full approval with pricing 
 
For the GCC-DR to operate effectively the mandate foundation of GCC-DR 
needs to be revised. The new mandate should state that the GCC-DR is the 
way forward for approvals within the GCC states for medicine and health 
products and this should include pricing of submitted products for approval. 
 
 Validation of authorized products in member states 
 
To minimize the work load, the GCC-DR should adopt and validate approved 
products already authorised in member states. In this regard the GCC-DR 
should develop guidelines for such validation and seek member states 
approval. The validation process should be a quality assurance process and 
ensure that this is within an acceptable standard for member state. 
 
There are also a number of recommendations for individual member state,  
 
 Harmonize regulations with GCC-DR 
 
GCC-DR regulations should be adopted by each member state and this should 
be a formality within the state legal framework. 
 
 Adopt mutual recognition 
 
Member states should adopt mutual recognition with other member states with 
a similar review system. This would allow the development of  the GCC-DR 
as an organisation similar to that of the European Medicines Agency. 
 
 Mutual recognition of QCL batch certificates 
 
Member states should adopt mutual recognition procedure for QCL batch 
certificates in order to reduce the work load and avoid unnecessary repetition 
in samples analysis.  
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 Exchange programmes for reviewers 
 
Member states should adopt a programme of exchange for reviewers to allow 
experience to be shared between member states.  
 
 Electronic processes 
 
Member states should adopt the electronic management of processes and 
documents. This will relieve the bottle necks in work performance including 
the review procedures. Commercially available work flow systems, document 
management system and electronic review systems are readily available and in 
use by many health authorities worldwide but especially in Europe this has 
been an established practice. Most European authorities including the 
European Medicines Agency use validated software which is well accepted 
and commercially available. 
 
 
Future work 
 It would be of value to continue the evaluation of the Oman pharmaceutical 
review process and analysis of the timelines for NAS‟s and EAS‟s for the 
period 2011-2014. In addition it would be helpful to understand if there have 
been any improvements in good review practice. 
  
 It would be advantageous to continue the evaluation of regulatory review 
times in the Gulf States for the period 2011-2014 and to make sure that 
responses are obtained from all states including UAE and Yemen. 
 
 As an evaluation of the GCC centralised procedure is fundamental to any 
future model that might be implemented, it would be essential to update the 
timeline data for products that have been reviewed between 2011-2014. 
 
 It would also be of value to repeat the evaluation of the Gulf States views and 
experiences, as well as pharmaceutical companies with the GCC centralised 
procedure over the past three years. 
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 It would be of value both to the member states and the rest of the world to 
understand from the seven Gulf States and the pharmaceutical industries what 
are the benefits of this new proposed system as well as the challenges.  
  
 
 
Conclusion 
 
In this research the Gulf Cooperation Council centralised procedure for the approval 
of pharmaceutical products was evaluated. The results demonstrated that the GCC-DR 
centralised procedure has contributed to a better review process both at the GCC-DR 
and national level. The GCC-DR needs to be revised and developed to an independent 
marketing authorization granting authority providing applicants with one license that 
covers all seven Gulf States. A new model for the GCC-DR CP has been proposed 
which should resolve many of the difficulties facing the GCC-DR currently and 
should improve its effectiveness and efficiency. 
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List of pharmaceutical companies respond to CACP 
 
 
 
 
 
 
1 Abbott 
2 Amriya Pharma 
3 Apopharma Inc 
4 AstraZeneca 
5 B.Braun 
6 CSL 
7 Eli-Lilly 
8 Glaxo Smith Kline 
9 Glaxo Smith Kline Consumer Healthcare 
10 Hospira 
11 Hovid 
12 Janssen 
13 Jazeera Pharmaceutical Industries 
14 Joriver 
15 Kilitch 
16 KSPICO 
17 Leo Pharma 
18 National Pharmaceutical Industries 
19 Novartis Pharma AG, Basel, Switzerland 
20 Oman Pharmaceutical Products  
21 Pfizer 
22 Pharmascience 
23 Qatar Pharma 
24 Ranbaxy 
25 Reckitt Benckiser 
26 Riyadh  Pharma 
27 Sandoz 
28 SEDICO 
29 Servier 
30 SPIMACO 
 
 
 
 
